WO2002083953A1 - Methods for identifying small molecules that bind specific rna structural motifs - Google Patents

Abstract

The present invention relates to a method for screening and identifying test compounds that bind to a preselected target ribonucleic acid ('RNA'). Direct, non-competitive binding assays are advantageously used to screen libraries of compounds for those that selectively bind to a preselected target RNA. Binding of target RNA molecules to a particular test compound is detected using any physical method that measures the altered physical property of the target RNA bound to a test compound. The structure of the test compound attached to the labeled RNA is also determined. The methods used will depend, in part, on the nature of the library screened. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads.

Description

METHODS FOR IDENTIFYING SMALL MOLECULES THAT BIND SPECIFIC RNA STRUCTURAL MOTIFS

This application claims the benefit of U.S. Provisional Application No. 60/282,965, filed April 11, 2001, which is incorporated herein by reference in its entirety.

1. INTRODUCTION

The present invention relates to a method for screening and identifying test compounds that bind to a preselected target ribonucleic acid ("RNA"). Direct, non- competitive binding assays are advantageously used to screen libraries of compounds for those that selectively bind to a preselected target RNA. Binding of target RNA molecules to a particular test compound is detected using any physical method that measures the altered physical property of the target RNA bound to a test compound. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads.

2. BACKGROUND OF THE INVENTION

Protein-nucleic acid interactions are involved in many cellular functions, including transcription, RNA splicing, mRNA decay, and mRNA translation. Readily accessible synthetic molecules that can bind with high affinity to specific sequences of single- or double-stranded nucleic acids have the potential to interfere with these interactions in a controllable way, making them attractive tools for molecular biology and medicine. Successful approaches for blocking function of target nucleic acids include using duplex-forming antisense oligonucleotides (Miller, 1996, Progress in Nucl. Acid Res. & Mol. Biol. 52:261-291; Ojwang & Rando, 1999, Achieving antisense inhibition by oligodeoxynucleotides containing N₇ modified 2'-deoxyguanosine using tumor necrosis factor receptor type 1, METHODS: A Companion to Methods in Enzymology 18:244-251) and peptide nucleic acids ("PNA") (Nielsen, 1999, Current Opinion in Biotechnology 10:71-75), which bind to nucleic acids via Watson-Crick base-pairing. Triplex-forming anti-gene oligonucleotides can also be designed (Ping et al, 1997, RNA 3:850-860; Aggarwal et al, 1996, Cancer Res. 56:5156-5164; U.S. Patent No. 5,650,316), as well as pyrrole-imidazole polyamide oligomers (Gottesfeld et al, 1997, Nature 387:202-205; White et al, 1998, Nature 391:468-471), which are specific for the major and minor grooves of a double helix, respectively. In addition to synthetic nucleic acids (i.e., antisense, ribozymes, and triplex- forming molecules), there are examples of natural products that interfere with deoxyribonucleic acid ("DNA") or RNA processes such as transcription or translation. For example, certain carbohydrate-based host cell factors, calicheamicin oligosaccharides, interfere with the sequence-specific binding of transcription factors to DNA and inhibit transcription in vivo (Ho et al, 1994, Proc. Natl. Acad. Sci. USA 91 :9203-9207; Liu et al, 1996, Proc. Natl. Acad. Sci. USA 93:940-944). Certain classes of known antibiotics have been characterized and were found to interact with RNA. For example, the antibiotic thiostreptone binds tightly to a 60-mer from ribosomal RNA (Cundliffe et al, 1990, in The Ribosome: Structure, Function & Evolution (Schlessinger et al, eds.) American Society for Microbiology, Washington, D.C. pp. 479-490). Bacterial resistance to various antibiotics often involves methylation at specific rRNA sites (Cundliffe, 1989, Ann. Rev. Microbiol. 43:207-233). Aminoglycosidic aminocyclitol (aminoglycoside) antibiotics and peptide antibiotics are known to inhibit group I intron splicing by binding to specific regions of the RNA (von Ahsen et al, 1991, Nature (London) 353:368-370). Some of these same aminoglycosides have also been found to inhibit hammerhead ribozyme function (Stage et al, 1995, RNA 1:95-101). In addition, certain aminoglycosides and other protein synthesis inhibitors have been found to interact with specific bases in 16S rRNA (Woodcock et al, 1991, EMBO J. 10:3099-3103). An oligonucleotide analog of the 16S rRNA has also been shown to interact with certain aminoglycosides (Purohit et al, 1994, Nature 370:659-662). A molecular basis for hypersensitivity to aminoglycosides has been found to be located in a single base change in mitochondrial rRNA (Hutchin et al, 1993, Nucleic Acids Res. 21 :4174-4179). Aminoglycosides have also been shown to inhibit the interaction between specific structural RNA motifs and the corresponding RNA binding protein. Zapp et al. (Cell, 1993, 74:969-978) has demonstrated that the aminoglycosides neomycin B, lividomycin A, and tobramycin can block the binding of Rev, a viral regulatory protein required for viral gene expression, to its viral recognition element in the IIB (or RRE) region of HIV RNA. This blockage appears to be the result of competitive binding of the antibiotics directly to the RRE RNA structural motif.

Single stranded sections of RNA can fold into complex tertiary structures consisting of local motifs such as loops, bulges, pseudoknots, guanosine quartets and turns (Chastain & Tinoco, 1991, Progress in Nucleic Acid Res. & Mol. Biol. 41:131-177; Chow & Bogdan, 1997, Chemical Reviews 97:1489-1514; Rando & Hogan, 1998, Biologic activity of guanosine quartet forming oligonucleotides in "Applied Antisense Oligonucleotide Technology" Stein. & Krieg (eds) John Wiley and Sons, New York, pages 335-352). Such structures can be critical to the activity of the nucleic acid and affect functions such as regulation of mRNA transcription, stability, or translation (Weeks & Crothers, 1993, Science 261:1574-1577). The dependence of these functions on the native three-dimensional structural motifs of single-stranded stretches of nucleic acids makes it difficult to identify or design synthetic agents that bind to these motifs using general, simple-to-use sequence-specific recognition rules for the formation of double- and triple- helical nucleic acids used in the design of antisense and ribozyme type molecules. Approaches to screening generally involve competitive assays designed to identify compounds that disrupt the interaction between a target RNA and a physiological, host cell factor(s) that had been previously identified to specifically interact with that particular target RNA. In general, such assays require the identification and characterization of the host cell factor(s) deemed to be required for the function of the target RNA. Both the target RNA and its preselected host cell binding partner are used in a competitive format to identify compounds that disrupt or interfere with the two components in the assay.

Citation or identification of any reference in Section 2 of this application is not an admission that such reference is available as prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention relates to methods for identifying compounds that bind to preselected target elements of nucleic acids including, but not limited to, specific RNA sequences, RNA structural motifs, and/or RNA structural elements. The specific target RNA sequences, RNA structural motifs, and/or RNA structural elements are used as targets for screening small molecules and identifying those that directly bind these specific sequences, motifs, and/or structural elements. For example, methods are described in which a preselected target RNA having a detectable label is used to screen a library of test compounds, preferably under physiologic conditions. Any complexes formed between the target RNA and a member of the library are identified using physical methods that detect the altered physical property of the target RNA bound to a test compound. In particular, the present invention relates to methods for using a target RNA having a detectable label to screen a library of test compounds free in solution, in labeled tubes or microtiter plate, or in a microarray. Compounds in the library that bind to the labeled target RNA will form a detectably labeled complex. The detectably labeled complex can then be identified and removed from the uncomplexed, unlabeled test compounds in the library, and from uncomplexed, labeled target RNA, by a variety of methods, including but not limited to, methods that differentiate changes in the electrophoretic, chromatographic, or thermostable properties of the complexed target RNA. Such methods include, but are not limited to, electrophoresis, fluorescence spectroscopy, surface plasmon resonance, mass spectrometry, scintillation, proximity assay, structure-activity relationships ("SAR") by NMR spectroscopy, size exclusion chromatography, affinity chromatography, and nanoparticle aggregation. The structure of the test compound attached to the labeled RNA is then determined. The methods used will depend, in part, on the nature of the library screened. For example, assays or microarrays of test compounds, each having an address or identifier, may be deconvoluted, e.g., by cross-referencing the positive sample to original compound list that was applied to the individual test assays. Another method for identifying test compounds includes de novo structure determination of the test compounds using mass spectrometry or nuclear magnetic resonance ("NMR"). The test compounds identified are useful for any purpose to which a binding reaction may be put, for example in assay methods, diagnostic procedures, cell sorting, as inhibitors of target molecule function, as probes, as sequestering agents and the like. In addition, small organic molecules which interact specifically with target RNA molecules may be useful as lead compounds for the development of therapeutic agents.

The methods described herein for the identification of compounds that directly bind to a particular preselected target RNA are well suited for high-throughput screening. The direct binding method of the invention offers advantages over drug screening systems for competitors that inhibit the formation of naturally-occurring RNA binding proteimtarget RNA complexes; i.e., competitive assays. The direct binding method of the invention is rapid and can be set up to be readily performed, e.g. , by a technician, making it amenable to high throughput screening. The method of the invention also eliminates the bias inherent in the competitive drug screening systems, which require the use of a preselected host cell factor that may not have physiological relevance to the activity of the target RNA. Instead, the methods of the invention are used to identify any compound that can directly bind to specific target RNA sequences, RNA structural motifs, and/or RNA structural elements, preferably under physiologic conditions. As a result, the compounds so identified can inhibit the interaction of the target RNA with any one or more of the native host cell factors (whether known or unknown) required for activity of the RNA in vivo.

The present invention may be understood more fully by reference to the detailed description and examples, which are intended to illustrate non-limiting embodiments of the invention. 3.1. Definitions

As used herein, a "target nucleic acid" refers to RNA, DNA, or a chemically modified variant thereof. In a preferred embodiment, the target nucleic acid is RNA. A target nucleic acid also refers to tertiary structures of the nucleic acids, such as, but not limited to loops, bulges, pseudoknots, guanosine quartets and turns. A target nucleic acid also refers to RNA elements such as, but not limited to, the HIV TAR element, internal ribosome entry site, "slippery site", instability elements, and adenylate uridylate-rich elements, which are described in Section 5.1. Non-limiting examples of target nucleic acids are presented in Section 5.1 and Section 6.

As used herein, a "library" refers to a plurality of test compounds with which a target nucleic acid molecule is contacted. A library can be a combinatorial library, e.g. , a collection of test compounds synthesized using combinatorial chemistry techniques, or a collection of unique chemicals of low molecular weight (less than 1000 daltons) that each occupy a unique three-dimensional space.

As used herein, a "label" or "detectable label" is a composition that is detectable, either directly or indirectly, by spectroscopic, photochemical, biochemical, immunochemicai, or chemical means. For example, useful labels include radioactive isotopes (e.g., ³²P, ³⁵S, and ³H), dyes, fluorescent dyes, electron-dense reagents, enzymes and their substrates (e.g., as commonly used in enzyme-linked immunoassays, e.g., alkaline phosphatase and horse radish peroxidase), biotin-streptavidin, digoxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available. Moreover, a label or detectable moiety can include a "affinity tag" that, when coupled with the target nucleic acid and incubated with a test compound or compound library, allows for the affinity capture of the target nucleic acid along with molecules bound to the target nucleic acid. One skilled in the art will appreciate that a affinity tag bound to the target nucleic acids has, by definition, a complimentary ligand coupled to a solid support that allows for its capture. For example, useful affinity tags and complimentary partners include, but are not limited to, biotin-streptavidin, complimentary nucleic acid fragments (e.g., oligo dT-oligo dA, oligo T-oligo A, oligo dG-oligo dC, oligo G-oligo C), aptamers, or haptens and proteins for which antisera or monoclonal antibodies are available. The label or detectable moiety is typically bound, either covalently, through a linker or chemical bound, or through ionic, van der Waals or hydrogen bonds to the molecule to be detected.

As used herein, a "dye" refers to a molecule that, when exposed to radiation, emits radiation at a level that is detectable visually or via conventional spectroscopic means. As used herein, a "visible dye" refers to a molecule having a chromophore that absorbs radiation in the visible region of the spectrum (i.e., having a wavelength of between about 400 nm and about 700 nm) such that the transmitted radiation is in the visible region and can be detected either visually or by conventional spectroscopic means. As used herein, an "ultraviolet dye" refers to a molecule having a chromophore that absorbs radiation in the ultraviolet region of the spectrum (i.e., having a wavelength of between about 30 nm and about 400 nm). As used herein, an "infrared dye" refers to a molecule having a chromophore that absorbs radiation in the infrared region of the spectrum (i.e., having a wavelength between about 700 nm and about 3,000 nm). A "chromophore" is the network of atoms of the dye that, when exposed to radiation, emits radiation at a level that is detectable visually or via conventional spectroscopic means. One of skill in the art will readily appreciate that although a dye absorbs radiation in one region of the spectrum, it may emit radiation in another region of the spectrum. For example, an ultraviolet dye may emit radiation in the visible region of the spectrum. One of skill in the art will also readily appreciate that a dye can transmit radiation or can emit radiation via fluorescence or phosphorescence.

The phrase "pharmaceutically acceptable salt(s)," as used herein includes but is not limited to salts of acidic or basic groups that may be present in test compounds identified using the methods of the present invention. Test compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that can be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., l,l'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Test compounds that include an amino moiety may form pharmaceutically or cosmetically acceptable salts with various amino acids, in addition to the acids mentioned above. Test compounds that are acidic in nature are capable of forming base salts with various pharmacologically or cosmetically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium lithium, zinc, potassium, and iron salts. By "substantially one type of test compound," as used herein, is meant that the assay can be performed in such a fasliion that at some point, only one compound need be used in each reaction so that, if the result is indicative of a binding event occurring between the target RNA molecule and the test compound, the test compound can be easily identified.

4. DESCRIPTION OF DRAWINGS

FIG. 1. Gel retardation analysis to detect peptide-RNA interactions. In 20 μl reactions containing increasing concentrations of Tat₄₇.₅₈ peptide (0.1 μM, 0.2 μM, 0.4 μM, 0.8 μM, 1.6 μM) 50 pmole TAR RNA oligonucleotide was added in TK buffer. The reaction mixture was then heated at 90 °C for 2 min and allowed to cool slowly to 24 °C. 10 ml of 30% glycerol was added to each sample and applied to a 12% non-denaturing polyacrylamide gel. The gel was electrophoresed using 1200 volt-hours at 4°C in TBE Buffer. Following electrophoresis, the gel was dried and the radioactivity was quantitated with a phosphorimager. The concentration of peptide added is indicated above each lane. FIG. 2. Gentamicin interacts with an oligonucleotide corresponding to the 16S rRNA. 20 μl reactions containing increasing concentrations of gentamicin (1 ng/ml, 10 ng/ml, 100 ng/ml, 1 μg/ml, 10 μg/ml, 50 μg/ml, 500 μg/ml) were added to 50 pmole RNA oligonucleotide in TKM buffer, heated at 90 °C for 2 min and allowed to cool slowly to 24 °C. Then 10 μl of 30% glycerol was added to each sample and the samples were applied to a 13.5% non- denaturing polyacrylamide gel. The gel was electrophoresed using 1200 volt-hours at 4 °C in TBE Buffer. Following electrophoresis, the gel was dried and the radioactivity was quantitated using a phosphorimager. The concentration of gentamicin added is indicated above each lane. FIG. 3. The presence of 10 pg/ml gentamicin produces a gel mobility shift in the presence of the 16S rRNA oligonucleotide. 20 μl reactions containing increasing concentrations of gentamicin (100 ng/ml, 10 ng/ml, 1 ng/ml, 100 pg/ml, and 10 pg/ml) were added to 50 pmole RNA oligonucleotide in TKM buffer were treated as described for Figure 2. FIG. 4. Gentamicin binding to the 16S rRNA oligonucleotide is weak in the absence of MgCl₂. Reaction mixtures containing gentamicin (1 mg/ml, 100 μg/ml, 10 μg/ml, 1 μg/ml, 0.1 μg/ml, and 10 ng/ml) were treated as described in Figure 2 except that the TKM buffer does not contain MgCl₂. FIG. 5. Gel retardation analysis to detect peptide-RNA interactions. In reactions t- containing increasing concentrations of Tat₄₇.₅₈ peptide (0.1 μM, 0.2 μM, 0.4 μM, 0.8 μM, 1.6 μM) 50 pmole TAR RNA oligonucleotide was added in TK buffer. The reaction mixture was then heated at 90 °C for 2 min and allowed to cool slowly to 24°C. The reactions were loaded onto a SCE9610 automated capillary electrophoresis apparatus (SpectruMedix; State College,

10 Pennsylvania). The peaks correspond to the amount of free TAR RNA

("TAR") or the Tat-TAR complex ("Tat-TAR"). The concentration of peptide added is indicated below each lane.

5. DETAILED DESCRIPTION OF THE INVENTION

1 The present invention relates to methods for identifying compounds that bind to preselected target elements of nucleic acids, in particular, RNAs, including but not limited to preselected target RNA sequencing structural motifs, or structural elements. Methods are described in which a preselected target RNA having a detectable label is used to screen a library of test compounds. Any complexes formed between the target RNA and

20 a member of the library are identified using physical methods that detect the altered physical property of the target RNA bound to a test compound. Changes in the physical property of the RNA-test compound complex relative to the target RNA or test compound can be measured by methods such as, but not limited to, methods that detect a change in mobility due to a change in mass, change in charge, or a change in thermostability. Such methods

25 include, but are not limited to, electrophoresis, fluorescence spectroscopy, surface plasmon resonance, mass spectrometry, scintillation, proximity assay, structure-activity relationships ("SAR") by NMR spectroscopy, size exclusion chromatography, affinity chromatography, and nanoparticle aggregation. In particular, the present invention relates to methods for using a target RNA having a detectable label to screen a library of test compounds free in

30 solution, in labeled tubes or microtiter plate, or in a microarray. Compounds in the library that bind to the labeled target RNA will form a detectably labeled complex. The detectably labeled complex can then be identified and removed from the unlabeled, uncomplexed test compounds in the library by a variety of methods capable of differentiating changes in the physical properties of the complexed target RNA. The structure of the test compound

35 attached to the labeled RNA is also determined. The methods used will depend, in part, on the nature of the library screened. For example, assays or microarrays of test compounds, each having an address or identifier, may be deconvoluted, e.g., by cross-referencing the positive sample to an original compound list that was applied to the individual test assays. Another method for identifying test compounds includes de novo structure determination of the test compounds using mass spectrometry or nuclear magnetic resonance ("NMR").

Thus, the methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of test compounds, in which the test compounds of the library that specifically bind a preselected target nucleic acid are easily distinguished from non-binding members of the library. The structures of the binding molecules are deciphered from the input library by methods depending on the type of library that is used. The test compounds so identified are useful for any purpose to which a binding reaction may be put, for example in assay methods, diagnostic procedures, cell sorting, as inhibitors of target molecule function, as probes, as sequestering agents and lead compounds for development of therapeutics, and the like. Small organic compounds that are identified to interact specifically with the target RNA molecules are particularly attractive candidates as lead compounds for the development of therapeutic agents.

The assay of the invention reduces bias introduced by competitive binding assays which require the identification and use of a host cell factor (presumably essential for modulating RNA function) as a binding partner for the target RNA. The assays of the present invention are designed to detect any compound or agent that binds to the target RNA, preferably under physiologic conditions. Such agents can then be tested for biological activity, without establishing or guessing which host cell factor or factors is required for modulating the function and/or activity of the target RNA.

Section 5.1 describes examples of protein-RNA interactions that are important in a variety of cellular functions and several target RNA elements that can be used to identify test compounds. Compounds that inhibit these interactions by binding to the RNA and successfully competing with the natural protein or host cell factor that endogenously binds to the RNA may be important, e.g. , in treating or preventing a disease or abnormal condition, such as an infection or unchecked growth. Section 5.2 describes detectable labels for target nucleic acids that are useful in the methods of the invention. Section 5.3 describes libraries of test compounds. Section 5.4 provides conditions for binding a labeled target RNA to a test compound of a library and detecting RNA binding to a test compound using the methods of the invention. Section 5.5 provides methods for separating complexes of target RNAs bound to a test compound from an unbound RNA. Section 5.6 describes methods for identifying test compounds that are bound to the target RNA. Section 5.7 describes a secondary, biological screen of test compounds identified by the methods of the invention to test the effect of the test compounds in vivo. Section 5.8 describes the use of test compounds identified by the methods of the invention for treating or preventing a disease or abnormal condition in mammals.

5.1. Biologically Important RNA-Host Cell Factor Interactions

Nucleic acids, and in particular RNAs, are capable of folding into complex tertiary structures that include bulges, loops, triple helices and pseudoknots, which can provide binding sites for host cell factors, such as proteins and other RNAs. RNA-protein and RNA-RNA interactions are important in a variety cellular functions, including transcription, RNA splicing, RNA stability and translation. Furthermore, the binding of such host cell factors to RNAs may alter the stability and translational efficiency of such RNAs, and according affect subsequent translation. For example, some diseases are associated with protein overproduction or decreased protein function. In this case, the identification of compounds to modulate RNA stability and translational efficiency will be useful to treat and prevent such diseases.

The methods of the present invention are useful for identifying test compounds that bind to target RNA elements in a high throughput screening assay of libraries of test compounds in solution. In particular, the methods of the present invention are useful for identifying a test compound that binds to a target RNA elements and inhibits the interaction of that RNA with one or more host cell factors in vivo. The molecules identified using the methods of the invention are useful for inhibiting the formation of a specific bound RNA:host cell factor complexes in vivo.

In some embodiments, test compounds identified by the methods of the invention are useful for increasing or decreasing the translation of messenger RNAs ("mRNAs"), e.g., protein production, by binding to one or more regulatory elements in the 5' untranslated region, the 3' untranslated region, or the coding region of the mRNA. Compounds that bind to mRNA can, inter alia, increase or decrease the rate of mRNA processing, alter its transport through the cell, prevent or enhance binding of the mRNA to ribosomes, suppressor proteins or enhancer proteins, or alter mRNA stability. Accordingly, compounds that increase or decrease mRNA translation can be used to treat or prevent disease. For example, diseases associated with protein overproduction, such as amyloidosis, or with the production of mutant proteins, such as Ras, can be treated or prevented by decreasing translation of the mRNA that codes for the overproduced protein, thus inhibiting production of the protein. Conversely, the symptoms of diseases associated with decreased protein function, such as hemophelia, may be treated by increasing translation of mRNA coding for the protein whose function is decreased, e.g., factor IX in some forms of hemophilia.

The methods of the invention can be used to identify compounds that bind to mRNAs coding for a variety of proteins with which the progression of diseases in mammals is associated. These mRNAs include, but are not limited to, those coding for amyloid protein and amyloid precursor protein; anti-angiogenic proteins such as angiostatin, endostatin, METH-1 and METH-2; apoptosis inhibitor proteins such as survivin, clotting factors such as Factor IX, Factor VIII, and others in the clotting cascade; collagens; cyclins and cyclin inhibitors, such as cyclin dependent kinases, cyclin Dl, cyclin E, WAF1, cdk4 inhibitor, and MTS1; cystic fibrosis transmembrane conductance regulator gene (CFTR); cytokines such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL- 13, IL-14, IL-15, IL-16, IL-17 and other interleukins; hematopoetic growth factors such as erythropoietin (Epo); colony stimulating factors such as G-CSF, GM-CSF, M-CSF, SCF and thrombopoietin; growth factors such as BNDF, BMP, GGRP, EGF, FGF, GDNF, GGF, HGF, IGF-1, IGF-2, KGF, myotrophin, NGF, OSM, PDGF, somatotrophin, TGF-β, TGF-α and VEGF; antiviral cytokines such as interferons, antiviral proteins induced by interferons, TTNF-α, and TNF-β; enzymes such as cathepsin K, cytochrome P-450 and other cytochromes, farnesyl transferase, glutathione-S transferases, heparanase, HMG CoA synthetase, N-acetyltransferase, phenylalanine hydroxylase, phosphodiesterase, ras carboxyl-terminal protease, telomerase and TNF converting enzyme; glycoproteins such as cadherins, e.g., N-cadherin and E-cadherin; cell adhesion molecules; selectins; transmembrane glycoproteins such as CD40; heat shock proteins; hormones such as 5-α reductase, atrial natriuretic factor, calcitonin, corticotrophin releasing factor, diuretic hormones, glucagon, gonadotropin, gonadotropin releasing hormone, growth hormone, growth hormone releasing factor, somatotropin, insulin, leptin, luteinizing hormone, luteinizing hormone releasing hormone, parathyroid hormone, thyroid hormone, and thyroid stimulating hormone; proteins involved in immune responses, including antibodies, CTLA4, hemagglutinin, MHC proteins, VLA-4, and kallikrein-kininogen-kinin system; ligands such as CD4; oncogene products such as sis, hst, protein tyrosine kinase receptors, ras, abl, mos, myc, fas, jun, H-ras, ki-ras, c-fins, bcl-2, L-myc, c-myc, gip, gsp, and HER-2; receptors such as bombesin receptor, estrogen receptor, GABA receptors, growth factor receptors including EGFR, PDGFR, FGFR, and NGFR, GTP-binding regulatory proteins, interleukin receptors, ion channel receptors, leukotriene receptor antagonists, lipoprotein receptors, opioid pain receptors, substance P receptors, retinoic acid and retinoid receptors, steroid receptors, T-cell receptors, thyroid hormone receptors, T5NF receptors; tissue plasminogen activator; transmembrane receptors; transmembrane transporting systems, such as calcium pump, proton pump, Na/Ca exchanger, MRPl, MRP2, PI 70, LRP, and cMOAT; transferrin; and tumor suppressor gene products such as APC, brcal, brca2, DCC, MCC, ■ MTS1, NF1, NF2, nm23, p53 and Rb. In addition to the eukaryotic genes listed above, the invention, as described, can be used to define molecules that interrupt viral, bacterial ^"or fungal transcription or translation efficiencies and therefore form the basis for a novel anti- infectious disease therapeutic. Other target genes include, but are not limited to, those disclosed in Section 5.1 and Section 6.

The methods of the invention can be used to identify mRNA-binding test compounds for increasing or decreasing the production of a protein, thus treating or preventing a disease associated with decreasing or increasing the production of said protein, respectively. The methods of the invention may be useful for identifying test compounds for treating or preventing a disease in mammals, including cats, dogs, swine, horses, goats, sheep, cattle, primates and humans. Such diseases include, but are not limited to, amyloidosis, hemophilia, Alzheimer's disease, atherosclerosis, cancer, giantism, dwarfism, hypothyroidism, hyperthyroidism, inflammation, cystic fibrosis, autoimmune disorders, diabetes, aging, obesity, neurodegenerative disorders, and Parkinson's disease. Other diseases include, but are not limited to, those described in Section 5.1 and diseases caused by aberrant expression of the genes disclosed in Example 6. In addition to the eukaryotic genes listed above, the invention, as described, can be used to define molecules that interrupt viral, bacterial or fungal transcription or translation efficiencies and therefore form the basis for a novel anti-infectious disease therapeutic.

In other embodiments, test compounds identified by the methods of the invention are useful for preventing the interaction of an RNA, such as a transfer RNA ("tRNA"), an enzymatic RNA or a ribosomal RNA ("rRNA"), with a protein or with another RNA, thus preventing, e.g., assembly of an in vivo protein-RNA or RNA-RNA complex that is essential for the viability of a cell. The term "enzymatic RNA," as used herein, refers to RNA molecules that are either self-splicing, or that form an enzyme by virtue of their association with one or more proteins, e.g., as in RNase P, telomerase or small nuclear ribonuclear protein particles. For example, inhibition of an interaction between rRNA and one or more ribosomal proteins may inhibit the assembly of ribosomes, rendering a cell incapable of synthesizing proteins. In addition, inhibition of the interaction of precursor rRNA with ribonucleases or ribonucleoprotein complexes (such as RNase P) that process the precursor rRNA prevent maturation of the rRNA and its assembly into ribosomes. Similarly, a tRNA:tRNA synthetase complex may be inhibited by test compounds identified by the methods of the invention such that tRNA molecules do not become charged with amino acids. Such interactions include, but are not limited to, rRNA interactions with ribosomal proteins, tRNA interactions with tRNA synthetase, RNase P protein interactions with RNase P RNA, and telomerase protein interactions with telomerase RNA.

In other embodiments, test compounds identified by the methods of the invention are useful for treating or preventing a viral, bacterial, protozoan or fungal infection. For example, transcriptional up-regulation of the genes of human immunodeficiency virus type 1 ("HIV-l ") requires binding of the HIV Tat protein to the HIV trans-activation response region RNA ("TAR RNA"). HIV TAR RNA is a 59-base stem-loop structure located at the 5 '-end of all nascent HIV-1 transcripts (Jones & Peterlin, 1994, Annu. Rev. Biochem. 63:717-43). Tat protein is known to interact with uracil 23 in the bulge region of the stem of TAR RNA. Thus, TAR RNA is a potential binding target for test compounds, such as small peptides and peptide analogs that bind to the bulge region of TAR RNA and inhibit formation of a Tat-TAR RNA complex involved in HIV-1 upregulation (see Hwang et a/., 1999 Proc. Natl. Acad. Sci. USA 96:12997-13002). Accordingly, test compounds that bind to TAR RNA are useful as anti-HIV therapeutics (Hamy et al, 1997, Proc. Natl. Acad. Sci. USA 94:3548-3553; Hamy et al, 1998, Biochemistry 37:5086-5095; Mei et al, 1998, Biochemistry 37:14204-14212), and therefore, are useful for treating or preventing AIDS.

The methods of the invention can be used to identify test compounds to treat or prevent viral, bacterial, protozoan or fungal infections in a patient. In some embodiments, the methods of the invention are useful for identifying compounds that decrease translation of microbial genes by interacting with mRNA, as described above, or for identifying compounds that inhibit the interactions of microbial RNAs with proteins or other ligands that are essential for viability of the virus or microbe. Examples of microbial target RNAs useful in the present invention for identifying antiviral, antibacterial, anti- protozoan and anti-fungal compounds include, but are not limited to, general antiviral and

-₀ anti-inflammatory targets such as mRNAs of INFα, INFγ, RNAse L, RNAse L inhibitor protein, PKR, tumor necrosis factor, interleukins 1-15, and IMP dehydrogenase; internal ribosome entry sites; HIV-1 CT rich domain and RNase H mRNA; HCV internal ribosome entry site (required to direct translation of HCV mRNA), and the 3 '-untranslated tail of HCV genomes; rotavirus NSP3 binding site, which binds the protein NSP3 that is required

~ for rotavirus mRNA translation; HBV epsilon domain; Dengue virus 5' and 3' untranslated regions, including IRES; INFα, INFβ and INFγ; plasmodium falciparum mRNAs; the 16S ribosomal subunit ribosomal RNA and the RNA component of RNase P of bacteria; and the RNA component of telomerase in fungi and cancer cells. Other target viral and bacterial mRNAs include, but are not limited to, those disclosed in Section 6.

One of skill in the art will appreciate that, although such target RNAs are functionally conserved in various species (e.g., from yeast to humans), they exhibit nucleotide sequence and structural diversity. Therefore, inhibition of, for example, yeast telomerase by an anti-fungal compound identified by the methods of the invention might not interfere with human telomerase and normal human cell proliferation.

Thus, the methods of the invention can be used to identify test compounds that interfere with one or more target RNA interactions with host cell factors that are important for cell growth or viability, or essential in the life cycle of a virus, a bacterium, a protozoa or a fungus. Such test compounds and/or congeners that demonstrate desirable biologic and pharmacologic activity can be administered to a patient in need thereof in order to treat or prevent a disease caused by viral, bacterial, protozoan, or fungal infections. Such diseases include, but are not limited to, HIV infection, AIDS, human T-cell leukemia, SIV infection, FIV infection, feline leukemia, hepatitis A, hepatitis B, hepatitis C, Dengue fever, malaria, rotavirus infection, severe acute gastroenteritis, diarrhea, encephalitis, hemorrhagic fever, syphilis, legionella, whooping cough, gonorrhea, sepsis, influenza, pneumonia, tinea infection, Candida infection, and meningitis.

Non-limiting examples of RNA elements involved in the regulation of gene expression, i.e., mRNA stability, translational efficiency via translational initiation and ribosome assembly, etc., include the HIV TAR element, internal ribosome entry site, "slippery site", instability elements, and adenylate uridylate-rich elements, as discussed below.

5.1.1. HIV TAR Element

Transcriptional up-regulation of the genes of human immunodeficiency virus type 1 ("HIV-1 ") requires binding of the HIV Tat protein to the HIV trans-activation response region RNA ("TAR RNA"), a 59-base stem-loop structure located at the 5' end of all nascent HIV-1 transcripts (Jones & Peterlin, 1994, Annu. Rev. Biochem. 63:717-43). Tat protein is known to interact with uracil 23 in the bulge region of the stem of TAR RNA. Thus, TAR RNA is a useful binding target for test compounds, such as small peptides and peptide analogs that bind to the bulge region of TAR RNA and inhibit formation of a Tat- TAR RNA complex involved in HIV-1 up-regulation (see Hwang et al.,1999 Proc. Natl. Acad. Sci. USA 96:12997-13002). Accordingly, test compounds that bind to TAR RNA can be useful as anti-HIV therapeutics (Hamy et al, 1997, Proc. Natl. Acad. Sci. USA 94:3548-3553; Hamy et al, 1998, Biochemistry 37:5086-5095; Mei et al, 1998, Biochemistry 37:14204-14212), and therefore, are useful for treating or preventing AIDS.

5.1.2. Internal Ribosome Entry Site ("IRES")

Internal ribosome entry sites ("IRES") are found in the 5' untranslated regions ("5' UTR") of several mRNAs, and are thought to be involved in the regulation of translational efficiency. When the IRES element is present on an mRNA downstream of a translational stop codon, it directs ribosomal re-entry (Ghattas et al, 1991, Mol. Cell. Biol. 11 :5848-5959), which permits initiation of translation at the start of a second open reading frame.

As reviewed by Jang et al, a large segment of the 5' nontranslated region, approximately 400 nucleotides in length, promotes internal entry of ribosomes independent of the non-capped 5' end of picornavirus mRNAs (mammalian plus-strand RNA viruses whose genomes serve as mRNA). This 400 nucleotide segment (IRES), maps approximately 200 nt down-stream from the 5' end and is highly structured. IRES elements of different picornaviruses, although functionally similar in vitro and in vivo, are not identical in sequence or structure. However, IRES elements of the genera entero- and rhinoviruses, on the one hand, and cardio- and aphthoviruses, on the other hand, reveal similarities corresponding to phylogenetic kinship. All IRES elements contain a conserved Yn-Xm-AUG unit (Y, pyrimidine; X, nucleotide) which appears essential for IRES function. The IRES elements of cardio-, entero- and aphthoviruses bind a cellular protein, p57. In the case of cardioviruses, the interaction between a specific stem-loop of the IREs is essential for translation in vitro. The IRES elements of entero- and cardioviruses also bind the cellular protein, p52, but the significance of this interaction remains to be shown. The function of p57 or p52 in cellular metabolism is unknown. Since picornaviral IRES elements function in vivo in the absence of any viral gene products, is speculated that IRES-like elements may also occur in specific cellular mRNAs releasing them from cap-dependent translation (Jang et al, 1990, Enzyme 44(l-4):292-309).

5.1.3. "Slippery Site"

Programmed, or directed, ribosomal frameshifting, when ribosomes shift from one translation reading frame to another and synthesize two viral proteins from a single viral mRNA, is directed by a unique site in viral mRNAs called the "slippery site." The slippery site directs ribosomal frameshifting in the -1 or +1 direction that causes the ribosome to slip by one base in the 5' direction thereby placing the ribosome in the new reading frame to produce a new protein.

Programmed, or directed, ribosomal frameshifting is of particular value to viruses that package their plus strands, as it eliminates the need to splice their mRNAs and reduces the risk of packaging defective genomes and regulates the ratio of viral proteins synthesized. Examples of programmed translational frameshifting (both +1 and -1 shifts) have been identified in ScV systems (Lopinski et al, 2000, Mol. Cell. Biol. 20(4):1095-103, retroviruses (Falk et al, 1993, J. Virol. 67:273-6277; Jacks & Varmus, 1985, Science 230:1237-1242; Morikawa & Bishop, 1992, Virology 186:389-397; Nam et al, 1993, J. Virol. 67:196-203); coronaviruses (Brierley et al, 1987, EMBO J. 6:3779-3785; Herold & Siddell, 1993, Nucleic Acids Res. 21:5838-5842); giardiaviruses, which are also members of the Totiviridae (Wang et al, 1993, Proc. Natl. Acad. Sci. USA 90:8595-8599); two bacterial genes (Blinkowa & Walker, 1990, Nucleic Acids Res., 18:1725-1729; Craigen & Caskey, 1986, Nature 322:273); bacteriophage genes (Condron et al, 1991, Nucleic Acids Res. 19:5607-5612); astroviruses (Marczinke et al, 1994, J. Virol. 68:5588-5595); the yeast EST3 gene (Lundblad & Morris, 1997, Curr. Biol. 7:969-976); and the rat, mouse, Xenopus, and Drosophila ornithine decarboxylase antizymes (Matsufuji et al, 1995, Cell 80:51-60); and a significant number of cellular genes (Herold & Siddell, 1993, Nucleic Acids Res. 21:5838-5842).

Drugs targeted to ribosomal frameshifting minimize the problem of virus drug resistance because this strategy targets a host cellular process rather than one introduced into the cell by the virus, which minimizes the ability of viruses to evolve drug- resistant mutants. Compounds that target the RNA elements involved in regulating programmed frameshifting should have several advantages, including (a) any selective pressure on the host cellular translational machinery to adapt to the drugs would have to occur at the host evolutionary time scale, which is on the order of millions of years, (b) ribosomal frameshifting is not used to express any host proteins, and (c) altering viral frameshifting efficiencies by modulating the activity of a host protein minimizing the likelihood that the virus will acquire resistance to such inhibition by mutations in its own genome.

5.1.4. Instability Elements

"Instability elements" may be defined as specific sequence elements that promote the recognition of unstable mRNAs by cellular turnover machinery. Instability elements have been found within mRNA protein coding regions as well as untranslated regions.

Altering the control of stability of normal mRNAs may lead to disease. The alteration of mRNA stability has been implicated in diseases such as, but not limited to, cancer, immune disorders, heart disease, and fibrotic disorders.

There are several examples of mutations that delete instability elements which then result in stabilization of mRNAs that may be involved in the onset of cancer. In Burkitt's lymphoma, a portion of the c-myc proto-oncogene is translocated to an Ig locus, producing a form of the c-myc mRNA that is five times more stable (see, e.g. , Kapstein et al, 1996, J. Biol. Chem. 271(31): 18875-84). The highly oncogenic v-fos mRNA lacks the 3' UTR adenylate uridylate rich element ("ARE") that is found in the more labile and weakly oncogenic c-fos mRNA (see, e.g., Schiavi et al, 1992, Biochim Biophys Acta. 1114(2-3):95-106). Differences between the benign cervical lesions brought about by nonintegrated circular human papillomavirus type 16 and its integrated form, that lacks the 3' UTR ARE and correlates with cervical carcinomas, may be a consequence of stabilizing the E6/E7 transcripts encoding oncogenic proteins. Integration of the virus results in deletion of the ARE instability element, resulting in stabilizion of the transcripts and over- expression of the proteins (see, e.g., Jeon & Lambert, 1995, Proc. Natl. Acad. Sci. USA 92(5):1654-8). Deletion of AREs from the 3' UTR of the IL-2 and IL-3 genes promotes increased stabilization of these mRNAs, high expression of these proteins, and leads to the formation of cancerous cells (see, e.g., Stoecklin et al, 2000, Mol. Cell. Biol. 20(11 ):3753-63).

Mutations in trans-acting factors involved in mRNA turnover may also promote cancer. In monocytic tumors, the lymphokine GM-CSF mRNA is specifically stabilized as a consequence of an oncogenic lesion in a trans-acting factor that controls mRNA turnover rates. Furthermore, the normally unstable IL-3 transcript is inappropriately long-lived in mast tumor cells. Similarly, the labile GM-CSF mRNA is greatly stabilized in bladder carcinoma cells. See, e.g., Bickel et al, 1990, J. Immunol. 145(3):840-5.

The immune system is regulated by a large number of regulatory molecules that either activate or inhibit the immune response. It has now been clearly demonstrated that stability of the transcripts encoding these proteins are highly regulated. Altered regulation of these molecules leads to mis-regulation of this process and can result in drastic medical consequences. For example, recent results using transgenic mice have shown that mis-regulation of the stability of the important modulator TNFα mRNA leads to diseases such as, but not limited to, rheumatoid arthritis and a Crohn's-like liver disease. See, e.g., Clark, 2000, Arthritis Res. 2(3): 172-4.

Smooth muscle in the heart is modulated by the β-adrenergic receptor, which in turn responds to the sympathetic neurotransmitter norepinephrine and the adrenal hormone epinephrine. Chronic heart failure is characterized by impairment of smooth muscle cells, which results, in part, from the more rapid decay of the β-adrenergic receptor mRNA. See, e.g., Ellis & Frielle, 1999, Biochem. Biophys. Res. Commun. 258(3):552-8. A large number of diseases result from over-expression of collagen. For

10 example, cirrhosis results from damage to the liver as a consequence of cancer, viral infection, or alcohol abuse. Such damage causes mis-regulation of collagen expression, leading to the formation of large collagen deposits. Recent results indicate that the sizeable increase in collagen expression is largely attributable to stabilization of its mRNA. See, e.g., Lindquist et al, 2000, Am. J. Physiol. Gastrointest. Liver Physiol. 279(3):G471-6.

15

5.1.5. Adenylate Uridylate-rich Elements ("ARE".

Adenylate uridylate-rich elements ("ARE") are found in the 3' untranslated regions ("3' UTR") of several mRNAs, and involved in the turnover of mRNAs, such as but not limited to transcription factors, cytokines, and lymphokines. AREs may function both

2 as stabilizing and destabilizing elements. ARE mRNAs are classified into five groups, depending on sequence (Bakheet et al, 2001, Nucl. Acids Res. 29(l):246-254). An ongoing database at the web site http://rc.kfshrc.edu.sa/ared contains ARE-containing mRNAs and their cluster groups, which is incorporated by reference in its entirety. The

ARE motifs are classified as follows:

25 Group I Cluster (AUUUAUUUAUUUAUUUAUUUA) SEQ ID NO: 1

Group II Cluster (AUUUAUUUAUUUAUUUA) stretch SEQ ID NO: 2

Group III Cluster (WAUUUAUUUAUUUAW) stretch SEQ ID NO: 3

Group IV Cluster (WWAUUUAUUUAWW) stretch SEQ ID NO: 4

30 Group V Cluster (WWWWAUUUAWWWW) stretch SEQ ID NO: 5

The ARE-mRNAs were clustered into five groups containing five, four, three and two pentameric repeats, while the last group contains only one pentamer within the 13-bp ARE pattern. Functional categories were assigned whenever possible according to NCBI-COG functional annotation (Tatusov et al, 2001, Nucleic Acids Research, 29(1): 5 22-28), in addition to the categories: inflammation, immune response, development/differentiation, using an extensive literature search. Group I contains many secreted proteins including GM-CSF, IL-1, IL-11, IL-12 and Gro-β that affect the growth of hematopoietic and immune cells (Witsell & Schook, 1992, Proc. Natl Acad. Sci. USA, 89:4754-4758). Although INFα is both a

, pro-inflammatory and anti-tumor protein, there is experimental evidence that it can act as a growth factor in certain leukemias and lymphomas (Liu et al, 2000, J. Biol. Chem. 275:21086-21093).

Unlike Group I, Groups II-V contain functionally diverse gene families comprising immune response, cell cycle and proliferation, inflammation and coagulation,

H „ angiogenesis, metabolism, energy, DNA binding and transcription, nutrient transportation and ionic homeostasis, protein synthesis, cellular biogenesis, signal transduction, and apoptosis (Bakheet et al, 2001, Nucl. Acids Res. 29(l):246-254).

Several groups have described ARE-binding proteins that influence the ARE-mRNA stability. Among the well-characterized proteins are the mammalian

. j. homologs of ELAV (embryonic lethal abnormal vision) proteins including AUF 1 , HuR and Hel-N2 (Zhang et al, 1993, Mol. Cell. Biol. 13:7652-7665; Levine et al, 1993, Mol. Cell. Biol. 13:3494-3504: Ma et al, 1996, J. Biol. Chem. 271:8144-8151). The zinc-finger protein tristetraprolin has been identified as another ARE-binding protein with destabilizing activity on TNFα, IL-3 and GM-CSF mRNAs (Stoecklin et al, 2000, Mol. Cell. Biol.

₂₀ 20:3753-3763; Carballo et al, 2000, Blood 95:1891-1899).

Since ARE-containing genes are clearly important in biological systems, including but not limited to a number of the early response genes that regulate cell proliferation and responses to exogenous agents, the identification of compounds that bind to one or more of the ARE clusters and potentially modulate the stability of the target RNA

25 can potentially be of value as a therapeutic.

5.2. Detectably Labeled Target RNAs

Target nucleic acids, including but not limited to RNA and DNA, useful in the methods of the present invention have a label that is detectable via conventional 0 spectroscopic means or radiographic means. Preferably, target nucleic acids are labeled with a covalently attached dye molecule. Useful dye-molecule labels include, but are not limited to, fluorescent dyes, phosphorescent dyes, ultraviolet dyes, infrared dyes, and visible dyes. Preferably, the dye is a visible dye.

Useful labels in the present invention can include, but are not limited to, 35 spectroscopic labels such as fluorescent dyes (e.g., fluorescein and derivatives such as fluorescein isothiocyanate (FITC) and Oregon Green™, rhodamine and derivatives (e.g., Texas red, tetramethylrhodimine isothiocynate (TRITC), bora-3a,4a-diaza-s-indacene (BODIPY®) and derivatives, etc.), digoxigenin, biotin, phycoerythrin, AMCA, CyDye™, and the like), radiolabels (e.g., ³H, ¹²⁵1, ³⁵S, ¹⁴C, ³ P, ³³P, etc.), enzymes (e.g., horse radish peroxidase, alkaline phosphatase etc.), spectroscopic colorimetric labels such as colloidal gold or colored glass or plastic (e.g. polystyrene, polypropylene, latex, etc.) beads, or nanoparticles - nanoclusters of inorganic ions with defined dimension from 0.1 to 1000 nm. Useful affinity tags and complimentary partners include, but are not limited to, biotin-streptavidin, complimentary nucleic acid fragments (e.g., oligo dT-oligo dA, oligo T-oligo A, oligo dG-oligo dC, oligo G-oligo C), aptamer-streptavidin, or haptens and proteins for which antisera or monoclonal antibodies are available. The label may be coupled directly or indirectly to a component of the detection assay (e.g., the detection reagent) according to methods well known in the art. A wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

In one embodiment, nucleic acids that are labeled at one or more specific locations are chemically synthesized using phosphoramidite or other solution or solid-phase methods. Detailed descriptions of the chemistry used to form polynucleotides by the phosphoramidite method are well known (see, e.g., Caruthers et αi., U.S. Pat. Nos. 4,458,066 and 4,415,732; Caruthers et αl, 1982, Genetic Engineering 4:1-17; Users Manual Model 392 and 394 Polynucleotide Synthesizers, 1990, pages 6-1 through 6-22, Applied Biosystems, Part No. 901237; Ojwang, et al, 1997, Biochemistry, 36:6033-6045). The phosphoramidite method of polynucleotide synthesis is the preferred method because of its efficient and rapid coupling and the stability of the starting materials. The synthesis is performed with the growing polynucleotide chain attached to a solid support, such that excess reagents, which are generally in the liquid phase, can be easily removed by washing, decanting, and/or filtration, thereby eliminating the need for purification steps between synthesis cycles.

The following briefly describes illustrative steps of a typical polynucleotide synthesis cycle using the phosphoramidite method. First, a solid support to which is attached a protected nucleoside monomer at its 3' terminus is treated with acid, e.g., trichloroacetic acid, to remove the 5 '-hydroxyl protecting group, freeing the hydroxyl group for a subsequent coupling reaction. After the coupling reaction is completed an activated intermediate is formed by contacting the support-bound nucleoside with a protected nucleoside phosphoramidite monomer and a weak acid, e.g., tetrazole. The weak acid protonates the nitrogen atom of the phosphoramidite forming a reactive intermediate. Nucleoside addition is generally complete within 30 seconds. Next, a capping step is performed, which terminates any polynucleotide chains that did not undergo nucleoside addition. Capping is preferably performed using acetic anhydride and 1 -methylimidazole. The phosphite group of the internucleotide linkage is then converted to the more stable phosphotriester by oxidation using iodine as the preferred oxidizing agent and water as the oxygen donor. After oxidation, the hydroxyl protecting group of the newly added nucleoside is removed with a protic acid, e.g., trichloroacetic acid or dichloroacetic acid, and the cycle is repeated one or more times until chain elongation is complete. After synthesis, the polynucleotide chain is cleaved from the support using a base, e.g., ammonium hydroxide or t-butyl amine. The cleavage reaction also removes any phosphate protecting groups, e.g., cyanoethyl. Finally, the protecting groups on the exocyclic amines of the bases and any protecting groups on the dyes are removed by treating the polynucleotide solution in base at an elevated temperature, e.g., at about 55°C. Preferably the various protecting groups are removed using ammonium hydroxide or t-butyl amine.

Any of the nucleoside phosphoramidite monomers can be labeled using standard phosphoramidite chemistry methods (Hwang et al, 1999, Proc. Natl. Acad. Sci. USA 96(23):12997-13002; Ojwang et al, 1997, Biochemistry. 36:6033-6045 and references cited therein). Dye molecules useful for covalently coupling to phosphoramidites preferably comprise a primary hydroxyl group that is not part of the dye's chromophore. Illustrative dye molecules include, but are not limited to, disperse dye CAS 4439-31-0, disperse dye CAS 6054-58-6, disperse dye CAS 4392-69-2 (Sigma-Aldrich, St. Louis, MO), disperse red, and 1-pyrenebutanol (Molecular Probes, Eugene, OR). Other dyes useful for coupling to phosphoramidites will be apparent to those of skill in the art, such as fiuoroscein, cy3, and cy5 fluorescent dyes, and may be purchased from, e.g., Sigma-Aldrich, St. Louis, MO or Molecular Probes, Inc., Eugene, OR.

In another embodiment, dye-labeled target RNA molecules are synthesized enzymatically using in vitro transcription (Hwang et al, 1999, Proc. Natl. Acad. Sci. USA 96(23):12997-13002 and references cited therein). In this embodiment, a template DNA is denatured by heating to about 90°C and an oligonucleotide primer is annealed to the template DNA, for example by slow-cooling the mixture of the denatured template and the primer from about 90°C to room temperature. A mixture of ribonucleoside-5'-triphosphates capable of supporting template-directed enzymatic extension of the primed template (e.g., a mixture including GTP, ATP, CTP, and UTP), including one or more dye-labeled ribonucleotides (Sigma-Aldrich, St. Louis, MO), is added to the primed template. Next, a polymerase enzyme is added to the mixture under conditions where the polymerase enzyme is active, which are well-known to those skilled in the art. A labeled polynucleotide is formed by the incorporation of the labeled ribonucleotides during polymerase-mediated strand synthesis.

In yet another embodiment of the invention, nucleic acid molecules are end- labeled after their synthesis. Methods for labeling the 5 '-end of an oligonucleotide include but are by no means limited to: (i) periodate oxidation of a 5 '-to-5' -coupled ribonucleotide, followed by reaction with an amine-reactive label (Heller & Morisson, 1985, in Rapid Detection and Identification of Infectious Agents, D.T. Kingsbury and S. Falkow, eds., pp. 245-256, Academic Press); (ii) condensation of ethylenediamine with 5'-phosphorylated polynucleotide, followed by reaction with an amine reactive label (Morrison, European Patent Application 232 967); (iii) introduction of an aliphatic amine substituent using an aminohexyl phosphite reagent in solid-phase DNA synthesis, followed by reaction with an amine reactive label (Cardullo etal, 1988, Proc. Natl. Acad. Sci. USA 85:8790-8794); and (iv) introduction of a thiophosphate group on the 5 '-end of the nucleic acid, using phosphatase treatment followed by end-labeling with ATP-7S and kinase, which reacts specifically and efficiently wάth maleimide-labeled fluorescent dyes (Czworkowski et al , 1991, Biochem. 30:4821-4830).

A detectable label should not be incorporated into a target nucleic acid at the specific binding site at which test compounds are likely to bind, since the presence of a covalently attached label might interfere sterically or chemically with the binding of the test compounds at this site. Accordingly, if the region of the target nucleic acid that binds to a host cell factor is known, a detectable label is preferably incorporated into the nucleic acid molecule at one or more positions that are spatially or sequentially remote from the binding region.

After synthesis, the labeled target nucleic acid can be purified using standard techniques known to those skilled in the art (see Hwang et al, 1999, Proc. Natl. Acad. Sci. USA 96(23):12997-13002 and references cited therein). Depending on the length of the target nucleic acid and the method of its synthesis, such purification techniques include, but are not limited to, reverse-phase high-performance liquid chromatography ("reverse-phase HPLC"), fast performance liquid chromatography ("FPLC"), and gel purification. After purification, the target RNA is refolded into its native conformation, preferably by heating to approximately 85-95°C and slowly cooling to room temperature in a buffer, e.g., a buffer comprising about 50 mM Tris-HCI, pH 8 and 100 mM NaCl.

In another embodiment, the target nucleic acid can also be radiolabeled. A radiolabel, such as, but not limited to, an isotope of phosphorus, sulfur, or hydrogen, may be incorporated into a nucleotide, which is added either after or during the synthesis of the target nucleic acid. Methods for the synthesis and purification of radiolabeled nucleic acids are well known to one of skill in the art. See, e.g., Sambrook et al, 1989, inMolecular Cloning: A Laboratory Manual, pp 10.2-10.70, Cold Spring Harbor Laboratory Press, and the references cited therein, which are hereby incorporated by reference in their entireties.

In another embodiment, the target nucleic acid can be attached to an inorganic nanoparticle. A nanoparticle is a cluster of ions with controlled size from 0.1 to 1000 mu comprised of metals, metal oxides, or semiconductors including, but not limited to Ag₂S, ZnS, CdS, CdTe, Au, or TiO₂. Nanoparticles have unique optical, electronic and catalytic properties relative to bulk materials which can be adjusted according to the size of the particle. Methods for the attachment of nucleic acids are well know to one of skill in the art (see, e.g., Niemeyer, 2001, Angew. Chem. Int. Ed. 40: 4129-4158, International Patent Publication WO/0218643, and the references cited therein, the disclosures of which are hereby incorporated by reference in their entireties).

5.3. Libraries of Small Molecules

Libraries screened using the methods of the present invention can comprise a variety of types of test compounds. In some embodiments, the test compounds are nucleic acid or peptide molecules. In a non-limiting example, peptide molecules can exist in a phage display library. In other embodiments, types of test compounds include, but are not limited to, peptide analogs including peptides comprising non-naturally occurring amino acids, e.g., D-amino acids, phosphorous analogs of amino acids, such as α-amino phosphoric acids and α-amino phosphoric acids, or amino acids having non-peptide linkages, nucleic acid analogs such as phosphorothioates and PNAs, hormones, antigens, synthetic or naturally occurring drugs, opiates, dopamine, serotonin, catecholamines, thrombin, acetylcholine, prostaglandins, organic molecules, pheromones, adenosine, sucrose, glucose, lactose and galactose. Libraries of polypeptides or proteins can also be used.

In a preferred embodiment, the combinatorial libraries are small organic molecule libraries, such as, but not limited to, benzodiazepines, isoprenoids, thiazolidinones, metathiazanones, pyrrolidines, morpholino compounds, and diazepindiones. In another embodiment, the combinatorial libraries comprise peptoids; random bio-oligomers; diversomers such as hydantoins, benzodiazepines and dipeptides; vinylogous polypeptides; nonpeptidal peptidomimetics; oligocarbamates; peptidyl phosphonates; peptide nucleic acid libraries; antibody libraries; or carbohydrate libraries. Combinatorial libraries are themselves commercially available (see, e.g., Advanced ChemTech Europe Ltd., Cambridgeshire, UK; ASINEX, Moscow Russia; BioFocus pic, Sittingbourne, UK; Bionet Research (A division of Key Organics Limited ), Camelford, UK; ChemBridge Corporation, San Diego, California; ChemDiv Inc, San Diego, California.; ChemRx Advanced Technologies, South San Francisco, California; ComGenex Inc., Budapest, Hungary; Evotec OAI Ltd, Abingdon, UK; IF LAB Ltd., Kiev, Ukraine; Maybridge pic, Cornwall, UK; PharmaCore, Inc., North Carolina; SIDDCO Inc, Tucson, Arizona; TimTec Inc, Newark, Delaware; Tripos Receptor Research Ltd, Bude, UK; Toslab,

. . Ekaterinburg, Russia).

In one embodiment, the combinatorial compound library for the methods of the present invention may be synthesized. There is a great interest in synthetic methods directed toward the creation of large collections of small organic compounds, or libraries, which could be screened for pharmacological, biological or other activity (Dolle, 2001, J. Comb. Chem. 3:477-517; Hall et al, 2001, J. Comb. Chem. 3:125-150; Dolle, 2000, J. Comb. Chem. 2:383-433; Dolle, 1999, J. Comb. Chem. 1:235-282). The synthetic methods applied to create vast combinatorial libraries are performed in solution or in the solid phase, i.e., on a solid support. Solid-phase synthesis makes it easier to conduct multi-step reactions and to drive reactions to completion with high yields because excess reagents can

__n be easily added and washed away after each reaction step. Solid-phase combinatorial synthesis also tends to improve isolation, purification and screening. However, the more traditional solution phase chemistry supports a wider variety of organic reactions than solid-phase chemistry. Methods and strategies for the synthesis of combinatorial libraries can be found in A Practical Guide to Combinatorial Chemistry, A.W. Czarnik and S.H. _ς Dewitt , eds., American Chemical Society, 1997; The Combinatorial Index, B.A. Bunin, Academic Press, 1998; Organic Synthesis on Solid Phase, F.Z. Dδrwald, Wiley-VCH, 2000; and Solid-Phase Organic Syntheses, Vol. I, A.W. Czarnik, ed., Wiley Interscience, 2001.

Combinatorial compound libraries of the present invention may be

-_n synthesized using apparatuses described in US Patent No. 6,358,479 to Frisina et al. , U.S. Patent No. 6,190,619 to Kilcoin et al, US Patent No. 6,132,686 to Gallup et al, US Patent No. 6,126,904 to Zuellig et al, US Patent No. 6,074,613 to Harness et al, US Patent No. 6,054,100 to Stanchfield et al, and US Patent No. 5,746,982 to Saneii et al. which are hereby incorporated by reference in their entirety. These patents describe synthesis

- apparatuses capable of holding a plurality of reaction vessels for parallel synthesis of multiple discrete compounds or for combinatorial libraries of compounds. In one embodiment, the combinatorial compound library can be synthesized in solution. The method disclosed in U.S. Patent No. 6,194,612 to Boger et al, which is hereby incorporated by reference in its entirety, features compounds useful as templates for solution phase synthesis of combinatorial libraries. The template is designed to peπnit reaction products to be easily purified from unreacted reactants using liquid/liquid or solid/liquid extractions. The compounds produced by combinatorial synthesis using the template will preferably be small organic molecules. Some compounds in the library may mimic the effects of non-peptides or peptides. In contrast to solid phase synthesize of combinatorial compound libraries, liquid phase synthesis does not require the use of specialized protocols for monitoring the individual steps of a multistep solid phase synthesis (Egner et al, 1995, J.Org. Chem. 60:2652; Anderson et al, 1995, J. Org. Chem. 60:2650; Fitch et al, 1994, J. Org. Chem. 59:7955; Look et al, 1994, J. Org. Chem. 49:7588; Metzger et al, 1993, Angew. Chem., Int. Ed. Engl. 32:894; Youngquist et al, 1994, Rapid Commun. Mass Spect. 8:77; Chu et al, 1995, J. Am. Chem. Soc. 117:5419; Brummel et al, 1994, Science 264:399; Stevanovic et al, 1993, Bioorg. Med. Chem. Lett. 3:431).

Combinatorial compound libraries useful for the methods of the present invention can be synthesized on solid supports. In one embodiment, a split synthesis method, a protocol of separating and mixing solid supports during the synthesis, is used to synthesize a library of compounds on solid supports (see Lam et al, 1997, Chem. Rev. 97:41-448; Ohlmeyer et al, 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926 and references cited therein). Each solid support in the final library has substantially one type of test compound attached to its surface. Other methods for synthesizing combinatorial libraries on solid supports, wherein one product is attached to each support, will be known to those of skill in the art (see, e.g., Nefzi et al, 1997, Chem. Rev. 97:449-472 and US Patent No. 6,087,186 to Cargill et al. which are hereby incorporated by reference in their entirety).

As used herein, the term "solid support" is not limited to a specific type of solid support. Rather a large number of supports are available and are known to one skilled in the art. Solid supports include silica gels, resins, derivatized plastic films, glass beads, cotton, plastic beads, polystyrene beads, alumina gels, and polysaccharides. A suitable solid support may be selected on the basis of desired end use and suitability for various synthetic protocols. For example, for peptide synthesis, a solid support can be a resin such as p- methylbenzhydrylamine (pMBHA) resin (Peptides International, Louisville, KY), polystyrenes (e.g., PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.), including chloromethylpolystyrene, hydroxymethylpolystyrene and aminomethylpolystyrene, poly (dimethylacrylamide)-grafted styrene co-divinyl-benzene (e.g., POLYHIPE resin, obtained from Aminotech, Canada), polyamide resin (obtained from Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (e.g., TENTAGEL or ARGOGEL, Bayer, Tubingen, Germany) polydimethylacrylamide resin (obtained from Milligen/Biosearch, California), or Sepharose (Pharmacia, Sweden). h one embodiment, the solid phase support is suitable for in vivo use, i.e., it can serve as a carrier or support for administration of the test compound to a patient (e.g., TENTAGEL, Bayer, Tubingen, Germany). In a particular embodiment, the solid support is palatable and/or orally ingestable.

In some embodiments of the present invention, compounds can be attached to solid supports via linkers. Linkers can be integral and part of the solid support, or they may be nonintegral that are either synthesized on the solid support or attached thereto after synthesis. Linkers are useful not only for providing points of test compound attachment to the solid support, but also for allowing different groups of molecules to be cleaved from the solid support under different conditions, depending on the nature of the linker. For example, linkers can be, inter alia, electrophilically cleaved, nucleophilically cleaved, photocleavable, enzymatically cleaved, cleaved by metals, cleaved under reductive conditions or cleaved under oxidative conditions.

In another embodiment, the combinatorial compound libraries can be assembled in situ using dynamic combinatorial chemistry as described in European Patent Application 1,118,359 Al to Lehn; Hue & Nguyen, 2001, Comb. Chem. High Throughput. Screen. 4:53-74; Lehn and Eliseev, 2001, Science 291:2331-2332; Cousins etal. 2000, Curr. Opin. Chem. Biol. 4: 270-279; and Karan & Miller, 2000, Drug. Disc. Today 5:67-75 which are incorporated by reference in their entirety.

Dynamic combinatorial chemistry uses non-covalent interaction with a target biomolecule, including but not limited to a protein, RNA, or DNA, to favor assembly of the most tightly binding molecule that is a combination of constituent subunits present as a mixture in the presence of the biomolecule. According to the laws of thermodynamics, when a collection of molecules is able to combine and recombine at equilibrium through reversible chemical reactions in solution, molecules, preferably one molecule, that bind most tightly to a templating biomolecule will be present in greater amount than all other possible combinations. The reversible chemical reactions include, but are not limited to, imine, acyl-hydrazone, amide, acetal, or ester formation between carbonyl-containing compounds and amines, hydrazines, or alcohols; thiol exchange between disulfides; alcohol exchange in borate esters; Diels- Alder reactions; thermal- or photoinduced sigmatropic or electrocyclic rearrangements; or Michael reactions.

In the preferred embodiment of this technique, the constituent components of the dynamic combinatorial compound library are allowed to combine and reach equilibrium in the absence of the target RNA and then incubated in the presence of the target RNA, preferably at physiological conditions, until a second equilibrium is reached. The second, perturbed, equilibrium (the so-called "templated mixture") can, but need not necessarily, be fixed by a further chemical transformation, including but not limited to reduction, oxidation, hydrolysis, acidification, or basification, to prevent restoration of the original equilibrium when the dynamical combinatorial compound library is separated from the target RNA.

In the preferred embodiment of this technique, the predominant product or products of the templated dynamic combinatorial library can separated from the minor products and directly identified. In another embodiment, the identity of the predominant product or products can be identified by a deconvolution strategy involving preparation of derivative dynamic combinatorial libraries, as described in European Patent Application 1,118,359 Al, which is incorporated by reference in their entirety, whereby each component of the mixture is, preferably one-by-one but possibly group-wise, left out of the mixture and the ability of the derivative library mixture at chemical equilibrium to bind the target RNA is measured. The components whose removal most greatly reduces the ability of the derivative dynamic combinatorial library to bind the target RNA are likely the components of the predominant product or products in the original dynamic combinatorial library.

5.4. Library Screening

After a target nucleic acid, such as but not limited to RNA or DNA, is labeled and a test compound library is synthesized or purchased or both, the labeled target nucleic acid is used to screen the library to identify test compounds that bind to the nucleic acid. Screening comprises contacting a labeled target nucleic acid with an individual, or small group, of the components of the compound library. Preferably, the contacting occurs in an aqueous solution, and most preferably, under physiologic conditions. The aqueous solution preferably stabilizes the labeled target nucleic acid and prevents denaturation or degradation of the nucleic acid without interfering with binding of the test compounds. The aqueous solution can be similar to the solution in which a complex between the target RNA and its corresponding host cell factor (if known) is formed in vitr^ao. For example, TK buffer, which is commonly used to form Tat protein-TAR RNA complexes in vitro, can be used in the methods of the invention as an aqueous solution to screen a library of test compounds for TAR RNA binding compounds.

The methods of the present invention for screening a library of test compounds preferably comprise contacting a test compound with a target nucleic acid in the presence of an aqueous solution, the aqueous solution comprising a buffer and a combination of salts, preferably approximating or mimicking physiologic conditions. The aqueous solution optionally further comprises non-specific nucleic acids, such as, but not limited to, DNA; yeast tRNA; salmon sperm DNA; homoribopolymers such as, but not limited to, poly IC, polyA, polyU, and polyC; and non-specific RNA. The non-specific RNA may be an unlabeled target nucleic acid having a mutation at the binding site, which renders the unlabeled nucleic acid incapable of interacting with a test compound at that site. For example, if dye-labeled TAR RNA is used to screen a library, unlabeled TAR RNA having a mutation in the uracil 23/cytosine 24 bulge region may also be present in the aqueous solution. Without being bound by any theory, the addition of unlabeled RNA that is essentially identical to the dye-labeled target RNA except for a mutation at the binding site might minimize interactions of other regions of the dye-labeled target RNA with test compounds or with the solid support and prevent false positive results.

The solution further comprises a buffer, a combination of salts, and optionally, a detergent or a surfactant. The pH of the solution typically ranges from about 5 to about 8, preferably from about 6 to about 8, most preferably from about 6.5 to about 8. A variety of buffers may be used to achieve the desired pH. Suitable buffers include, but are not limited to, Tris, Mes, Bis-Tris, Ada, Aces, Pipes, Mopso, Bis-Tris propane, Bes, Mops, Tes, Hepes, Dipso, Mobs, Tapso, Trizma, Heppso, Popso, TEA, Epps, Tricine, Gly- Gly, Bicine, and sodium-potassium phosphate. The buffering agent comprises from about 10 mM to about 100 mM, preferably from about 25 mM to about 75 mM, most preferably from about 40 mM to about 60 mM buffering agent. The pH of the aqeuous solution can be optimized for different screening reactions, depending on the target RNA used and the types of test compounds in the library, and therefore, the type and amount of the buffer used in the solution can vary from screen to screen. In a preferred embodiment, the aqueous solution has a pH of about 7.4, which can be achieved using about 50 mM Tris buffer.

In addition to an appropriate buffer, the aqueous solution further comprises a combination of salts, from about 0 mM to about 100 mM KCl, from about 0 mM to about 1 M NaCl, and from about 0 mM to about 200 mM MgCl₂. In a preferred embodiment, the combination of salts is about 100 mM KCl, 500 mM NaCl, and 10 mM MgCl₂. Without being bound by any theory, Applicant has found that a combination of KCl, NaCl, and MgCl₂ stabilizes the target RNA such that most of the RNA is not denatured or digested over the course of the screening reaction. The optional concentration of each salt used in the aqueous solution is dependent on the particular target RNA used and can be determined using routine experimentation.

The solution optionally comprises from about 0.01% to about 0.5% (w/v) of a detergent or a surfactant. Without being bound by any theory, a small amount of detergent or surfactant in the solution might reduce non-specific binding of the target RNA to the solid support and control aggregation and increase stability of target RNA molecules. Typical detergents useful in the methods of the present invention include, but are not limited to, anionic detergents, such as salts of deoxycholic acid, 1-heptanesulfonic acid, N- laurylsarcosine, lauryl sulfate, 1 -octane sulfonic acid and taurocholic acid; cationic detergents such as benzalkonium chloride, cetylpyridinium, methylbenzethonium chloride, and decamethonium bromide; zwitterionic detergents such as CHAPS, CHAPSO, alkyl betaines, alkyl amidoalkyl betaines, N-dodecyl-N,N-dimethyl-3-ammonio-l- propanesulfonate, and phosphatidylcholine; and non-ionic detergents such as n-decyl a-D- glucopyranoside, n-decyl β-D-maltopyranoside, n-dodecyl β-D-maltoside, n-octyl β-D- glucopyranoside, sorbitan esters, n-tetradecyl β-D-maltoside, octylphenoxy polyethoxyethanol (Nonidet P-40), nonylphenoxypolyethoxyethanol (NP-40), and tritons. Preferably, the detergent, if present, is a nonionic detergent. Typical surfactants useful in the methods of the present invention include, but are not limited to, ammonium lauryl sulfate, polyethylene glycols, butyl glucoside, decyl glucoside, Polysorbate 80, lauric acid, myristic acid, palmitic acid, potassium palmitate, undecanoic acid, lauryl betaine, and lauryl alcohol. More preferably, the detergent, if present, is Triton X-100 and present in an amount of about 0.1% (w/v).

Non-specific binding of a labeled target nucleic acid to test compounds can be further minimized by treating the binding reaction with one or more blocking agents. In one embodiment, the binding reactions are treated with a blocking agent, e.g., bovine serum albumin ("BSA"), before contacting with to the labeled target nucleic acid. In another embodiment, the binding reactions are treated sequentially with at least two different blocking agents. This blocking step is preferably performed at room temperature for from about 0.5 to about 3 hours. In a subsequent step, the reaction mixture is further treated with unlabeled RNA having a mutation at the binding site. This blocking step is preferably performed at about 4°C for from about 12 hours to about 36 hours before addition of the dye-labeled target RNA. Preferably, the solution used in the one or more blocking steps is substantially similar to the aqueous solution used to screen the library with the dye-labeled target RNA, e.g. , in pH and salt concentration.

Once contacted, the mixture of labeled target nucleic acid and the test compound is preferably maintained at 4°C for from about 1 day to about 5 days, preferably from about 2 days to about 3 days with constant agitation. To identify the reactions in which binding to the labeled target nucleic acid occurred, after the incubation period, bound from free compounds are determined using an electrophoretic technique (see Section 5.5.1), or any of the methods disclosed in Section 5.5 infra. In another embodiment, the complexed target nucleic acid does not need to be separated from the free target nucleic acid if a technique (i.e., spectrometry) that diferentiates between bound and unbound target nucleic acids is used.

The methods for identifying small molecules bound to labeled nucleic acid will vary with the type of label on the target nucleic acid. For example, if a target RNA is labeled with a visible of fluorescent dye, the target RNA complexes are preferably identified using a chromatographic technique that separates bound from free target by an electrophoretic or size differential technique using individual reactions. The reactions corresponding to changes in the migration of the complexed RNA can be cross-referenced to the small molecule compound(s) added to said reaction. Alternatively, complexed target RNA can be screened en masse and then separated from free target RNA using an electrophoretic or size differential technique, the resultant complexed target is then analyzed using a mass spectrometric technique. In this fashion the bound small molecule can be identified on the basis of its molecular weight. In this reaction a priori knowledge of the exact molecular weights of all compounds within the library is known. In another embodiment, the test compounds bound to the target nucleic acid may not require separation from the unbound target nucleic acid if a technique such as, but not limited to, spectrometry is used.

5.5. Separation Methods for Screening Test Compounds

Any method that detects an altered physical property of a target nucleic acid complexed to a test compound from the unbound target nucleic acid may be used for separation of the complexed and non-complexed target nucleic acids. Methods that can be utilized for the physical separation of complexed target RNA from unbound target RNA include, but are not limited to, electrophoresis, fluorescence spectroscopy, surface plasmon resonance, mass spectrometry, scintillation, proximity assay, structure-activity relationships ("SAR") by NMR spectroscopy, size exclusion chromatography, affinity chromatography, and nanoparticle aggregation.

5.5.1. Electrophoresis

Methods for separation of the complex of a target RNA bound to a test compound from the unbound RNA comprises any method of electrophoretic separation, including but not limited to, denaturing and non-denaturing polyacrylamide gel electrophoresis, urea gel electrophoresis, gel filtration, pulsed field gel electrophoresis, two dimensional gel electrophoresis, continuous flow electrophoresis, zone electrophoresis, agarose gel electrophoresis, and capillary electrophoresis.

In a preferred embodiment, an automated electrophoretic system comprising a capillary cartridge having a plurality of capillary tubes is used for high-throughput screening of test compounds bound to target RNA. Such an apparatus for performing automated capillary gel electrophoresis is disclosed in U.S. Patent Nos. 5,885,430; 5,916,428; 6,027,627; and 6,063,251, the disclosures of which are incorporated by reference in their entireties.

The device disclosed in U.S. Patent No. 5,885,430, which is incorporated by reference in its entirety, allows one to simultaneously introduce samples into a plurality of capillary tubes directly from microtiter trays having a standard size. U.S. Patent No. 5,885,430 discloses a disposable capillary cartridge which can be cleaned between electrophoresis runs, the cartridge having a plurality of capillary tubes. A first end of each capillary tube is retained in a mounting plate, the first ends collectively forming an array in the mounting plate. The spacing between the first ends corresponds to the spacing between the centers of the wells of a microtiter tray having a standard size. Thus, the first ends of the capillary tubes can simultaneously be dipped into the samples present in the tray's wells. The cartridge is provided with a second mounting plate in which the second ends of the capillary tubes are retained. The second ends of the capillary tubes are arranged in an array which corresponds to the wells in the microtiter tray, which allows for each capillary tube to be isolated from its neighbors and therefore free from cross-contamination, as each end is dipped into an individual well.

Plate holes may be provided in each mounting plate and the capillary tubes inserted through these plate holes. In such a case, the plate holes are sealed airtight so that the side of the mounting plate having the exposed capillary ends can be pressurized. Application of a positive pressure in the vicinity of the capillary openings in this mounting plate allows for the introduction of air and fluids during electrophoretic operations and also can be used to force out gel and other materials from the capillary tubes during reconditioning. The capillary tubes may be protected from damage using a needle comprising a cannula and/or plastic tubes, and the like when they are placed in these plate holes. When metallic cannula or the like are used, they can serve as electrical contacts for current flow during electrophoresis. In the presence of a second mounting plate, the second mounting plate is provided with plate holes through which the second ends of the capillary tubes project. In this instance, the second mounting plate serves as a pressure containment member of a pressure cell and the second ends of the capillary tubes communicate with an internal cavity of the pressure cell. The pressure cell is also formed with an inlet and an outlet. Gels, buffer solutions, cleaning agents, and the like may be introduced into the internal cavity through the inlet, and each of these can simultaneously enter the second ends of the capillaries.

In another preferred embodiment, the automated electrophoretic system can comprise a chip system consisting of complex designs of interconnected channels that perform and analyze enzyme reactions using part of a channel design as a tiny, continuously operating electrophoresis material, where reactions with one sample are going on in one area of the chip while electrophoretic separation of the products of another sample is taking place in a different part of the chip. Such a system is disclosed in U.S. Patent Nos. 5,699,157; 5,842,787; 5,869,004; 5,876,675; 5,942,443; 5,948,227; 6,042,709; 6,042,710; 6,046,056; 6,048,498; 6,086,740; 6,132,685; 6,150,119; 6,150,180; 6,153,073; 6,167,910; 6,171,850; and 6,186,660, the disclosures of which are incorporated by reference in their entireties.

The system disclosed in U.S. Patent No. 5,699,157, which is hereby incorporated by reference in its entirety, provides for a microfluidic system for high-speed electrophoretic analysis of subject materials for applications in the fields of chemistry, biochemistry, biotechnology, molecular biology and numerous other areas. The system has a channel in a substrate, a light source and a photoreceptor. The channel holds subject materials in solution in an electric field so that the materials move through the channel and separate into bands according to species. The light source excites fluorescent light in the species bands and the photoreceptor is arranged to receive the fluorescent light from the bands. The system further has a means for masking the channel so that the photoreceptor can receive the fluorescent light only at periodically spaced regions along the channel. The system also has an unit connected to analyze the modulation frequencies of light intensity received by the photoreceptor so that velocities of the bands along the channel are determined, which allows the materials to be analyzed.

The system disclosed in U.S. Patent No. 5,699,157 also provides for a method of performing high-speed electrophoretic analysis of subject materials, which comprises the steps of holding the subject materials in solution in a channel of a microfluidic system; subjecting the materials to an electric field so that the subject materials move through the channel and separate into species bands; directing light toward the channel; receiving light from periodically spaced regions along the channel simultaneously; and analyzing the frequencies of light intensity of the received light so that velocities of the bands along the channel can be determined for analysis of said materials. The determination of the velocity of a species band determines the electrophoretic mobility of the species and its identification.

U.S. Patent No. 5,842,787, which is hereby incorporated by reference in its entirety, is generally directed to devices and systems employ channels having, at least in part, depths that are varied over those which have been previously described (such as the device disclosed in U.S. Patent No. 5,699,157), wherein said channel depths provide numerous beneficial and unexpected results such as but not limited to, a reduction in sample perturbation, reduced non-specific sample mixture by diffusion, and increased resolution.

In another embodiment, the electrophoretic method of separation comprises polyacrylamide gel electrophoresis. In a preferred embodiment, the polyacrylamide gel electrophoresis is non-denaturing, so as to differentiate the mobilities of the target RNA bound to a test compound from free target RNA. If the polyacrylamide gel electrophoresis is denaturing, then the target RNA:test compound complex must be cross-linked prior to electrophoresis to prevent the disassociation of the target RNA from the test compound during electrophoresis. Such techniques are well known to one of skill in the art.

In one embodiment of the method, the binding of test compounds to target nucleic acid can be detected, preferably in an automated fashion, by gel electrophoretic analysis of interference footprinting. RNA can be degraded at specific base sites by enzymatic methods such as ribonucleases A, U₂, CL₃, T_l5 Phy M, and B. cereus or chemical methods such as diethylpyrocarbonate, sodium hydroxide, hydrazine, piperidine formate, dimethyl sulfate,

[2,12-dimethyl-3,7,l l,17-tetraazacyclo[l 1.3.1]heρtadeca-l(17),2,l 1,13,15-pentaenato] nickel(II) (NiCR), cobalt(II)chloride, or iron(II) ethylenediaminetetraacetate (Fe-EDTA) as described for example in Zheng et al, 1999, Biochem. 37:2207-2214; Latham & Cech, 1989, Science 245:276-282; and Sambrook et al, 2001, in Molecular Cloning: A Laboratory Manual, pp 12.61-12.73, Cold Spring Harbor Laboratory Press, and the references cited therein, which are hereby incorporated by reference in their entireties. The specific pattern of cleavage sites is determined by the accessibility of particular bases to the reagent employed to initiate cleavage and, as such, is therefore is determined by the three-dimensional structure of the RNA.

The interaction of small molecules with a target nucleic acid can change the accessibility of bases to these cleavage reagents both by causing conformational changes in the target nucleic acid or by covering a base at the binding interface. When a test compound binds to the nucleic acid and changes the accessibility of bases to cleavage reagents, the observed cleavage pattern will change. This method can be used to identify and characterize the binding of small molecules to RNA as described, for example, by Prudent et al, 1995, J. Am. Chem. Soc. 117:10145-10146 and Mei et al, 1998, Biochem. 37:14204-14212.

In the preferred embodiment of this technique, the detectably labeled target nucleic acid is incubated with an individual test compound and then subjected to treatment with a cleavage reagent, either enzymatic or chemical. The reaction mixture can be preferably be examined directly, or treated further to isolate and concentrate the nucleic acid. The fragments produced are separated by electrophoresis and the pattern of cleavage can be compared to a cleavage reaction performed in the absence of test compound. A change in the cleavage pattern directly indicates that the test compound binds to the target nucleic acid. Multiple test compounds can be examined both in parallel and serially.

Other embodiments of electrophoretic separation include, but are not limited to urea gel electrophoresis, gel filtration, pulsed field gel electrophoresis, two dimensional gel electrophoresis, continuous flow electrophoresis, zone electrophoresis, and agarose gel electrophoresis.

5.5.2. Fluorescence Spectroscopy

In a preferred embodiment, fluorescence polarization spectroscopy, an optical detection method that can differentiate the proportion of a fluorescent molecule that is either bound or unbound in solution (e.g., the labeled target nucleic acid of the present invention), can be used to read reaction results without electrophoretic separation of the samples. Fluorescence polarization spectroscopy can be used to read the reaction results in the chip system disclosed in U.S. Patent Nos. 5,699,157; 5,842,787; 5,869,004; 5,876,675; 5,942,443; 5,948,227; 6,042,709; 6,042,710; 6,046,056; 6,048,498; 6,086,740; 6,132,685; 6,150,119; 6,150,180; 6,153,073; 6,167,910; 6,171,850; and 6,186,660, the disclosures of which are incorporated by reference in their entireties. The application of fluorescence polarization spectroscopy to the chip system disclosed in the U.S. Patents listed supra is fast, efficient, and well-adapted for high-throughput screening.

In another embodiment, a compound that has an affinity for the target nucleic acid of interest can be labeled with a fluorophore to screen for test compounds that bind to the target nucleic acid. For example, a pyrene-containing aminoglycoside analog was used to accurately monitor antagonist binding to a prokaryotic 16S rRNA A site (which comprises the natural target for aminoglycoside antibiotics) in a screen using a fluorescence quenching technique in a 96-well plate format (Hamasaki & Rando, 1998, Anal. Biochem. 261(2): 183-90).

In another embodiment, fluorescence resonance energy transfer (FRET) can be used to screen for test compounds that bind to the target nucleic acid. FRET, a characteristic change in fluorescence, occurs when two fluorophores with overlapping emission and excitation wavelength bands are held together in close proximity, such as by a binding event. In the preferred embodiment, the fluorophore on the target nucleic acid and the fluorophore on the test compounds will have overlapping excitation and emission spectra such that one fluorophore (the donor) transfers its emission energy to excite the other fluorophore (the acceptor). The acceptor preferably emits light of a different wavelength upon relaxing to the ground state, or relaxes non-radiatively to quench fluorescence. FRET is very sensitive to the distance between the two fluorophores, and allows measurement of molecular distances less than 10 nm. For example, U.S, Patent 6,337,183 to Arenas et al, which is incorporated by reference in its entirety, describes a screen for compounds that bind RNA that uses FRET to measure the effect of test compounds on the stability of a target RNA molecule where the target RNA is labeled with both fluorescent acceptor and donor molecules and the distance between the two fluorophores as determined by FRET provides a measure of the folded structure of the RNA. Matsumoto et al. (2000, Bioorg. Med. Chem. Lett. 10:1857-1861) describe a system where a peptide that binds to HIV-l TAR RNA is labeled on one end with a fluorescein fluorophore and a tetramethylrhodamine on the other end. The conformational change of the peptide upon binding to the RNA provided a FRET signal to screen for compounds that bound to the TAR RNA.

In the preferred embodiment, both the target nucleic acid and a compound that has an affinity for the target nucleic acid of interest are labeled with fluorophores with overlapping emission and excitation spectra (donor and acceptor), including but not limited to fluorescein and derivatives, rhodamine and derivatives, cyanine dyes and derivatives, bora-3a,4a-diaza-s-indacene (BODIPY®) and derivatives, pyrene, nanoparticles, or non-fluorescent quenching molecules. Binding of a labeled test compound to the target nucleic acid can be identified by the change in observable fluorescence as a result of FRET.

If the target nucleic acid is labeled with the donor fluorophore, then the test compounds is labeled with the acceptor fluorophore. Conversely, if the target nucleic acid is labeled with the acceptor fluorophore, then the test compounds is labeled with the donor fluorophore. A wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions. The fluorophore on the target nucleic acid must be in close proximity to the binding site of the test compounds, but should not be incorporated into a target nucleic acid at the specific binding site at which test compounds are likely to bind, since the presence of a covalently attached label might interfere sterically or chemically with the binding of the test compounds at this site.

In yet another embodiment, homogeneous time-resolved fluorescence ("HTRF") techniques based on time-resolved energy transfer from lanthanide ion complexes to a suitable acceptor species can be adapted for high-throughput screening for inhibitors of RNA-protein complexes (Hemmila, 1999, J. Biomol. Screening 4:303-307; Mathis, 1999, J. Biomol. Screening 4:309-313). HTRF is similar to fluorescence resonance energy transfer using conventional organic dye pairs, but has several advantages, such as increased sensitivity and efficiency, and background elimination (Xavier et al, 2000, Trends Biotechnol. 18(8):349-356).

Fluorescence spectroscopy has traditionally been used to characterize DNA- protein and protein-protein interactions, but fluorescence spectroscopy has not been widely used to characterize RNA-protein interactions because of an interfering absorption of RNA nucleotides with the intrinsic tryptophan fluorescence of proteins (Xavier et al, 2000, Trends Biotechnol. 18(8):349-356.). However, fluorescence spectroscopy has been used in studying the single tryptophan residue within the arginine-rich RNA-binding domain of Rev protein and its interaction with the RRE in a time-resolved fluorescence study (Kwon & Carson, 1998, Anal. Biochem. 264:133-140). Thus, in this invention, fluorescence spectroscopy is less preferred if the test compounds or peptides or proteins possess intrinsic tryptophan fluorescence. However, fluorescence spectroscopy can be used for test compounds that do not possess intrinsic fluorescence.

5.5.3. Surface Plasmon Resonance ("SPR" ,

Surface plasmon resonance (SPR) can be used for determining kinetic rate constants and equilibrium constants for macromolecular interactions by following the association project in "real time" (Schuck, 1997, Annu. Rev. Biophys. Biomol. Struct. 26:541-566).

The principle of SPR is summarized by Xavier et al. (Trends Biotechnol., 2000, 18(8):349-356) as follows. Total internal reflection occurs at the boundary between two substances of different refractive index. The incident light's electromagnetic field penetrates beyond the interface as an evanescent wave, which extends a few hundred nanometers beyond the surface into the medium. Insertion of a thin gold foil at the interace produced SPR owing to the absorption of the energy from the evanescent wave by free electron clouds of the metal (plasmons). As a result of this absorbance, there is a drop in the intensity of the reflected light at a particular angle of incidence. The evanescent wave profile depends exquisitely on the refractive index of the medium it probes. Thus, the angle at which absorption occurs is very sensitive to the refractive changes in the external medium. All proteins and nucleic acids are known to change the refractive index of water by a similar amount per unit mass, irrespective of their amino acid or nucleotide composition (the refractive index change is different for proteins and nucleic acids). When the protein or nucleic acid content of the layer at the sensor changes, the refractive index also changes. Typically, one member of a complex is immobilized in a dextran layer and then the other member is introduced into the solution, either in a flow cell (Biacore AB, Uppsala, Sweden) or a stirred cuvette (Affinity Sensors, Santa Fe, New Mexico). It has been determined that there is a linear correlation between the surface concentration of protein or nucleic acid and the shift in resonance angle, which can be used to quantitate kinetic rate constants and/or the equilibrium constants.

In the present invention, the target RNA may be immobilized to the sensor surface through a streptavidin-biotin linkage, the linkage of which is disclosed by Crouch et al. (Methods Mol. Biol, 1999, 118:143-160). The RNA is biotinylated either during synthesis or post-synthetically via the conversion of the 3' terminal ribonucleoside of the RNA into a reactive free amino group or using a T7 polymerase incorporated guanosine monophosphorothioate at the 5' end. SPR has been used to determine the stoichiometry and affinity of the interaction between the HIV Rev protein and the RRE (Van Ryk & Venkatesan, 1999, J. Biol. Chem. 274:17452-17463) and the aminoglycoside antibiotics with RRE and a model RNA derived from the 16S ribosomal A site, respectively (Hendrix et al, 1997, J. Am. Chem. Soc. 119:3641-3648; Wong et al, 1998, Chem. Biol. 5:397- 406).

In one embodiment of the present invention, the target nucleic acid can be immobilized to a sensor surface (e.g., by a streptavidin-biotin linkage) and SPR can be used to (a) determine whether the target RNA binds a test compound and (b) further characterize the binding of the target nucleic acids of the present invention to a test compound.

5.5.4. Mass Spectrometry

An automated method for analyzing mass spectrometer data which can analyze complex mixtures containing many thousands of components and can correct for background noise, multiply charged peaks and atomic isotope peaks is described in U.S. Patent No. 6,147,344, which is hereby incorporated by reference in its entirety. The system disclosed in U.S. Patent No. 6,147,344 is a method for analyzing mass spectrometer data in which a control sample measurement is performed providing a background noise check. The peak height and width values at each m/z ratio as a function of time are stored in a memory. A mass spectrometer operation on a material to be analyzed is performed and the peak height and width values at each m/z ratio versus time are stored in a second memory location. The mass spectrometer operation on the material to be analyzed is repeated a fixed number of times and the stored control sample values at each m/z ratio level at each time increment are subtracted from each corresponding one from the operational runs, thus producing a difference value at each mass ratio for each of the multiple runs at each time increment. If the MS value minus the background noise does not exceed a preset value, the m/z ratio data point is not recorded, thus eliminating background noise, chemical noise and false positive peaks from the mass spectrometer data. The stored data for each of the multiple runs is then compared to a predetermined value at each m/z ratio and the resultant series of peaks, which are now determined to be above the background, is stored in the m/z points in which the peaks are of significance.

One possibility for the utilization of mass spectrometry in high throughput screening is the integration of SPR with mass spectrometry. Approaches that have been tried are direct analysis of the analyte retained on the sensor chip and mass spectrometry with the eluted analyte (Sonksen et al, 1998, Anal. Chem. 70:2731-2736; Nelson & Krone,

1999, J. Mol. Recog. 12:77-93). Further developments, especially in the interfacing of the sensor chip with the mass spectrometer and in reusing the sensor chip, are required to make SPR combined with mass spectroscopy a high-throughput method for biomolecular interaction analysis and the screening of targets for small molecule inhibitors (Xavier et al,

2000, Trends Biotechnol. 18(8):349-356).

In one embodiment of the present invention, the target nucleic acid complexed to a test compound can be determined by any of the mass spectrometry processed described supra. Furthermore, mass spectrometry can also be used to elucidate the structure of the test compound.

5.5.5. Scintillation Proximity Assay ("SPA")

Scintillation Proximity Assay ("SPA") is a method that can be used for screening small molecules that bind to the target RNAs. SPA would involve radiolabeling either the target RNA or the test compound and then quantitating its binding to the other member to a bead or a surface impregnated with a scintillant (Cook, 1996, Drug Discov. Today 1 :287-294). Currently, fluorescence-based techniques are preferred for high- throughput screening (Pope et al, 1999, Drug Discov. Today 4:350-362).

Screening for small molecules that inhibit Tat peptide:TAR RNA interaction has been performed with SPA, and inhibitors of the interaction were isolated and characterized (Mei et al, 1991, Bioorg. Med. Chem. 5:1173-1184; Mei et al, 1998, Biochemistry 37:14204-14212). A similar approach can be used to identify small molecules that directly bind to a preselected target RNA element in accordance with the invention can be utilized.

SPA can be adapted to high throughput screening by the availability of microplates, wherein the scintillant is directly incorporated into the plastic of the microtiter wells (Nakayama et al, 1998, J. Biomol. Screening 3:43-48). Thus, one embodiment of the present invention comprises (a) labeling of the target nucleic acid with a radioactive or fluorescent label; (b) contacted the labeled nucleic acid with test compounds, wherein each test compound is in a microtiter well coated with scintillant and is tethered to the microtiter well; and (c) identifying and quantifying the test compounds bound to the target nucleic acid with SPA, wherein the test compound is identified by virtue of its location in the microplate.

5.5.6. Structure-Activity Relationships ("SAR") by NMR Spectroscopy

NMR spectroscopy is a valuable technique for identifying complexed target nucleic acids by qualitatively determining changes in chemical shift, specifically from distances measured using relaxation effects, and NMR-based approaches have been used in the identification of small molecule binders of protein drug targets (Xavier et al, 2000, Trends Biotechnol. 18(8):349-356). The determination of structure-activity relationships ("SAR") by NMR is the first method for NMR described in which small molecules that bind adjacent subsites are identified by two-dimentional Η-^N spectra of the target protein (Shuker et al, 1996, Science 274:1531-1534). The signal from the bound molecule is monitored by employing line broadening, transferred NOEs and pulsed field gradient diffusion measurements (Moore, 1999, Curr. Opin. Biotechnol. 10:54-58). A strategy for lead generation by NMR using a library of small molecules has been recently described (Fejzo et al, 1999, Chem. Biol. 6:755-769).

In one embodiment of the present invention, the target nucleic acid complexed to a test compound can be determined by SAR by NMR. Furthermore, SAR by NMR can also be used to elucidate the structure of the test compound.

5.5.7. Size Exclusion Chromatography

In another embodiment of the present invention, size-exclusion chromatography is used to purify test compounds that are bound to a target nucleic from a complex mixture of compounds. Size-exclusion chromatography separates molecules based on their size and uses gel-based media comprised of beads with specific size distributions. When applied to a column, this media settles into a tightly packed matrix and forms a complex array of pores. Separation is accomplished by the inclusion or exclusion of molecules by these pores based on molecular size. Small molecules are included into the pores and, consequently, their migration through the matrix is retarded due to the added distance they must travel before elution. Large molecules are excluded from the pores and migrate with the void volume when applied to the matrix. In the present invention, a target nucleic acid is incubated with a mixture of test compounds while free in solution and allowed to reach equilibrium. When applied to a size exclusion column, test compounds free in solution are retained by the column, and test compounds bound to the target nucleic acid are passed through the column. In a preferred embodiment, spin columns commonly used for "desalting" of nucleic acids will be employed to separate bound from unbound test compounds (e.g., Bio-Spin columns manufactured by BIO-RAD). In another embodiment, the size exclusion matrix is packed into multiwell plates to allow high throughput separation of mixtures (e.g., PLASMID 96-well SEC plates manufactured by Millipore).

5.5.8. Affinity Chromatography

In one embodiment of the present invention, affinity capture is used to purify test compounds that are bound to a target nucleic acid labeled with an affinity tag from a complex mixture of compounds. To accomplish this, a target nucleic acid labeled with an affinity tag is incubated with a mixture of test compounds while free in solution and then captured to a solid support once equilibrium has been established; alternatively, target nucleic acids labeled with an affinity tag can be captured to a solid support first and then allowed to reach equilibrium with a mixture of test compounds. The solid support is typically comprised of, but not limited to, cross-linked agarose beads that are coupled with a ligand for the affinity tag. Alternatively, the solid support may be a glass, silicon, metal, or carbon, plastic (polystyrene, polypropylene) surface with or without a self-assembled monolayer (SAM) either with a covalently attached ligand for the affinity tag, or with inherent affinity for the tag on the target nucleic acid.

Once the complex between the target nucleic acid and test compound has reached equilibrium and has been captured, one skilled in the art will appreciate that the retention of bound compounds and removal of unbound compounds is facilitated by washing the solid support with large excesses of binding reaction buffer. Furthermore, retention of high affinity compounds and removal of low affinity compounds can be accomplished by a number of means that increase the stringency of washing; these means include, but are not limited to, increasing the number and duration of washes, raising the salt concentration of the wash buffer, addition of detergent or surfactant to the wash buffer, and addition of non-specific competitor to the wash buffer.

In one embodiment, the test compounds themselves are detectably labeled with fluorescent dyes, radioactive isotopes, or nanoparticles. When the test compounds are applied to the captured target nucleic acid in a spatially addressed fashion (e.g., in separate wells of a 96-well microplate), binding between the test compounds and the target nucleic acid can be determined by the presence of the detectable label on the test compound using fluorescence.

Following the removal of unbound compounds, bound compounds with high affinity for the target nucleic acid can be eluted from the immobilized target nucleic acids and analyzed. The elution of test compounds can be accomplished by any means that break the non-covalent interactions between the target nucleic acid and compound. Means for elution include, but are not limited to, changing the pH, changing the salt concentration, the application of organic solvents, and the application of molecules that compete with the bound ligand. In a preferred embodiment, the means employed for elution will release the compound from the target RNA, but will not effect the interaction between the affinity tag and the solid support, thereby achieving selective elution of test compound. Moreover, a preferred embodiment will employ an elution buffer that is volatile to allow for subsequent concentration by lyophilization of the eluted compound (e.g., 0 M to 5 M ammonium acetate). 5.5.9. Nanoparticle Aggregation

In one embodiment of the present invention, both the target nucleic acid and the test compounds are labeled with nanoparticles. A nanoparticle is a cluster of ions with controlled size from 0.1 to 1000 nm comprised of metals, metal oxides, or semiconductors including, but not limited to Ag₂S, ZnS, CdS, CdTe, Au, or TiO₂. Methods for the attachment of nucleic acids and small molecules to nanoparticles are well know to one of skill in the art (reviewed in Niemeyer, 2001, Angew. Chem. Int. Ed. 40:4129-4158. The references cited therein are hereby incorporated by reference in their entireties). In particular, if multiple copies of the target nucleic acid are attached to a single nanoparticle and multiple copies of a test compound are attached to another nanoparticle, then interaction between the test compound and target nucleic acid will induce aggregation of nanoparticles as described, for example, by Mitchel et al. 1999, J. Am. Chem. Soc. 121 : 8122-8123. The aggregate can be detected by changes in absorbance or fluorescence spectra and physically separated from the unbound components through filtration or centrifugation.

5.6. Methods for Identifying or Characterizing the Test Compounds Bound to the Target Nucleic Acids

If the library comprises arrays or microarrays of test compounds, wherein each test compound has an address or identifier, the test compound can be deconvoluted, e.g., by cross-referencing the positive sample to original compound list that was applied to the individual test assays.

If the library is a peptide or nucleic acid library, the sequence of the test compound can be determined by direct sequencing of the peptide or nucleic acid. Such methods are well known to one of skill in the art.

A number of physico-chemical techniques can be used for the de novo characterization of test compounds bound to the target.

5.6.1. Mass Spectrometry

Mass spectrometry (e.g., electrospray ionization ("ESI") and matrix-assisted laser desorption-ionization ("MALDI"), Fourier-transform ion cyclotron resonance ("FT- ICR")) can be used both for high-throughput screening of test compounds that bind to a target RNA and elucidating the structure of the test compound. Thus, one example of mass spectroscopy is that separation of a bound and unbound complex and test compound structure elucidation can be carried out in a single step. MALDI uses a pulsed laser for desorption of the ions and a time-of-flight analyzer, and has been used for the detection of noncovalent tRNA:amino-acyl-tRNA synthetase complexes (Gruic-Sovulj et al, 1997, J. Biol. Chem. 272:32084-32091). However, covalent cross-linking between the target nucleic acid and the test compound is required for detection, since a non-covalently bound complex may dissociate during the MALDI process.

ESI mass spectrometry ("ESI-MS") has been of greater utility for studying non-covalent molecular interactions because, unlike the MALDI process, ESI-MS generates molecular ions with little to no fragmentation (Xavier et al, 2000, Trends Biotechnol. 18(8):349-356). ESI-MS has been used to study the complexes formed by HIV Tat peptide and protein with the TAR RNA (Sannes-Lowery et al, 1997, Anal. Chem. 69:5130-5135).

Fourier-transform ion cyclotron resonance ("FT-ICR") mass spectrometry provides high-resolution spectra, isotope-resolved precursor ion selection, and accurate mass assignments (Xavier et al, 2000, Trends Biotechnol. 18(8):349-356). FT-ICR has been used to study the interaction of aminoglycoside antibiotics with cognate and non- cognate RNAs (Hofstadler et al, 1999, Anal. Chem. 71:3436-3440; Griffey et al, 1999, Proc. Natl. Acad. Sci. USA 96:10129-10133). As true for all of the mass spectrometry methods discussed herein, FT-ICR does not require labeling of the target RNA or a test compound.

An advantage of mass spectroscopy is not only the elucidation of the structure of the test compound, but also the determination of the structure of the test compound bound to the preselected target RNA. Such information can enable the discovery of a consensus structure of a test compound that specifically binds to a preselected target RNA.

5.6.2. NMR Spectroscopy

As described above, NMR spectroscopy is a technique for identifying binding sites in target nucleic acids by qualitatively determining changes in chemical shift, specifically from distances measured using relaxation effects. Examples of NMR that can be used for the invention include, but are not limited to, one-dimentional NMR, two- dimentional NMR, correlation spectroscopy ("COSY"), and nuclear Overhauser effect ("NOE") spectroscopy. Such methods of structure determination of test compounds are well known to one of skill in the art.

Similar to mass spectroscopy, an advantage of NMR is the not only the elucidation of the structure of the test compound, but also the determination of the structure of the test compound bound to the preselected target RNA. Such information can enable the discovery of a consensus structure of a test compound that specifically binds to a preselected target RNA.

5.6.3. Vibrational Spectroscopy

Vibrational spectroscopy (e.g. infrared (IR) spectroscopy or Raman spectroscopy) can be used for elucidating the structure of the test compound on the isolated bead.

Infrared spectroscopy measures the frequencies of infrared light (wavelengths from 100 to 10,000 nm) absorbed by the test compound as a result of excitation of vibrational modes according to quantum mechanical selection rules which require that absorption of light cause a change in the electric dipole moment of the molecule. The infrared spectrum of any molecule is a unique pattern of absorption wavelengths of varying intensity that can be considered as a molecular fingerprint to identify any compound.

Infrared spectra can be measured in a scanning mode by measuring the absorption of individual frequencies of light, produced by a grating which separates frequencies from a mixed-frequency infrared light source, by the test compound relative to a standard intensity (double-beam instrument) or pre-measured ('blank') intensity (single-beam instrument). In a preferred embodiment, infrared spectra are measured in a pulsed mode (FT-IR) where a mixed beam, produced by an interferometer, of all infrared light frequencies is passed through or reflected off the test compound. The resulting interferogram, which may or may not be added with the resulting interferograms from subsequent pulses to increase the signal strength while averaging random noise in the electronic signal, is mathematically transformed into a spectrum using Fourier Transform or Fast Fourier Transform algorithms.

Raman spectroscopy measures the difference in frequency due to absorption of infrared frequencies of scattered visible or ultraviolet light relative to the incident beam. The incident monochromatic light beam, usually a single laser frequency, is not truly absorbed by the test compound but interacts with the electric field transiently. Most of the light scattered off the sample with be unchanged (Rayleigh scattering) but a portion of the scatter light will have frequencies that are the sum or difference of the incident and molecular vibrational frequencies. The selection rules for Raman (inelastic) scattering require a change in polarizability of the molecule. While some vibrational transitions are observable in both infrared and Raman spectrometry, must are observable only with one or the other technique. The Raman spectrum of any molecule is a unique pattern of absorption wavelengths of varying intensity that can be considered as a molecular fingerprint to identify any compound.

Raman spectra are measured by submitting monochromatic light to the sample, either passed through or preferably reflected off, filtering the Rayleigh scattered light, and detecting the frequency of the Raman scattered light. An improved Raman spectrometer is described in US Patent No. 5,786,893 to Fink et al, which is hereby incorporated by reference.

Vibrational microscopy can be measured in a spatially resolved fashion to address single beads by integration of a visible microscope and spectrometer. A microscopic infrared spectrometer is described in U.S. Patent No. 5,581,085 to Refiner et al. , which is hereby incorporated by reference in its entirety. An instrument that simultaneously performs a microscopic infrared and microscopic Raman analysis on a sample is described in U.S. Patent No. 5,841,139 to Sostek et al, which is hereby incorporated by reference in its entirety.

In the preferred embodiment, test compounds can be identified by matching the IR or Raman spectra of a test compound to a dataset of vibrational (IR or Raman) spectra previously acquired for each compound in the combinatorial library. By this method, the spectra of compounds with known structure are recorded so that comparison with these spectra can identify compounds again when isolated from RNA binding experiments.

5.7. Secondary Biological Screens

The test compounds identified in the binding assay (for convenience referred to herein as a "lead" compound) can be tested for biological activity using host cells containing or engineered to contain the target RNA element coupled to a functional readout system. For example, the lead compound can be tested in a host cell engineered to contain the target RNA element controlling the expression of a reporter gene. In this example, the lead compounds are assayed in the presence or absence of the target RNA. Alternatively, a phenotypic or physiological readout can be used to assess activity of the target RNA in the presence and absence of the lead compound.

In one embodiment, the lead compound can be tested in a host cell engineered to contain the target RNA element controlling the expression of a reporter gene, such as, but not limited to, β-galactosidase, green fluorescent protein, red fluorescent protein, luciferase, chloramphenicol acetyltransferase, alkaline phosphatase, and β- lactamase. In a preferred embodiment, a cDNA encoding the target element is fused upstream to a reporter gene wherein translation of the reporter gene is repressed upon binding of the lead compound to the target RNA. In other words, the steric hindrance caused by the binding of the lead compound to the target RNA repressed the translation of the reporter gene. This method, termed the translational repression assay procedure ("TRAP") has been demonstrated in E. coli and S. cerevisiae (Jain & Belasco, 1996, Cell 87(1): 115-25; Huang & Schreiber, 1997, Proc. Natl. Acad. Sci. USA 94:13396-13401).

In another embodiment, a phenotypic or physiological readout can be used to assess activity of the target RNA in the presence and absence of the lead compound. For example, the target RNA may be overexpressed in a cell in which the target RNA is endogenously expressed. Where the target RNA controls expression of a gene product involved in cell growth or viability, the in vivo effect of the lead compound can be assayed by measuring the cell growth or viability of the target cell. Alternatively, a reporter gene can also be fused downstream of the target RNA sequence and the effect of the lead compound on reporter gene expression can be assayed.

Alternatively, the lead compounds identified in the binding assay can be tested for biological activity using animal models for a disease, condition, or syndrome of interest. These include animals engineered to contain the target RNA element coupled to a functional readout system, such as a transgenic mouse. Animal model systems can also be used to demonstrate safety and efficacy.

Compounds displaying the desired biological activity can be considered to be lead compounds, and will be used in the design of congeners or analogs possessing useful pharmacological activity and physiological profiles. Following the identification of a lead compound, molecular modeling techniques can be employed, which have proven to be useful in conjunction with synthetic efforts, to design variants of the lead that can be more effective. These applications may include, but are not limited to, Pharmacophore Modeling (cf Lamothe, et al.1997, J. Med. Chem. 40: 3542; Mottola et al. 1996, J. Med. Chem. 39: 285; Beusen etal. 1995, Biopolymers 36: 181; P. Fossa et al. 1998, Comput. Aided Mol. Des. 12: 361), QSAR development (cf. Siddiqui et al. 1999, J. Med. Chem. 42: 4122; Barreca et al. 1999 Bioorg. Med. Chem. 7: 2283; Kroemer et al. 1995, J. Med. Chem. 38: 4917; Schaal et al. 2001, J. Med. Chem. 44: 155; Buolamwini & Assefa 2002, J. Mol. Chem. 45: 84), Virtual docking and screening/scoring (cf. Anzini et al. 2001, J. Med. Chem. 44: 1134; Faaland et al. 2000, Biochem. Cell. Biol. 78: 415; Silvestri et al 2000, Bioorg. Med. Chem. 8: 2305; J. Lee et al. 2001, Bioorg. Med. Chem. 9: 19), and Structure Prediction using RNA structural programs including, but not limited to mFold (as described by Zuker et al. Algorithms and Thermodynamics for RNA Secondary Structure Prediction: A Practical Guide in RNA Biochemistry and Biotechnology pp. 11-43, J. Barciszewski & B.F.C. Clark, eds. (NATO ASI Series, Kluwer Academic Publishers, 1999) and Mathews et al. 1999 J. Mol. Biol. 288: 911-940); RNAmotif (Macke et al 2001, Nucleic Acids Res. 29: 4724-4735; and the Vienna RNA package (Hofacker et al. 1994, Monatsh. Chem. 125: 167-188).

Further examples of the application of such techniques can be found in several review articles, such as Rotivinen et al, 1988, Acta Pharmaceutical Fennica 97:159-166; Ripka, 1998, New Scientist 54-57; McKinaly & Rossmann, 1989, Annu. Rev. Pharmacol. Toxiciol. 29:111-122; Perry & Davies, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989); Lewis & Dean, 1989, Proc. R. Soc. Lond. 236:125-140 and 141-162; Askew et al, 1989, J. Am. Chem. Soc. I l l : 1082-1090. Molecular modeling tools employed may include those from Tripos, Inc., St. Louis, Missouri (e.g., Sybyl/UNITY, CONCORD, DiverseSolutions), Accelerys, San Diego, California (e.g., Catalyst, Wisconsin Package {BLAST, etc.}), Schrodinger, Portland, Oregon (e.g., QikProp, QikFit, Jaguar) or other such vendors as BioDesign, Inc. (Pasadena, California), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario, Canada), and may include privately designed and/or "academic" software (e.g. RNAMotif, mFOLD). These application suites and programs include tools for the atomistic construction and analysis of structural models for drug-like molecules, proteins, and DNA or RNA and their potential interactions. They also provide for the calculation of important physical properties, such as solubility estimates, permeability metrics, and empirical measures of molecular "draggability" (e.g., Lipinski "Rule of 5" as described by Lipinski et al. 1997, Adv. Drug Delivery Rev. 23: 3-25). Most importantly, they provide appropriate metrics and statistical modeling power (such as the patented CoMFA technology in Sybyl as described in US Patents 6,240,374 and 6,185,506) to develop Quantitative Structural Activity Relationships (QSARs) which are used to guide the synthesis of more efficacious clinical development candidates while improving desirable physical properties, as determined by results from the aforementioned secondary screening protocols.

5.8. Use of Identified Compounds That Bind RNA to Treat/Prevent Disease

Biologically active compounds identified using the methods of the invention or a pharmaceutically acceptable salt thereof can be administered to a patient, preferably a mammal, more preferably a human, suffering from a disease whose progression is associated with a target RNA:host cell factor interaction in vivo. In certain embodiments, such compounds or a pharmaceutically acceptable salt thereof is administered to a patient, preferably a mammal, more preferably a human, as a preventative measure against a disease associated with an RNA:host cell factor interaction in vivo.

In one embodiment, "treatment" or "treating" refers to an amelioration of a disease, or at least one discernible symptom thereof. In another embodiment, "treatment" or "treating" refers to an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient. In yet another embodiment, "treatment" or "treating" refers to inhibiting the progression of a disease, either physically, e.g., stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both. In yet another embodiment, "treatment" or "treating" refers to delaying the onset of a disease.

In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered to a patient, preferably a mammal, more preferably a human, as a preventative measure against a disease associated with an RNA:host cell factor interaction in vivo. As used herein, "prevention" or "preventing" refers to a reduction of the risk of acquiring a disease. In one embodiment, the compound or a pharmaceutically acceptable salt thereof is administered as a preventative measure to a patient. According to this embodiment, the patient can have a genetic predisposition to a disease, such as a family history of the disease, or a non-genetic predisposition to the disease. Accordingly, the compound and pharmaceutically acceptable salts thereof can be used for the treatment of one manifestation of a disease and prevention of another.

When administered to a patient, the compound or a pharmaceutically acceptable salt thereof is preferably administered as component of a composition that optionally comprises a pharmaceutically acceptable vehicle. The composition can be administered orally, or by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa, etc.) and may be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer the compound and pharmaceutically acceptable salts thereof.

Methods of administration include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the practitioner. In most instances, administration will result in the release of the compound or a pharmaceutically acceptable salt thereof into the bloodstream. hi specific embodiments, it may be desirable to administer the compound or a pharmaceutically acceptable salt thereof locally. This may be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non- porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

In certain embodiments, it may be desirable to introduce the compound or a pharmaceutically acceptable salt thereof into the central nervous system by any suitable route, including intraventricular, intrathecal and epidural injection. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the compound and pharmaceutically acceptable salts thereof can be formulated as a suppository, with traditional binders and vehicles such as triglycerides.

In another embodiment, the compound and pharmaceutically acceptable salts thereof can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.).

In yet another embodiment, the compound and pharmaceutically acceptable salts thereof can be delivered in a controlled release system (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled- release systems discussed in the review by Langer, 1990, Science 249:1527-1533) may be used. In one embodiment, a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al, 1980, Surgery 88:507 Saudek et al, 1989, N. Engl. J. Med. 321 :574). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al, 1985, Science 228:190; During et al, 1989, Ann. Neurol. 25:351; Howard et al, 1989, J. Neurosurg. 71 : 105). In yet another embodiment, a controlled-release system can be placed in proximity of a target RNA of the compound or a pharmaceutically acceptable salt thereof, thus requiring only a fraction of the systemic dose.

Compositions comprising the compound or a pharmaceutically acceptable salt thereof ("compound compositions") can additionally comprise a suitable amount of a pharmaceutically acceptable vehicle so as to provide the form for proper administration to the patient.

In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, mammals, and more particularly in humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is administered. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. When administered to a patient, the pharmaceutically acceptable vehicles are preferably sterile. Water is a preferred vehicle when the compound of the invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Compound compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

Compound compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained- release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule (see e.g., U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical vehicles are described in Remington's Pharmaceutical Sciences, Alfonso R. Gennaro, ed., Mack Publishing Co. Easton, PA, 19th ed., 1995, pp. 1447 to 1676, incorporated herein by reference. In a preferred embodiment, the compound or a pharmaceutically acceptable salt thereof is formulated in accordance with routine procedures as a pharmaceutical composition adapted for oral administration to human beings. Compositions for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs,, for example. Orally administered compositions may contain one or more agents, for example, sweetening agents. such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of λvintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compositions. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. Such vehicles are preferably of pharmaceutical grade. Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions may also include a solubilizing agent.

In another embodiment, the compound or a pharmaceutically acceptable salt thereof can be formulated for intravenous administration. Compositions for intravenous administration may optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the compound or a pharmaceutically acceptable salt thereof is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compound or a pharmaceutically acceptable salt thereof is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration. The amount of a compound or a pharmaceutically acceptable salt thereof that will be effective in the treatment of a particular disease will depend on the nature of the disease, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration, and the seriousness of the disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for oral administration are generally about 0.001 milligram to about 200 milligrams of a compound or a pharmaceutically acceptable salt thereof per kilogram body weight per day. In specific preferred embodiments of the invention, the oral dose is about 0.01 milligram to about 100 milligrams per kilogram body weight per day, more preferably about 0.1 milligram to about 75 milligrams per kilogram body weight per day, more preferably about 0.5 milligram to 5 milligrams per kilogram body weight per day. The dosage amounts described herein refer to total amounts administered; that is, if more than one compound is administered, or if a compound is administered with a therapeutic agent, then the preferred dosages correspond to the total amount administered. Oral compositions preferably contain about 10% to about 95% active ingredient by weight.

Suitable dosage ranges for intravenous (i.v.) administration are about 0.01 milligram to about 100 milligrams per kilogram body weight per day, about 0.1 milligram to about 35 milligrams per kilogram body weight per day, and about 1 milligram to about 10 milligrams per kilogram body weight per day. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight per day to about 1 mg/kg body weight per day. Suppositories generally contain about 0.01 milligram to about 50 milligrams of a compound of the invention per kilogram body weight per day and comprise active ingredient in the range of about 0.5% to about 10% by weight.

Recommended dosages for intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual, intracerebral, intravaginal, transdermal administration or administration by inhalation are in the range of about 0.001 milligram to about 200 milligrams per kilogram of body weight per day. Suitable doses for topical administration are in the range of about 0.001 milligram to about 1 milligram, depending on the area of administration. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Such animal models and systems are well known in the art.

The compound and pharmaceutically acceptable salts thereof are preferably assayed in vitro and in vivo, for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays can be used to determine whether it is preferable to administer the compound, a pharmaceutically acceptable salt thereof, and/or another therapeutic agent. Animal model systems can be used to demonstrate safety and efficacy. A variety of compounds can be used for treating or preventing diseases in mammals. Types of compounds include, but are not limited to, peptides, peptide analogs including peptides comprising non-natural amino acids, e.g., D-amino acids, phosphorous analogs of amino acids, such as α-amino phosphonic acids and α-amino phosphinic acids, or amino acids having non-peptide linkages, nucleic acids, nucleic acid analogs such as phosphorothioates or peptide nucleic acids ("PNAs"), hormones, antigens, synthetic or

10 naturally occurring drugs, opiates, dopamine, serotonin, catecholamines, thrombin, acetylcholine, prostaglandins, organic molecules, pheromones, adenosine, sucrose, glucose, lactose and galactose.

6. EXAMPLE: THERAPEUTIC TARGETS

15

The therapeutic targets presented herein are by way of example, and the present invention is not to be limited by the targets described herein. The therapeutic targets presented herein as DNA sequences are understood by one of skill in the art that the sequences can be converted to RNA sequences.

20

6.1. Tumor Necrosis Factor Alpha ("TNF-α")

GenBank Accession # X01394:

1 gcagaggacc agctaagagg gagagaagca actacagacc ccccctgaaa acaaccctca 61 gacgccacat cccctgacaa gctgccaggc aggttctctt cctctcacat actgacccac

»^ 121 ggctccaccc tctctcccct ggaaaggaca ccatgagcac tgaaagcatg atccgggacg

181 tggagctggc cgaggaggcg ctccccaaga agacaggggg gccccagggc tccaggcggt 241 gcttgttcct cagcctcttc tccttcctga tcgtggcagg cgccaccacg ctcttctgcc 301 tgctgcactt tggagtgatc ggcccccaga gggaagagtt ccccagggac ctctctctaa 361 tcagccctct ggcccaggca gtcagatcat cttctcgaac cccgagtgac aagcctgtag

™ 421 cccatgttgt agcaaaccct caagctgagg ggcagctcca gtggctgaac cgccgggcca 481 atgccctcct ggccaatggc gtggagctga gagataacca gctggtggtg ccatcagagg 541 gcctgtacct catctactcc caggtcctct tcaagggcca aggctgcccc tccacccatg 601 tgctcctcac ccacaccatc agccgcatcg ccgtctccta ccagaccaag gtcaacctcc 661 tctctgccat caagagcccc tgccagaggg agaccccaga gggggctgag gccaagccct

₃₅ 721 ggtatgagcc catctatctg ggaggggtct tccagctgga gaagggtgac cgactcagcg

781 ctgagatcaa tcggcccgac tatctcgact ttgccgagtc tgggcaggtc tactttggga 841 tcattgccct gtgaggagga cgaacatcca accttcccaa acgcctcccc tgccccaatc 901 cctttattac cccctccttc agacaccctc aacctcttct ggctcaaaaa gagaattggg 961 ggcttagggt cggaacccaa gcttagaact ttaagcaaca agaccaccac ttcgaaacct 1021 gggattcagg aatgtgtggc ctgcacagtg aattgctggc aaccactaag aattcaaact 1081 ggggcctcca gaactcactg gggcctacag ctttgatccc tgacatctgg aatctggaga 1141 ccagggagcc tttggttctg gccagaatgc tgcaggactt gagaagacct cacctagaaa 1201 ttgacacaag tggaccttag gccttcctct ctccagatgt ttccagactt ccttgagaca 1261 cggagcccag ccctccccat ggagccagct ccctctattt atgtttgcac ttgtgattat 1321 ttattattta tttattattt atttatttac agatgaatgt atttatttgg gagaccgggg 1381 tatcctgggg gacccaatgt aggagctgcc ttggctcaga catgttttcc gtgaaaacgg 1441 agctgaacaa taggctgttc ccatgtagcc ccctggcctc tgtgccttct tttgattatg 1501 ttttttaaaa tatttatctg attaagttgt ctaaacaatg ctgatttggt gaccaactgt 1561 cactcattgc tgagcctctg ctccccaggg gagttgtgtc tgtaatcgcc ctactattca 1621 gtggcgagaa ataaagtttg ctt (SEQ ID NO: 6)

General Target Regions:

(1) 5' Untranslated Region - nts 1 - 152

(2) 3' Untranslated Region - nts 852 - 1643

Initial Specific Target Motif:

Group I AU-Rich Element (ARE) Cluster in 3' untranslated region 5' AUUUAUUUAUUUAUUUAUUUA 3' (SEQ ID NO: 1)

6.2. Granulocyte-macrophage Colony Stimulating Factor ("GM-CSF")

GenBank Accession # NM_000758:

1 gctggaggat gtggctgcag agcctgctgc tcttgggcac tgtggcctgc agcatctctg 61 cacccgcccg ctcgcccagc cccagcacgc agccctggga gcatgtgaat gccatccagg 121 aggcccggcg tctcctgaac ctgagtagag acactgctgc tgagatgaat gaaacagtag 181 aagtcatctc agaaatgttt gacctccagg agccgacctg cctacagacc cgcctggagc 241 tgtacaagca gggcctgcgg ggcagcctca ccaagctcaa gggccccttg accatgatgg 301 ccagccacta caagcagcac tgccctccaa ccccggaaac ttcctgtgca acccagacta 361 tcacctttga aagtttcaaa gagaacctga aggactttct gcttgtcatc ccctttgact 421 gctgggagcc agtccaggag tgagaccggc cagatgaggc tggccaagcc ggggagctgc 481 tctctcatga aacaagagct agaaactcag gatggtcatc ttggagggac caaggggtgg 541 gccacagcca tggtgggagt ggcctggacc tgccctgggc cacactgacc ctgatacagg 601 catggcagaa gaatgggaat attttatact gacagaaatc agtaatattt atatatttat ^" 661 atttttaaaa tatttattta tttatttatt taagttcata ttccatattt attcaagatg 721 ttttaccgta ataattatta ttaaaaatat gcttct (SEQ ID NO: 7)

GenBank Accession # XM_003751 :

1 tctggaggat gtggctgcag agcctgctgc tcttgggcac tgtggcctgc agcatctctg 61 cacccgcccg ctcgcccagc cccagcacgc agccctggga gcatgtgaat gccatccagg 121 aggcccggcg tctcctgaac ctgagtagag acactgctgc tgagatgaat gaaacagtag 181 aagtcatctc agaaatgttt gacctccagg agccgacctg cctacagacc cgcctggagc 241 tgtacaagca gggcctgcgg ggcagcctca ccaagctcaa gggccccttg accatgatgg 301 ccagccacta caagcagcac tgccctccaa ccccggaaac ttcctgtgca acccagacta 361 tcacctttga aagtttcaaa gagaacctga aggactttct gcttgtcatc ccctttgact 421 gctgggagcc agtccaggag tgagaccggc cagatgaggc tggccaagcc ggggagctgc 481 tctctcatga aacaagagct agaaactcag gatggtcatc ttggagggac caaggggtgg 541 gccacagcca tggtgggagt ggcctggacc tgccctgggc cacactgacc ctgatacagg 601 catggcagaa gaatgggaat attttatact gacagaaatc agtaatattt atatatttat 661 atttttaaaa tatttattta tttatttatt taagttcata ttccatattt attcaagatg 721 ttttaccgta ataattatta ttaaaaatat gcttct (SEQ ID NO: 8)

General Target Regions:

(1) 5' Untranslated Region - nts 1 - 32

(2) 3' Untranslated Region - nts 468 - 789

Initial Specific Target Motif:

Group I AU-Rich Element (ARE) Cluster in 3' untranslated region 5' AUUUAUUUAUUUAUUUAUUUA 3' (SEQ ID NO: 1)

6.3. Interleukin 2 ("IL-2")

GenBank Accession # U25676:

1 atcactctct ttaatcacta ctcacattaa cctcaactcc tgccacaatg tacaggatgc 61 aactcctgtc ttgcattgca ctaattcttg cacttgtcac aaacagtgca cctacttcaa 121 gttcgacaaa gaaaacaaag aaaacacagc tacaactgga gcatttactg ctggatttac 181 agatgatttt gaatggaatt aataattaca agaatcccaa actcaccagg atgctcacat 241 ttaagtttta catgcccaag aaggccacag aactgaaaca gcttcagtgt ctagaagaag 301 aactcaaacc tctggaggaa gtgctgaatt tagctcaaag caaaaacttt cacttaagac 361 ccagggactt aatcagcaat atcaacgtaa tagttctgga actaaaggga tctgaaacaa 421 cattcatgtg tgaatatgca gatgagacag caaccattgt agaatttctg aacagatgga 481 ttaccttttg tcaaagcatc atctcaacac taacttgata attaagtgct tcccacttaa 541 aacatatcag gccttctatt tatttattta aatatttaaa ttttatattt attgttgaat 601 gtatggttgc tacctattgt aactattatt cttaatctta aaactataaa tatggatctt 661 ttatgattct ttttgtaagc cctaggggct ctaaaatggt ttaccttatt tatcccaaaa 721 atatttatta ttatgttgaa tgttaaatat agtatctatg tagattggtt agtaaaacta 781 tttaataaat ttgataaata taaaaaaaaa aaacaaaaaa aaaaa (SEQ ID NO: 9)

General Target Regions:

(1) 5' Untranslated Region - nts 1 - 47

(2) 3 ' Untranslated Region - nts 519- 825

Initial Specific Target Motifs:

Group III AU-Rich Element (ARE) Cluster in 3' untranslated region 5' NAUUUAUUUAUUUAN 3' (SEQ ID NO: 10)

6.4. Interleukin 6 ("IL-6")

GenBank Accession # NM_000600:

1 ttctgccctc gagcccaccg ggaacgaaag agaagctcta tctcgcctcc aggagcccag 61 ctatgaactc cttctccaca agcgccttcg gtccagttgc cttctccctg gggctgctcc 121 tggtgttgcc tgctgccttc cctgccccag tacccccagg agaagattcc aaagatgtag 181 ccgccccaca cagacagcca ctcacctctt cagaacgaat tgacaaacaa attcggtaca 241 tcctcgacgg catctcagcc ctgagaaagg agacatgtaa caagagtaac atgtgtgaaa 301 gcagcaaaga ggcactggca gaaaacaacc tgaaccttcc aaagatggct gaaaaagatg 361 gatgcttcca atctggattc aatgaggaga cttgcctggt gaaaatcatc actggtcttt 421 tggagtttga ggtataccta gagtacctcc agaacagatt tgagagtagt gaggaacaag 481 ccagagctgt gcagatgagt acaaaagtcc tgatccagtt cctgcagaaa aaggcaaaga 541 atctagatgc aataaccacc cctgacccaa ccacaaatgc cagcctgctg acgaagctgc 601 aggcacagaa ccagtggctg caggacatga caactcatct cattctgcgc agctttaagg 661 agttcctgca gtccagcctg agggctcttc ggcaaatgta gcatgggcac ctcagattgt 721 tgttgttaat gggcattcct tcttctggtc agaaacctgt ccactgggca cagaacttat 781 gttgttctct atggagaact aaaagtatga gcgttaggac actattttaa ttatttttaa 841 tttattaata tttaaatatg tgaagctgag ttaatttatg taagtcatat ttatattttt 901 aagaagtacc acttgaaaca ttttatgtat tagttttgaa ataataatgg aaagtggcta 961 tgcagtttga atatcctttg tttcagagcc agatcatttc ttggaaagtg taggcttacc 1021 tcaaataaat ggctaactta tacatatttt taaagaaata tttatattgt atttatataa 1081 tgtataaatg gtttttatac caataaatgg cattttaaaa aattc (SEQ ID NO: 11)

General Target Regions:

(1) 5' Untranslated Region - nts 1 - 62

(2) 3' Untranslated Region - nts 699 - 1125

Initial Specific Target Motifs:

Group III AU-Rich Element (ARE) Cluster in 3' untranslated region 5' NAUUUAUUUAUUUAN 3' (SEQ ID NO: 10)

6.5. Vascular Endothelial Growth Factor ("VEGF")

GenBank Accession # AF022375:

1 aagagctcca gagagaagtc gaggaagaga gagacggggt cagagagagc gcgcgggcgt 61 gcgagcagcg aaagcgacag gggcaaagtg agtgacctgc ttttgggggt gaccgccgga 121 gcgcggcgtg agccctcccc cttgggatcc cgcagctgac cagtcgcgct gacggacaga 181 cagacagaca ccgcccccag ccccagttac cacctcctcc ccggccggcg gcggacagtg 241 gacgcggcgg cgagccgcgg gcaggggccg gagcccgccc ccggaggcgg ggtggagggg 301 gtcggagctc gcggcgtcgc actgaaactt ttcgtccaac ttctgggctg ttctcgcttc 361 ggaggagccg tggtccgcgc gggggaagcc gagccgagcg gagccgcgag aagtgctagc 421 tcgggccggg aggagccgca gccggaggag ggggaggagg aagaagagaa ggaagaggag 481 agggggccgc agtggcgact cggcgctcgg aagccgggct catggacggg tgaggcggcg 541 gtgtgcgcag acagtgctcc agcgcgcgcg ctccccagcc ctggcccggc ctcgggccgg 601 gaggaagagt agctcgccga ggcgccgagg agagcgggcc gccccacagc ccgagccgga 661 gagggacgcg agccgcgcgc cccggtcggg cctccgaaac catgaacttt ctgctgtctt 721 gggtgcattg gagccttgcc ttgctgctct acctccacca tgccaagtgg tcccaggctg 781 cacccatggc agaaggagga gggcagaatc atcacgaagt ggtgaagttc atggatgtct 841 atcagcgcag ctactgccat ccaatcgaga ccctggtgga catcttccag gagtaccctg 901 atgagatcga gtacatcttc aagccatcct gtgtgcccct gatgcgatgc gggggctgct 961 ccaatgacga gggcctggag tgtgtgccca ctgaggagtc caacatcacc atgcagatta 1021 tgcggatcaa acctcaccaa ggccagcaca taggagagat gagcttccta cagcacaaca 1081 aatgtgaatg cagaccaaag aaagatagag caagacaaga aaatccctgt gggccttgct 1141 cagagcggag aaagcatttg tttgtacaag atccgcagac gtgtaaatgt tcctgcaaaa 1201 acacacactc gcgttgcaag gcgaggcagc ttgagttaaa cgaacgtact tgcagatgtg 126 acaagccgag gcggtgagcc gggcaggagg aaggagcctc cctcagggtt tcgggaacca 132 gatctctctc caggaaagac tgatacagaa cgatcgatac agaaaccacg ctgccgccac 138 cacaccatca ccatcgacag aacagtcctt aatccagaaa cctgaaatga aggaagagga 144 gactctgcgc agagcacttt gggtccggag ggcgagactc cggcggaagc attcccgggc 150 gggtgaccca gcacggtccc tcttggaatt ggattcgcca ttttattttt cttgctgcta 156 aatcaccgag cccggaagat tagagagttt tatttctggg attcctgtag acacacccac 162 ccacatacat acatttatat atatatatat tatatatata taaaaataaa tatctctatt 168 ttatatatat aaaatatata tattcttttt ttaaattaac agtgctaatg ttattggtgt 174 cttcactgga tgtatttgac tgctgtggac ttgagttggg aggggaatgt tcccactcag 180 atcctgacag ggaagaggag gagatgagag actctggcat gatctttttt ttgtcccact 186 tggtggggcc agggtcctct cccctgccca agaatgtgca aggccagggc atgggggcaa 192 atatgaccca gttttgggaa caccgacaaa cccagccctg gcgctgagcc tctctacccc 198 aggtcagacg gacagaaaga caaatcacag gttccgggat gaggacaccg gctctgacca 204 ggagtttggg gagcttcagg acattgctgt gctttgggga ttccctccac atgctgcacg 210 cgcatctcgc ccccaggggc actgcctgga agattcagga gcctgggcgg ccttcgctta 216 ctctcacctg cttctgagtt gcccaggagg ccactggcag atgtcccggc gaagagaaga 222 gacacattgt tggaagaagc agcccatgac agcgcccctt cctgggactc gccctcatcc 228 tcttcctgct ccccttcctg gggtgcagcc taaaaggacc tatgtcctca caccattgaa 234 accactagtt ctgtcccccc aggaaacctg gttgtgtgtg tgtgagtggt tgaccttcct 240 ccatcccctg gtccttccct tcccttcccg aggcacagag agacagggca ggatccacgt 246 gcccattgtg gaggcagaga aaagagaaag tgttttatat acggtactta tttaatatcc 252 ctttttaatt agaaattaga acagttaatt taattaaaga gtagggtttt ttttcagtat 258 tcttggttaa tatttaattt caactattta tgagatgtat cttttgctct ctcttgctct 264 cttatttgta ccggtttttg tatataaaat tcatgtttcc aatctctctc tccctgatcg 270 gtgacagtca ctagcttatc ttgaacagat atttaatttt gctaacactc agctctgccc 276 tccccgatcc cctggctccc cagcacacat tcctttgaaa gagggtttca atatacatct 282 acatactata tatatattgg gcaacttgta tttgtgtgta tatatatata tatatgttta 288 tgtatatatg tgatcctgaa aaaataaaca tcgctattct gttttttata tgttcaaacc 294 aaacaagaaa aaatagagaa ttctacatac taaatctctc tcctttttta attttaatat 300 ttgttatcat ttatttattg gtgctactgt ttatccgtaa taattgtggg gaaaagatat 306 taacatcacg tctttgtctc tagtgcagtt tttcgagata ttccgtagta catatttatt 312 tttaaacaac gacaaagaaa tacagatata tcttaaaaaa aaaaaa (SEQ ID NO: 12)

General Target Regions:

(1) 5' Untranslated Region - nts 1 - 701 (2) 3 ' Untranslated Region - nts 1275 - 3166

Initial Specific Target Motifs:

(1) Internal Ribosome Entry Site (IRES) in 5' untranslated region nts 513 -704 5'CCGGGCUCAUGGACGGGUGAGGCGGCGGUGUGCGCAGACAGU GCUCCAGCGCGCGCGCUCCCCAGCCCUGGCCCGGCCUCGGGCCG GGAGGAAGAGUAGCUCGCCGAGGCGCCGAGGAGAGCGGGCCGC CCCACAGCCCGAGCCGGAGAGGGACGCGAGCCGCGCGCCCCGGU CGGGCCUCCGAAACCAUGAACUUUCUGCUGUCUUGGGUGCAUU GGAGCCUUGCCUUGCUGCUCUACCUCCACCAUG 3' (SEQ ID NO: 13)

(2) Group III AU-Rich Element (ARE) Cluster in 3' untranslated region 5' NAUUUAUUUAUUUAN 3' (SEQ ID NO: 10)

6.6. Human Immunodeficiency Virus I ("HIV-1")

GenBank Accession # NC_001802:

1 ggtctctctg gttagaccag atctgagcct gggagctctc tggctaacta gggaacccac 61 tgcttaagcc tcaataaagc ttgccttgag tgcttcaagt agtgtgtgcc cgtctgttgt 121 gtgactctgg taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca 181 gtggcgcccg aacagggacc tgaaagcgaa agggaaacca gaggagctct ctcgacgcag 241 gactcggctt gctgaagcgc gcacggcaag aggcgagggg cggcgactgg tgagtacgcc 301 aaaaattttg actagcggag gctagaagga gagagatggg tgcgagagcg tcagtattaa 361 gcgggggaga attagatcga tgggaaaaaa ttcggttaag gccaggggga aagaaaaaat 421 ataaattaaa acatatagta tgggcaagca gggagctaga acgattcgca gttaatcctg 481 gcctgttaga aacatcagaa ggctgtagac aaatactggg acagctacaa ccatcccttc 541 agacaggatc agaagaactt agatcattat ataatacagt agcaaccctc tattgtgtgc 601 atcaaaggat agagataaaa gacaccaagg aagctttaga caagatagag gaagagcaaa 661 acaaaagtaa gaaaaaagca cagcaagcag cagctgacac aggacacagc aatcaggtca 721 gccaaaatta ccctatagtg cagaacatcc aggggcaaat ggtacatcag gccatatcac 781 ctagaacttt aaatgcatgg gtaaaagtag tagaagagaa ggctttcagc ccagaagtga 841 tacccatgtt ttcagcatta tcagaaggag ccaccccaca agatttaaac accatgctaa 901 acacagtggg gggacatcaa gcagccatgc aaatgttaaa agagaccatc aatgaggaag 961 ctgcagaatg ggatagagtg catccagtgc atgcagggcc tattgcacca ggccagatga 1021 gagaaccaag gggaagtgac atagcaggaa ctactagtac ccttcaggaa caaataggat 1081 ggatgacaaa taatccacct atcccagtag gagaaattta taaaagatgg ataatcctgg 114 gattaaataa aatagtaaga atgtatagcc ctaccagcat tctggacata agacaaggac 120 caaaggaacc ctttagagac tatgtagacc ggttctataa aactctaaga gccgagcaag 126 cttcacagga ggtaaaaaat tggatgacag aaaccttgtt ggtccaaaat gcgaacccag 132 attgtaagac tattttaaaa gcattgggac cagcggctac actagaagaa atgatgacag 138 catgtcaggg agtaggagga cccggccata aggcaagagt tttggctgaa gcaatgagcc 144 aagtaacaaa ttcagctacc ataatgatgc agagaggcaa ttttaggaac caaagaaaga 150 ttgttaagtg tttcaattgt ggcaaagaag ggcacacagc cagaaattgc agggccccta 156 ggaaaaaggg ctgttggaaa tgtggaaagg aaggacacca aatgaaagat tgtactgaga 162 gacaggctaa ttttttaggg aagatctggc cttcctacaa gggaaggcca gggaattttc 168 ttcagagcag accagagcca acagccccac cagaagagag cttcaggtct ggggtagaga 174 caacaactcc ccctcagaag caggagccga tagacaagga actgtatcct ttaacttccc 180 tcaggtcact ctttggcaac gacccctcgt cacaataaag ataggggggc aactaaagga 186 agctctatta gatacaggag cagatgatac agtattagaa gaaatgagtt tgccaggaag 192 atggaaacca aaaatgatag ggggaattgg aggttttatc aaagtaagac agtatgatca 198 gatactcata gaaatctgtg gacataaagc tataggtaca gtattagtag gacctacacc 204 tgtcaacata attggaagaa atctgttgac tcagattggt tgcactttaa attttcccat 210 tagccctatt gagactgtac cagtaaaatt aaagccagga atggatggcc caaaagttaa 216 acaatggcca ttgacagaag aaaaaataaa agcattagta gaaatttgta cagagatgga 222 aaaggaaggg aaaatttcaa aaattgggcc tgaaaatcca tacaatactc cagtatttgc 228 cataaagaaa aaagacagta ctaaatggag aaaattagta gatttcagag aacttaataa 234 gagaactcaa gacttctggg aagttcaatt aggaatacca catcccgcag ggttaaaaaa 240 gaaaaaatca gtaacagtac tggatgtggg tgatgcatat ttttcagttc ccttagatga 246 agacttcagg aagtatactg catttaccat acctagtata aacaatgaga caccagggat 252 tagatatcag tacaatgtgc ttccacaggg atggaaagga tcaccagcaa tattccaaag 258 tagcatgaca aaaatcttag agccttttag aaaacaaaat ccagacatag ttatctatca 264 atacatggat gatttgtatg taggatctga cttagaaata gggcagcata gaacaaaaat 270 agaggagctg agacaacatc tgttgaggtg gggacttacc acaccagaca aaaaacatca 276 gaaagaacct ccattccttt ggatgggtta tgaactccat cctgataaat ggacagtaca 282 gcctatagtg ctgccagaaa aagacagctg gactgtcaat gacatacaga agttagtggg 288 gaaattgaat tgggcaagtc agatttaccc agggattaaa gtaaggcaat tatgtaaact 294 ccttagagga accaaagcac taacagaagt aataccacta acagaagaag cagagctaga 300 actggcagaa aacagagaga ttctaaaaga accagtacat ggagtgtatt atgacccatc 306 aaaagactta atagcagaaa tacagaagca ggggcaaggc caatggacat atcaaattta 312 tcaagagcca tttaaaaatc tgaaaacagg aaaatatgca agaatgaggg gtgcccacac 318 taatgatgta aaacaattaa cagaggcagt gcaaaaaata accacagaaa gcatagtaat 324 atggggaaag actcctaaat ttaaactgcc catacaaaag gaaacatggg aaacatggtg 330 gacagagtat tggcaagcca cctggattcc tgagtgggag tttgttaata cccctccctt 336 agtgaaatta tggtaccagt tagagaaaga acccatagta ggagcagaaa ccttctatgt 342 agatggggpa gctaacaggg agactaaatt aggaaaagca ggatatgtta ctaatagagg 348 aagacaaaaa gttgtcaccc taactgacac aacaaatcag aagactgagt tacaagcaat 354 ttatctagct ttgcaggatt cgggattaga agtaaacata gtaacagact cacaatatgc 360 attaggaatc attcaagcac aaccagatca aagtgaatca gagttagtca atcaaataat 366 agagcagtta ataaaaaagg aaaaggtcta tctggcatgg gtaccagcac acaaaggaat 372 tggaggaaat gaacaagtag ataaattagt cagtgctgga atcaggaaag tactattttt 378 agatggaata gataaggccc aagatgaaca tgagaaatat cacagtaatt ggagagcaat 384 ggctagtgat tttaacctgc cacctgtagt agcaaaagaa atagtagcca gctgtgataa 390 atgtcagcta aaaggagaag ccatgcatgg acaagtagac tgtagtccag gaatatggca 396 actagattgt acacatttag aaggaaaagt tatcctggta gcagttcatg tagccagtgg 402 atatatagaa gcagaagtta ttccagcaga aacagggcag gaaacagcat attttctttt 408 aaaattagca ggaagatggc cagtaaaaac aatacatact gacaatggca gcaatttcac 414 cggtgctacg gttagggccg cctgttggtg ggcgggaatc aagcaggaat ttggaattcc 420 ctacaatccc caaagtcaag gagtagtaga atctatgaat aaagaattaa agaaaattat 426 aggacaggta agagatcagg ctgaacatct taagacagca gtacaaatgg cagtattcat 432 ccacaatttt aaaagaaaag gggggattgg ggggtacagt gcaggggaaa gaatagtaga 438 cataatagca acagacatac aaactaaaga attacaaaaa caaattacaa aaattcaaaa 444 ttttcgggtt tattacaggg acagcagaaa tccactttgg aaaggaccag caaagctcct 450 ctggaaaggt gaaggggcag tagtaataca agataatagt gacataaaag tagtgccaag 456 aagaaaagca aagatcatta gggattatgg aaaacagatg gcaggtgatg attgtgtggc 462 aagtagacag gatgaggatt agaacatgga aaagtttagt aaaacaccat atgtatgttt 468 cagggaaagc taggggatgg ttttatagac atcactatga aagccctcat ccaagaataa 474 gttcagaagt acacatccca ctaggggatg ctagattggt aataacaaca tattggggtc 480 tgcatacagg agaaagagac tggcatttgg gtcagggagt ctccatagaa tggaggaaaa 486 agagatatag cacacaagta gaccctgaac tagcagacca actaattcat ctgtattact 492 ttgactgttt ttcagactct gctataagaa aggccttatt aggacacata gttagcccta 498 ggtgtgaata tcaagcagga cataacaagg taggatctct acaatacttg gcactagcag 504 cattaataac accaaaaaag ataaagccac ctttgcctag tgttacgaaa ctgacagagg 510 atagatggaa caagccccag aagaccaagg gccacagagg gagccacaca atgaatggac 516 actagagctt ttagaggagc ttaagaatga agctgttaga cattttccta ggatttggct 522 ccatggctta gggcaacata tctatgaaac ttatggggat acttgggcag gagtggaagc 528 cataataaga attctgcaac aactgctgtt tatccatttt cagaattggg tgtcgacata 534 gcagaatagg cgttactcga cagaggagag caagaaatgg agccagtaga tcctagacta 540 gagccctgga agcatccagg aagtcagcct aaaactgctt gtaccaattg ctattgtaaa 546 aagtgttgct ttcattgcca agtttgtttc ataacaaaag ccttaggcat ctcctatggc 552 aggaagaagc ggagacagcg acgaagagct catcagaaca gtcagactca tcaagcttct 558 ctatcaaagc agtaagtagt acatgtaatg caacctatac caatagtagc aatagtagca 564 ttagtagtag caataataat agcaatagtt gtgtggtcca tagtaatcat agaatatagg 570 aaaatattaa gacaaagaaa aatagacagg ttaattgata gactaataga aagagcagaa 576 gacagtggca atgagagtga aggagaaata tcagcacttg tggagatggg ggtggagatg 582 gggcaccatg ctccttggga tgttgatgat ctgtagtgct acagaaaaat tgtgggtcac 588 agtctattat ggggtacctg tgtggaagga agcaaccacc actctatttt gtgcatcaga 594 tgctaaagca tatgatacag aggtacataa tgtttgggcc acacatgcct gtgtacccac 600 agaccccaac ccacaagaag tagtattggt aaatgtgaca gaaaatttta acatgtggaa 606 aaatgacatg gtagaacaga tgcatgagga tataatcagt ttatgggatc aaagcctaaa 612 gccatgtgta aaattaaccc cactctgtgt tagtttaaag tgcactgatt tgaagaatga 618 tactaatacc aatagtagta gcgggagaat gataatggag aaaggagaga taaaaaactg 624 ctctttcaat atcagcacaa gcataagagg taaggtgcag aaagaatatg cattttttta 630 taaacttgat ataataccaa tagataatga tactaccagc tataagttga caagttgtaa 636 cacctcagtc attacacagg cctgtccaaa ggtatccttt gagccaattc ccatacatta 642 ttgtgccccg gctggttttg cgattctaaa atgtaataat aagacgttca atggaacagg 648 accatgtaca aatgtcagca cagtacaatg tacacatgga attaggccag tagtatcaac 654 tcaactgctg ttaaatggca gtctagcaga agaagaggta gtaattagat ctgtcaattt 660 cacggacaat gctaaaacca taatagtaca gctgaacaca tctgtagaaa ttaattgtac 666 aagacccaac aacaatacaa gaaaaagaat ccgtatccag agaggaccag ggagagcatt 672 tgttacaata ggaaaaatag gaaatatgag acaagcacat tgtaacatta gtagagcaaa 678 atggaataac actttaaaac agatagctag caaattaaga gaacaatttg gaaataataa 684 aacaataatc tttaagcaat cctcaggagg ggacccagaa attgtaacgc acagttttaa 690 ttgtggaggg gaatttttct actgtaattc aacacaactg tttaatagta cttggtttaa 696 tagtacttgg agtactgaag ggtcaaataa cactgaagga agtgacacaa tcaccctccc 702 atgcagaata aaacaaatta taaacatgtg gcagaaagta ggaaaagcaa tgtatgcccc 708 tcccatcagt ggacaaatta gatgttcatc aaatattaca gggctgctat taacaagaga 714 tggtggtaat agcaacaatg agtccgagat cttcagacct ggaggaggag atatgaggga 720 caattggaga agtgaattat ataaatataa agtagtaaaa attgaaccat taggagtagc 726 acccaccaag gcaaagagaa gagtggtgca gagagaaaaa agagcagtgg gaataggagc 732 tttgttcctt gggttcttgg gagcagcagg aagcactatg ggcgcagcct caatgacgct 738 gacggtacag gccagacaat tattgtctgg tatagtgcag cagcagaaca atttgctgag 744 ggctattgag gcgcaacagc atctgttgca actcacagtc tggggcatca agcagctcca 750 ggcaagaatc ctggctgtgg aaagatacct aaaggatcaa cagctcctgg ggatttgggg 756 ttgctctgga aaactcattt gcaccactgc tgtgccttgg aatgctagtt ggagtaataa 762 atctctggaa cagatttgga atcacacgac ctggatggag tgggacagag aaattaacaa 768 ttacacaagc ttaatacact ccttaattga agaatcgcaa aaccagcaag aaaagaatga 774 acaagaatta ttggaattag ataaatgggc aagtttgtgg aattggttta acataacaaa 780 ttggctgtgg tatataaaat tattcataat gatagtagga ggcttggtag gtttaagaat 786 agtttttgct gtactttcta tagtgaatag agttaggcag ggatattcac cattatcgtt 792 tcagacccac ctcccaaccc cgaggggacc cgacaggccc gaaggaatag aagaagaagg 798 tggagagaga gacagagaca gatccattcg attagtgaac ggatccttgg cacttatctg 804 ggacgatctg cggagcctgt gcctcttcag ctaccaccgc ttgagagact tactcttgat 810 tgtaacgagg attgtggaac ttctgggacg cagggggtgg gaagccctca aatattggtg 816 gaatctccta cagtattgga gtcaggaact aaagaatagt gctgttagct tgctcaatgc 822 cacagccata gcagtagctg aggggacaga tagggttata gaagtagtac aaggagcttg 828 tagagctatt cgccacatac ctagaagaat aagacagggc ttggaaagga ttttgctata 834 agatgggtgg caagtggtca aaaagtagtg tgattggatg gcctactgta agggaaagaa 840 tgagacgagc tgagccagca gcagataggg tgggagcagc atctcgagac ctggaaaaac 846 atggagcaat cacaagtagc aatacagcag ctaccaatgc tgcttgtgcc tggctagaag 852 cacaagagga ggaggaggtg ggttttccag tcacacctca ggtaccttta agaccaatga 858 cttacaaggc agctgtagat cttagccact ttttaaaaga aaagggggga ctggaagggc 864 taattcactc ccaaagaaga caagatatcc ttgatctgtg gatctaccac acacaaggct 870 acttccctga ttagcagaac tacacaccag ggccaggggt cagatatcca ctgacctttg 876 gatggtgcta caagctagta ccagttgagc cagataagat agaagaggcc aataaaggag 882 agaacaccag cttgttacac cctgtgagcc tgcatgggat ggatgacccg gagagagaag 888 tgttagagtg gaggtttgac agccgcctag catttcatca cgtggcccga gagctgcatc 894 cggagtactt caagaactgc tgacatcgag cttgctacaa gggactttcc gctggggact 900 ttccagggag gcgtggcctg ggcgggactg gggagtggcg agccctcaga tcctgcatat 906 aagcagctgc tttttgcctg tactgggtct ctctggttag accagatctg agcctgggag 912 ctctctggct aactagggaa cccactgctt aagcctcaat aaagcttgcc ttgagtgctt 918 c (SEQ ID NO: 14)

Initial Specific Target Motifs:

(1) Trans-activation response region/Tat protein binding site - TAR RNA - nts 1 - 60 "Minimal" TAR RNA element 5' GGCAGAUCUGAGCCUGGGAGCUCUCUGCC 3' (SEQ ID NO: 15) (2) Gag/Pol Frameshifting Site - "Minimal" frameshifting element 5'

UUUUUUAGGGAAGAUCUGGCCUUCCUACAAGGGAAGGCCAGG GAAUUUUCUU 3' (SEQ IDNO: 16)

6.7. Hepatitis C Virus ("HCV" - Genotypes la & lb)

GenBank Accession # NC_001433:

1 ttgggggcga cactccacca tagatcactc ccctgtgagg aactactgtc ttcacgcaga 61 aagcgtctag ccatggcgtt agtatgagtg ttgtgcagcc tccaggaccc cccctcccgg 121 gagagccata gtggtctgcg gaaccggtga gtacaccgga attgccagga cgaccgggtc 181 ctttcttgga tcaacccgct caatgcctgg agatttgggc gtgcccccgc gagactgcta 241 gccgagtagt gttgggtcgc gaaaggcctt gtggtactgc ctgatagggt gcttgcgagt 301 gccccgggag gtctcgtaga ccgtgcatca tgagcacaaa tcctaaacct caaagaaaaa 361 ccaaacgtaa caccaaccgc cgcccacagg acgttaagtt cccgggcggt ggtcagatcg 421 ttggtggagt ttacctgttg ccgcgcaggg gccccaggtt gggtgtgcgc gcgactagga 481 agacttccga gcggtcgcaa cctcgtggaa ggcgacaacc tatccccaag gctcgccggc 541 ccgagggtag gacctgggct cagcccgggt acccttggcc cctctatggc aacgagggta 601 tggggtgggc aggatggctc ctgtcacccc gtggctctcg gcctagttgg ggccccacag 661 acccccggcg taggtcgcgt aatttgggta aggtcatcga tacccttaca tgcggcttcg 721 ccgacctcat ggggtacatt ccgcttgtcg gcgcccccct agggggcgct gccagggccc 781 tggcacatgg tgtccgggtt ctggaggacg gcgtgaacta tgcaacaggg aatctgcccg 841 gttgctcttt ctctatcttc ctcttagctt tgctgtcttg tttgaccatc ccagcttccg 901 cttacgaggt gcgcaacgtg tccgggatat accatgtcac gaacgactgc tccaactcaa 961 gtattgtgta tgaggcagcg gacatgatca tgcacacccc cgggtgcgtg ccctgcgtcc 1021 gggagagtaa tttctcccgt tgctgggtag cgctcactcc cacgctcgcg gccaggaaca 1081 gcagcatccc caccacgaca atacgacgcc acgtcgattt gctcgttggg gcggctgctc 1141 tctgttccgc tatgtacgtt ggggatctct gcggatccgt ttttctcgtc tcccagctgt 1201 tcaccttctc acctcgccgg tatgagacgg tacaagattg caattgctca atctatcccg 1261 gccacgtatc aggtcaccgc atggcttggg atatgatgat gaactggtca cctacaacgg 1321 ccctagtggt atcgcagcta ctccggatcc cacaagccgt cgtggacatg gtggcggggg 1381 cccactgggg tgtcctagcg ggccttgcct actattccat ggtggggaac tgggctaagg 1441 tcttgattgt gatgctactc tttgctggcg ttgacgggca cacccacgtg acagggggaa 1501 gggtagcctc cagcacccag agcctcgtgt cctggctctc acaaggccca tctcagaaaa 1561 tccaactcgt gaacaccaac ggcagctggc acatcaacag gaccgctctg aattgcaatg 162 actccctcca aactgggttc attgctgcgc tgttctacgc acacaggttc aacgcgtccg 168 ggtgcccaga gcgcatggct agctgccgcc ccatcgatga gttcgctcag gggtggggtc 174 ccatcactca tgatatgcct gagagctcgg accagaggcc atattgctgg cactacgcgc 180 ctcgaccgtg cgggatcgtg cctgcgtcgc aggtgtgtgg tccagtgtat tgcttcactc 186 cgagccctgt tgtagtgggg acgaccgatc gtttcggcgc tcctacgtat agctgggggg 192 agaatgagac agacgtgctg ctacttagca acacgcggcc gcctcaaggc aactggtttg 198 ggtgcacgtg gatgaacagc actgggttca ccaagacgtg cgggggccct ccgtgcaaca 204 tcgggggggt cggcaacaac accttggtct gccccacgga ttgcttccgg aagcaccccg 210 aggccactta cacaaagtgt ggctcggggc cctggttgac acccaggtgc atggttgact 216 acccatacag gctctggcac tacccctgca ctgttaactt taccgtcttt aaggtcagga 222 tgtatgtggg gggcgtggag cacaggctca atgctgcatg caattggact cgaggagagc 228 gctgtgactt ggaggacagg gataggtcag aactcagccc gctgctgctg tctacaacag 234 agtggcagat actgccctgt tccttcacca ccctaccggc cctgtccact ggcttgatcc 240 atcttcaccg gaacatcgtg gacgtgcaat acctgtacgg tatagggtcg gcagttgtct 246 cctttgcaat caaatgggag tatatcctgt tgcttttcct tcttctggcg gacgcgcgcg 252 tctgtgcctg cttgtggatg atgctgctga tagcccaggc tgaggccacc ttagagaacc 258 tggtggtcct caatgcggcg tctgtggccg gagcgcatgg ccttctctcc ttcctcgtgt 264 tcttctgcgc cgcctggtac atcaaaggca ggctggtccc tggggcggca tatgctctct 270 atggcgtatg gccgttgctc ctgctcttgc tggccttacc accacgagct tatgccatgg 276 accgagagat ggctgcatcg tgcggaggcg cggtttttgt aggtctggta ctcttgacct 282 tgtcaccata ctataaggtg ttcctcgcta ggctcatatg gtggttacaa tattttatca 288 ccagagccga ggcgcacttg caagtgtggg tcccccctct caatgttcgg ggaggccgcg 294 atgccatcat cctccttaca tgcgcggtcc atccagagct aatctttgac atcaccaaac 300 tcctgctcgc catactcggt ccgctcatgg tgctccaggc tggcataact agagtgccgt 306 actttgtacg cgctcagggg ctcatccgtg catgcatgtt agtgcggaag gtcgctggag 312 gccactatgt ccaaatggcc ttcatgaagc tggccgcgct gacaggtacg tacgtatatg 318 accatcttac tccactgcgg gattgggccc acgcgggcct acgagacctt gcggtggcag 324 tagagcccgt cgtcttctct gacatggaga ctaaactcat cacctggggg gcagacaccg 330 cggcgtgtgg ggacatcatc tcgggtctac cagtctccgc ccgaaggggg aaggagatac 336 ttctaggacc ggccgatagt tttggagagc aggggtggcg gctccttgcg cctatcacgg 342 cctattccca acaaacgcgg ggcctgcttg gctgtatcat cactagcctc acaggtcggg 348 acaagaacca ggtcgatggg gaggttcagg tgctctccac cgcaacgcaa tctttcctgg 354 cgacctgcgt caatggcgtg tgttggaccg tctaccatgg tgccggctcg aagaccctgg 360 ccggcccgaa gggtccaatc acccaaatgt acaccaatgt agaccaggac ctcgtcggct 366 ggccggcgcc ccccggggcg cgctccatga caccgtgcac ctgcggcagc tcggaccttt 372 acttggtcac gaggcatgct gatgtcgttc cggtgcgccg gcggggcgac agcaggggga 378 gcctgctttc ccccaggccc atctcctacc tgaagggctc ctcgggtgga ccactgcttt 384 gcccttcggg gcacgttgta ggcatcttcc gggctgctgt gtgcacccgg ggggttgcga 390 aggcggtgga cttcataccc gttgagtcta tggaaactac catgcggtct ccggtcttca 396 cagacaactc atcccctccg gccgtaccgc aaacattcca agtggcacat ttacacgctc 402 ccactggcag cggcaagagc accaaagtgc cggctgcata tgcagcccaa gggtacaagg 408 tgctcgtcct aaacccgtcc gttgccgcca cattgggctt tggagcgtat atgtccaagg 414 cacatggcat cgagcctaac atcagaactg gggtaaggac catcaccacg ggcggcccca 420 tcacgtactc cacctattgc aagttccttg ccgacggtgg atgctccggg ggcgcctatg 426 acatcataat atgtgatgaa tgccactcaa ctgactcgac taccatcttg ggcatcggca 432 cagtcctgga tcaggcagag acggctggag cgcggctcgt cgtgctcgcc accgccacgc 438 ctccgggatc gatcaccgtg ccacacccca acatcgagga agtggccctg tccaacactg 444 gagagattcc cttctatggc aaagccatcc ccattgaggc catcaagggg ggaaggcatc 450 tcatcttctg ccattccaag aagaagtgtg acgagctcgc cgcaaagctg acaggcctcg 456 gactcaatgc tgtagcgtat taccggggtc tcgatgtgtc cgtcataccg actagcggag 462 acgtcgttgt cgtggcaaca gacgctctaa tgacgggttt taccggcgac tttgactcag 468 tgatcgactg caacacatgt gtcacccaga cagtcgattt cagcttggat cccaccttca 474 ccattgagac gacaacgctg ccccaagacg cggtgtcgcg tgcgcagcgg cgaggtagga 480 ctggcagggg caggagtggc atctacaggt ttgtgactcc aggagaacgg ccctcaggca 486 tgttcgactc ctcggtcctg tgtgagtgct atgacgcagg ctgcgcttgg tatgagctca 492 cgcccgctga gacctcggtt aggttgcggg cttacctaaa tacaccaggg ttgcccgtct 498 gccaggacca cctagagttc tgggagagcg tcttcacagg cctcacccac atagatgccc 504 acttcttgtc ccagaccaaa caggcaggag acaacctccc ctacctggta gcataccaag 510 ccacagtgtg cgccagggct caggctccac ctccatcgtg ggaccaaatg tggaagtgtc 516 tcatacggct aaagcccaca ctgcatgggc caacgcccct gctgtacagg ctaggagccg 522 ttcaaaatga ggtcactctc acacacccca taaccaaata catcatggca tgcatgtcgg 528 ctgacctgga ggtcgtcact agcacctggg tgctagtagg cggagtcctt gcggctctgg 534 ccgcgtactg cctgacgaca ggcagcgtgg tcattgtggg caggatcatc ttgtccggga 540 ggccagctgt tattcccgac agggaagtcc tctaccagga gttcgatgag atggaagagt 546 gtgcttcaca cctcccttac atcgagcaag gaatgcagct cgccgagcaa ttcaaacaga 552 aggcgctcgg attgctgcaa acagccacca agcaagcgga ggctgctgct cccgtggtgg 558 agtccaagtg gcgagccctt gaggtcttct gggcgaaaca catgtggaac ttcatcagcg 564 ggatacagta cttggcaggc ctatccactc tgcctggaaa ccccgcgata gcatcattga 570 tggcttttac agcctctatc accagcccgc tcaccaccca aaataccctc ctgtttaaca 576 tcttgggggg atgggtggct gcccaactcg ctccccccag cgctgcttcg gctttcgtgg 582 gcgccggcat tgccggtgcg gccgttggca gcataggtct cgggaaggta cttgtggaca 588 ttctggcggg ctatggggcg ggggtggctg gcgcactcgt ggcctttaag gtcatgagcg 594 gcgagatgcc ctccactgag gatctggtta atttactccc tgccatcctt tctcctggcg 600 ccctggttgt cggggtcgtg tgcgcagcaa tactgcgtcg gcacgtgggc ccgggagagg 606 gggctgtgca gtggatgaac cggctgatag cgttcgcttc gcggggtaac cacgtctccc 612 ccacgcacta tgtgcccgag agcgacgccg cggcgcgtgt tactcagatc ctctccagcc 618 ttaccatcac tcagttgctg aagaggcttc atcagtggat taatgaggac tgctccacgc 624 cttgttccgg ctcgtggcta aaggatgttt gggactggat atgcacggtg ttgagtgact 630 tcaagacttg gctccagtcc aagctcctgc cgcggttacc gggactccct ttcctgtcat 636 gccaacgcgg gtacaaggga gtctggcggg gggatggcat catgcaaacc acctgcccat 642 gtggagcaca gatcaccgga catgtcaaaa atggctccat gaggattgtt gggccaaaaa 648 cctgcagcaa cacgtggcat ggaacattcc ccatcaacgc atacaccacg ggcccctgca 654 cgccctcccc agcgccgaac tattccaggg cgctgtggcg ggtggctgct gaggagtacg 660 tggaggttac gcgggtgggg gatttccact acgtgacggg catgaccact gacaacgtga 666 aatgcccatg ccaggttcca gcccctgaat ttttcacgga ggtggatgga gtacggttgc 672 acaggtatgc tccagtgtgc aaacctctcc tacgagagga ggtcgtattc caggtcgggc 678 tcaaccagta cctggtcggg tcacagctcc catgtgagcc cgaaccggat gtggcagtgc 684 tcacttccat gctcaccgac ccctctcata ttacagcaga gacggccaag cgtaggctgg 690 ccagggggtc tcccccctcc ttggccagct cttcagctag ccagttgtct gcgccttctt 696 tgaaggcgac atgtactacc catcatgact ccccggacgc tgacctcatc gaggccaacc 702 tcctgtggcg gcaggagatg ggcgggaaca tcacccgtgt ggagtcagaa aataaggtgg 708 taatcctgga ctctttcgat ccgattcggg cggtggagga tgagagggaa atatccgtcc 714 cggcggagat cctgcgaaaa cccaggaagt tccccccagc gttgcccata tgggcacgcc 720 cggattacaa ccctccactg ctagagtcct ggaaggaccc ggactacgtc cccccggtgg 726 tacacgggtg ccctttgcca tctaccaagg cccccccaat accacctcca cggaggaaga 732 ggacggttgt cctgacagag tccaccgtgt cttctgcctt ggcggagctc gctactaaga 738 cctttggcag ctccgggtcg tcggccgttg acagcggcac ggcgactggc cctcccgatc 744 aggcctccga cgacggcgac aaaggatccg acgttgagtc gtactcctcc atgccccccc 750 tcgagggaga gccaggggac cccgacctca gcgacgggtc ttggtctacc gtgagcgggg 756 aagctggtga ggacgtcgtc tgctgctcaa tgtcctatac atggacaggt gccttgatca 762 cgccatgcgc tgcggaggag agcaagttgc ccatcaatcc gttgagcaac tctttgctgc 768 gtcaccacag tatggtctac tccacaacat ctcgcagcgc aagtctgcgg cagaagaagg 774 tcacctttga cagactgcaa gtcctggacg accactaccg ggacgtgctc aaggagatga 780 aggcgaaggc gtccacagtt aaggctaggc ttctatctat agaggaggcc tgcaaactga 786 cgcccccaca ttcggccaaa tccaaatttg gctacggggc gaaggacgtc cggagcctat 7921 ccagcagggc cgtcaaccac atccgctccg tgtgggagga cttgctggaa gacactgaaa 7981 caccaattga taccaccatc atggcaaaaa atgaggtttt ctgcgtccaa ccagagaaag 8041 gaggccgcaa gccagctcgc cttatcgtat tcccagacct gggggtacgt gtatgcgaga 8101 agatggccct ttacgacgtg gtctccaccc ttcctcaggc cgtgatgggc ccctcatacg 8161 gattccagta ctctcctggg cagcgggtcg agttcctggt gaatacctgg aaatcaaaga 8221 aatgccctat gggcttctca tatgacaccc gctgctttga ctcaacggtc actgagaatg 8281 acatccgtac tgaggaatca atttaccaat gttgtgactt ggcccccgaa gccaggcagg 8341 ccataaggtc gctcacagag cggctttatg tcgggggtcc cctgactaat tcgaaggggc 8401 agaactgcgg ttatcgccgg tgccgcgcaa gtggcgtgct gacgactagc tgcggcaaca 8461 ccctcacatg ttacttgaag gccactgcgg cctgtcgagc tgcaaagctc caggactgca 8521 cgatgctcgt gaacggagac gaccttgtcg ttatctgtga gagtgcggga acccaggagg 8581 atgcggcggc cctacgagcc ttcacggagg ctatgactag gtattccgcc ccccccgggg 8641 acccgcccca accagaatac gacttggagc tgataacgtc atgctcctcc aatgtgtcgg 8701 tcgcgcacga tgcatccggc aaaagggtgt actacctcac ccgtgacccc accacccccc 8761 tcgcacgggc tgcgtgggag acagttagac acactccagt caactcctgg ctaggcaata 8821 tcatcatgta tgcgcccacc ctatgggcga ggatgattct gatgactcat ttcttctcta 8881 tccttctagc tcaggagcaa cttgaaaaag ccctggattg tcagatctac ggggcctgtt 8941 actccattga gccacttgac ctacctcaga tcattgaacg actccatggt cttagcgcat 9001 tttcactcca cagttactct ccaggtgaga tcaatagggt ggcttcatgc ctcaggaaac 9061 ttggggtacc gcctttgcga gtctggagac atcgggccag aagtgtccgc gctaagctac 9121 tgtcccaggg ggggagggct gccacttgcg gcaagtacct cttcaactgg gcagtaaaga 9181 ccaagcttaa actcactcca atcccggctg cgtcccagct agacttgtcc ggctggttcg 9241 ttgctggtta caacggggga gacatatatc acagcctgtc tcgtgcccga ccccgttggt 9301 tcatgttgtg cctactccta ctttctgtag gggtaggcat ctacctgctc cccaaccggt 9361 gaacggggag ctaaccactc caggccaata ggccattccc tttttttttt ttc (SEQ ID NO: 17)

General Target Region:

5' Untranslated Region - nts 1 - 328 - Internal Ribosome Entry Site (IRES):

5'UUGGGGGCGACACUCCACCAUAGAUCACUCCCCUGUGAGGAACUACUGUCU

UCACGCAGAAAGCGUCUAGCCAUGGCGUUAGUAUGAGUGUUGUGCAGCCUC

CAGGACCCCCCCUCCCGGGAGAGCCAUAGUGGUCUGCGGAACCGGUGAGUAC

ACCGGAAUUGCCAGGACGACCGGGUCCUUUCUUGGAUCAACCCGCUCAAUGC

CUGGAGAUUUGGGCGUGCCCCCGCGAGACUGCUAGCCGAGUAGUGUUGGGU

CGCGAAAGGCCUUGUGGUACUGCCUGAUAGGGUGCUUGCGAGUGCCCCGGG

AGGUCUCGUAGACCGUGCAU3' (SEQ ID NO: 18) Initial Specific Target Motifs:

(1) Subdomain flic within HCV IRES - nts 213 - 226 5ΑUUUGGGCGUGCCC3' (SEQ ID NO: 19)

(2) Subdomain Hid within HCV IRES - nts 241-267 5'GCCGAGUAGUGUUGGGUCGCGAAAGGC3' (SEQ ID NO: 20)

6.8. Ribonuclease P RNA ("RNaseP")

GenBank Accession #s

XI 5624 Homo sapiens RNaseP HI RNA:

1 atgggcggag ggaagctcat cagtggggcc acgagctgag tgcgtcctgt cactccactc 61 ccatgtccct tgggaaggtc tgagactagg gccagaggcg gccctaacag ggctctccct 121 gagcttcagg gaggtgagtt cccagagaac ggggctccgc gcgaggtcag actgggcagg 181 agatgccgtg gaccccgccc ttcggggagg ggcccggcgg atgcctcctt tgccggagct 241 tggaacagac tcacggccag cgaagtgagt tcaatggctg aggtgaggta ccccgcaggg 301 gacctcataa cccaattcag accactctcc tccgcccatt (SEQ ID NO: 21)

U64885 Staphylococcus aureus RNaseP (rrnB) RNA:

1 gaggaaagtc cgggctcaca cagtctgaga tgattgtagt gttcgtgctt gatgaaacaa 61 taaatcaagg cattaatttg acggcaatga aatatcctaa gtctttcgat atggatagag 121 taatttgaaa gtgccacagt gacgtagctt ttatagaaat ataaaaggtg gaacgcggta 181 aacccctcga gtgagcaatc caaatttggt aggagcactt gtttaacgga attcaacgta 241 taaacgagac acacttcgcg aaatgaagtg gtgtagacag atggttatca cctgagtacc 301 agtgtgacta gtgcacgtga tgagtacgat ggaacagaac gcggcttat (SEQ ID NO: 22)

M17569 Escherichia coli RNA component (Ml RNA) of ribonuclease P

(rnpB) gene: 1 gaagctgacc agacagtcgc cgcttcgtcg tcgtcctctt cgggggagac gggcggaggg 61 gaggaaagtc cgggctccat agggcagggt gccaggtaac gcctgggggg gaaacccacg 121 accagtgcaa cagagagcaa accgccgatg gcccgcgcaa gcgggatcag gtaagggtga 181 aagggtgcgg taagagcgca ccgcgcggct ggtaacagtc cgtggcacgg taaactccac 241 ccggagcaag gccaaatagg ggttcataag gtacggcccg tactgaaccc gggtaggctg 301 cttgagccag tgagcgattg ctggcctaga tgaatgactg tccacgacag aacccggctt 361 atcggtcagt ttcacct (SEQ ID NO: 23) Z70692 Mycobacterium tuberculosis RNaseP (rnpB) RNA:

1 ccaccggtta cgatcttgcc gaccatggcc ccacaatagg gccggggaga cccggcgtca 61 gtggtgggcg gcacggtcag taacgtctgc gcaacacggg gttgactgac gggcaatatc 121 ggctccatag cgtcggccgc ggatacagta aaggagcatt ctgtgacgga aaagacgccc 181 gacgacgtct tcaaacttgc caaggacgag aaggtcgaat atgtcgacgt ccggttctgt 241 gacctgcctg gcatcatgca gcacttcacg attccggctt cggcctttga caagagcgtg 301 tttgacgacg gcttggcctt tgacggctcg tcgattcgcg ggttccagtc gatccacgaa 361 tccgacatgt tgcttcttcc cgatcccgag acggcgcgca tcgacccgtt ccgcgcggcc 421 aagacgctga atatcaactt ctttgtgcac gacccgttca ccctggagcc gtactcccgc 481 gacccgcgca acatcgcccg caaggccgag aactacctga tcagcactgg catcgccgac 541 accgcatact tcggcgccga ggccgagttc tacattttcg attcggtgag cttcgactcg 601 cgcgccaacg gctccttcta cgaggtggac gccatctcgg ggtggtggaa caccggcgcg 661 gcgaccgagg ccgacggcag tcccaaccgg ggctacaagg tccgccacaa gggcgggtat 721 ttcccagtgg cccccaacga ccaatacgtc gacctgcgcg acaagatgct gaccaacctg 781 atcaactccg gcttcatcct ggagaagggc caccacgagg tgggcagcgg cggacaggcc 841 gagatcaact accagttcaa ttcgctgctg cacgccgccg acgacatgca gttgtacaag 901 tacatcatca agaacaccgc ctggcagaac ggcaaaacgg tcacgttcat gcccaagccg 961 ctgttcggcg acaacgggtc cggcatgcac tgtcatcagt cgctgtggaa ggacggggcc 1021 ccgctgatgt acgacgagac gggttatgcc ggtctgtcgg acacggcccg tcattacatc 1081 ggcggcctgt tacaccacgc gccgtcgctg ctggccttca ccaacccgac ggtgaactcc 1141 tacaagcggc tggttcccgg ttacgaggcc ccgatcaacc tggtctatag ccagcgcaac 1201 cggtcggcat gcgtgcgcat cccgatcacc ggcagcaacc cgaaggccaa gcggctggag 1261 ttccgaagcc ccgactcgtc gggcaacccg tatctggcgt tctcggccat gctgatggca 1321 ggcctggacg gtatcaagaa caagatcgag ccgcaggcgc ccgtcgacaa ggatctctac 1381 gagctgccgc cggaagaggc cgcgagtatc ccgcagactc cgacccagct gtcagatgtg 1441 atcgaccgtc tcgaggccga ccacgaatac ctcaccgaag gaggggtgtt cacaaacgac 1501 ctgatcgaga cgtggatcag tttcaagcgc gaaaacgaga tcgagccggt caacatccgg 1561 ccgcatccct acgaattcgc gctgtactac gacgtttaag gactcttcgc agtccgggtg 1621 tagagggagc ggcgtgtcgt tgccagggcg ggcgtcgagg tttttcgatg ggtgacggtg 1681 gccggcaacg gcgcgccgac caccgctgcg aagagcccgt ttaagaacgt tcaaggacgt 1741 ttcagccggg tgccacaacc cgcttggcaa tcatctcccg accgccgagc gggttgtctt 1801 tcacatgcgc cgaaactcaa gccacgtcgt cgcccaggcg tgtcgtcgcg gccggttcag 1861 gttaagtgtc ggggattcgt cgtgcgggcg ggcgtccacg ctgaccaacg gggcagtcaa 1921 ctcccgaaca ctttgcgcac taccgccttt gcccgccgcg tcacccgtag gtagttgtcc 1981 aggaattccc caccgtcgtc gtttcgccag ccggccgcga ccgcgaccgc attgagctgg 204 cgcccgggtc ccggcagctg gtcggtgggc ttgccgcgca ccaacaccag cgcgttgcgg 210 gcccgggtgg cggtcagcca ggcctgacgg agcagctcca cgtcggctgc gggaaccaga 216 tcggcggccg cgatgacatc cagggattgc agcgtcgagg tgttgtgcag ggcgggaacc 222 tggtgcgcat gctgtagctg cagcaactgc acggtccatt cgatgtcggc cagtccgccg 228 cggcccagtt tggtgtgtgt gttggggtcg gcaccgcgcg gcaaccgctc ggactcgata 234 cgggccttga tgcggcgaat ctcgcgcacc gagtcagcgg acacaccgtc gggcggatac 240 cgcgttttgt cgaccatccg taggaatcgc tgacccaact cggcatcgcc ggcaaccgcg 246 tgtgcgcgta gcagggcctg gatctcccat ggctgtgccc actgctcgta gtatgcggcg 252 taggacccca gggtgcggac cagcggaccg ttgcggccct cgggtcgcaa attggcgtcg 258 agctccagcg gcggatcgac gctgggtgtc cccagcagcg cccgaacccg ctcggcgatc 264 gatgtcgacc atttcaccgc ccgtgcatcg tcgacgccgg tggccggctc acagacgaac 270 atcacgtcgg catccgaccc gtagcccaac tcggcaccac ccagccgacc catgccgatg 276 accgcgatgg ccgccggggc gcgatcgtcg tcgggaaggc tggcccggat catgacgtcc 282 agcgcggcct gcagcaccgc cacccacacc gacgtcaacg cccggcacac ctcggtgacc 288 tcgagcaggc cgagcaggtc cgccgaaccg atgcgggcca gctctcgacg acgcagcgtg 294 cgcgcgccgg cgatggcccg ctccgggtcg gggtagcggc tcgccgaggc gatcagcgcc 300 cgagccacgg cggcgggctc ggtctcgagc agcttcgggc ccgcaggccc gtcctcgtac 306 tgctggatga cccgcggcgc gcgcatcaac agatccggca catacgccga ggtacccaag 312 acatgcatga gccgcttggc caccgcgggc ttgtcccgca gcgtggccag gtaccagctt 318 tcggtggcca gcgcctcact gagccgccgg taggccagca gtccgccgtc gggatcgggg 324 gcatacgaca tccagtccag cagcctgggc agcagcaccg actgcacccg tccgcgccgg 330 ccgctttgat tgaccaacgc cgacatgtgt ttcaacgcgg tctgcggtcc ctcgtagccc 336 agcgcggcca gccggcgccc cgcggcctcc aacgtcatgc cgtgggcgat ctccaacccg 342 gtcgggccga tcgattccag cagcggttga tagaagagtt tggtgtgtaa cttcgacacc 348 cgcacgttct gcttcttgag ttcctcccgc agcaccccgg ccgcatcgtt tcggccatcg 354 ggccggatgt gggccgcgcg cgccagccag cgcactgcct cctcgtcttc gggatcggga 360 agcaggtggg tgcgcttgag ccgctgcaac tgcagtcggt gctcgagcag cctgaggaac 366 tcatacgacg cggtcatgtt cgccgcgtcc tcacgcccga tgtagccgcc ttcgcccaac 372 gccgccaatg cgtccaccgt ggacgccacc cgtaacgact cgtcgctacg ggcatgaacc 378 agctgcagta gctgtacggc gaactccacg tcgcgcaatc cgccgctgcc gagtttgagc 384 tcgcggccgc ggacatcggc gggcaccagc tgctccaccc gccgccgcat ggcctgcacc 390 tcgaccacaa agtcttcgcg ctcgcaggct cgccacacca tcggcatcaa ggcggtcagg 396 taacgctcgc caagttccgc gtcgccaacg actggccgtg ctttcagcaa cgcctgaaac 402 tcccaggtct tggcccagcg ctggtagtag gcgatgtgcg actcgagcgt acggaccagc 408 tccccgttgc gcccctccgg acgcagggcg gcgtccacct cgaaaaaggc cgccgaggcc 414 acccgcatca tctcgctggc cacgcgcgcg ttgcgcgggt cggagcgctc ggcaacgaat 420 atgacatcga cgtcgctgac gtagttcagt tcgcgcgcac cgcacttgcc catcgcgatg 426 accgccaggc gcggtggcgg gtgctcgccg cacacgctcg cctcggccac gcgcagcgcc 432 gccgccagag cggcgtccgc ggcgtccgcc aggcgtgcgg ccaccacggt gaatggcagc 438 accggttcgt cctcgaccgt cgcggccagg tcgagagcgg ccagcattag cacgtagtcg 444 cggtactggg ttcgcaatcg gtgcacgagc gagcccggca taccctccga ttcctcgacg 450 cactcgacga acgaccgctg cagctggtca tgggacggca gtgtgacctt gccccgcagc 456 aatttccagg actgcggatg ggcgaccagg tgatcgccca acgccagcga cgagcccagc 462 accgagaaca gccgcccgcg cagactgcgt tcgcgcagca gagccgcgtt gagctcgtcc 468 catccggtgt ctggattctc cgacagccgg atcaaggcgc gcagcgcggc atcggcgtcc 474 ggagcgcgtg acagcgacca cagcaggtcg acgtgcgcct gatcctcgtg ccgatcccac 480 cccagctgag ccagacgctc accagcaggg gggtcaacta atccgagccg gccaacgctg 486 ggcaacttcg gccgctgcgt ggcgagtttg gtcacgacca cgacggtagc gcaaagcgcg 492 tcggcgtcgg atcaaccggt agatctgggc tacagcgaca ggtaggtgcg cagctcgtat 498 ggcgtgacgt ggctgcggta gttcgcccac tccgtgcgct tgttgcgcaa gaaaaagtca 504 aaaacgtgct cccccaaggc ctccgcgacg agttcggagg cctccatggc gcgcagcgca 510 ctatccaaac tggacggcaa ttctcggtac cccatcgctc ggcgttcctc gggtgtgagg 516 tcccatacgt tgtcctcggc ctgcgggccc agcacgtaac ccttctctac accccgcaat 522 cccgcggcca gcagcacggc gaatgtcaga tagggattgc acgccgaatc agggctgcgt 528 acttcgaccc gccgcgacga ggtcttgtgc ggcgtgtaca tcggcacccg cactagggcg 534 gatcggttgg cggcccccca cgacgcggcc gtgggcgctt cgccgccctg caccagccgc 540 ttgtaagagt tgacccactg atttgtgacc gcgctgatct cgcaagcgtg ctccaggatc 546 ccggcgatga acgatttacc cacttccgac agctgcagcg gatcatcagc gctgtggaac 552 gcgttgacat caccctcgaa caggctcatg tgggtgtgca tcgccgagcc cgggtgctgg 558 ccgaatggct tgggcatgaa cgacgcccgg gcgccctctt ccagcgcgac ttctttgatg 564 acgtagcgga aggtcatcac gttgtcagcc atcgacagag cgtcggcaaa ccgcaggtcg 570 atctcctgct ggccgggtgc gccttcgtga tggctgaact ccaccgagat gcccatgaat 576 tccagggcat cgatcgcgtg gcggcgaaag ttcaaggcgg agtcgtgcac cgcttggtcg 582 aaatagccgg cgttgtcgac cgggacgggc accgacccgt cctcgggtcc gggcttgagc 588 aggaagaact cgatttcggg atgcacgtag caggagaagc cgagttcgcc ggccttcgtc 594 agctgccgcc gcaacacgtg ccgcgggtcc gcccacgacg gcgagccgtc cggcatggtg 600 atgtcgcaaa acatccgcgc tgagtggtgg tggccggaac tggtggccca gggcagcacc 606 tggaaggtcg acgggtccgg gtgcgccacc gtatcggatt ccgagacccg cgcaaagccc 612 tcgatcgagg atccgtcgaa gccgatgcct tcctcgaagg cgccctcgag ttcggctggg 618 gcgatggcga ccgacttgag gaaaccgagc acgtctgtga accacagccg gacgaagcgg 624 atgtcgcgtt cttccagggt acgaagaacg aattccttct gtcggtccat acctcgaaca 630 gtatgcactg tctgttaaaa ccgtgttacc gatgcccggc cagaagcgtt gcggggcggc 636 ccgcaagggg agtgcgcggt gagttcaggg cgcgcaccgc agactcgtcg gcggcaaggt 642 cccgtcgaga aaatagtgca tcaccgcaga gtccacacac tggttgccat cgaacaccgc 648 agtgtgttgg gtgccgtcga aggtgatcag cggtgcgccc agctggcggg ccaggtctac 654 cccggactga tacggagtgg ccgggtcgtg ggtggtggac accacgacga ccttgccagc 660 cccggccggc gccgcggggt gcggcgtcga cgttgccggc accggccaca gcgcgcacag 666 atcgcggggg gcggatccgg tgaactgccc gtagctaagg aacggggcga cctgacggat 672 ccgttggtcg gcggccaccc aggccgctgg atcggccggt gtgggcgcat cgacgcaccg 678 gaccgcgttg aacgcgtcct ggtcgttgct gtagtgcccg tctgcatccc ggccgtcata 684 gtcgtcggca agcaccagca agtcgccggc gtcgctgccg cgctgcagcc ccagcagacc 690 actggtcagg tacttccagc gctgagggct gtacagcgcg ttgatggtgc ccgtcgtcgc 696 gtcggcgtag ctcaggccac gtggatccga cgtcttaccc ggcttctgca ccagcgggtc 702 aaccagggcg tggtagcggt tgacccactg ggccgagtcg gtgcccagag ggcaggccgg 708 cgagcgggcg cagtcggcgg cgtagtcatt gaaagcggtc tgaaatcccg ccatttggct 714 gatgctttcc tcgattgggc taacggctgg atcgatagcg ccgtcgagga ccatcgcccg 720 cacatgagta ccgaaccgtt ccaggtaagc ggtgcccaac tcggtgccgt agctgtatcc 726 gaggtagttg atctgatcgt cacctaacgc ttggcgaacc atgtccatgt cccgtgcgac 732 ggacgcggta ccgatattgg ccaagaagct gaagcccatc cggtcaacac agtcctgggc 738 caactgccgg tagacctgtt cgacgtgggt gacaccggcc ggactgtagt cggccatcgg 744 atcgcgccgg tacgcgtcga actcggcgtc ggtgcgacac cgcaacgcag gggtcgagtg 750 gccgacccct ctcgggtcga agcccaccag gtcgaagtgg cggagaatgt cggtgtcggc 756 gatcgcgggt gccatagcgg cgaccatgtc gaccgccgac gccccgggtc ccccaggatt 762 gaccagcagt gctccgaatc gctgtcccgt cgcggggacg cggatcaccg ccaacttcgc 768 ttgtgtccca ccgggttggt cgtagtcgac ggggacggac accgtcgcgc agcgtgcagt 774 gcgaatttcg ctggtgtcgg cgatgaactc gcggcagctg ttccaactct gttgcggcgc 780 cacgaccggc gcacccgggg tttggccggc gccgggttct tcagtcgcgc cggccaacgg 786 gggcgctgct aggggcagtc cgccgagcag caacccgaag gacagcagcg ccgagctcaa 792 cggtctgcgg cgccacatgg ccgccatcgt ctcaccggcg aatacctgtg acggcgcgaa 798 atgatcacac cttcgtttct tcgccccgct agcacttggc gccgctgggc ggcgtggtgc 804 cgccgattaa atacgccgtc acgtactcgt caatgcagct gtcgccctgg aataccaccg 810 tgtgctgggt tccgtcgaag gtcagcaacg aaccgcgaag ctggttcgcc aggtcgaccc 816 cggccttgta cggcgtcgcc gggtcatggg tggtggatac caccaccgtc ggcactaggc 822 cgggcgccga gacggcatgg ggctgacttg tgggtggcac cggccagaac gcgcaggtgc 828 ccagcggcgc atcaccggtg aacttcccgt agctcatgaa cggtgcgatc tcccgggcgc U ggcggtcttc gtcgatgacc ttgtcgcgat cggtaaccgg gggctgatcg acgcaattga )1 tcgccacccg cgcgtcaccg gaattgttgt agcggccgtg cgagtcccga cgcatgtaca >1 tgtcggccag agccagcagg gtgtctccgc gattgtcgac cagctccgac agcccgtcgg \1 tcaagtgttg ccacagattc ggtgagtaca gcgccataat ggtgcccacg atggcgtcgc !1 tataactcag cccgcgcgga tccttcgtgc gcgccggcct gctgatcctc gggttgtccg H ggtcgaccaa cggatcgacc aggctgtggt agacctcgac ggctttggcc gggtcggcgc )1 ccagcgggca gcccgcgttc ttggcgcagt cggcggcata gttgttgaac gcgtcctgga 51 agcccttggc ctggcgcagc tccgcctcga tgggatcggc attggggtcg acggcaccgt \1 cgagaatcat tgcccgcacc cgctgcggaa attcctcggc atacgcggag ccgatccggg >1 tgccgtacga gtagcccagg taggtcagct tgtcgtcgcc caacgccgcg cgaatggcat H ccaggtcctt ggcgacgttg accgtcccga catgggccag aaagttcttg cccatcttgt )1 ccacacagcg accgacgaat tgcttggtct cgttctcgat gtgcgccaca ccctcccggc >1 tgtagtcaac ctgcggctcg gcccgcagcc ggtcgttgtc ggcatcggag ttgcaccaga >1 tcgccggccg ggacgacgcc accccgcggg ggtcgaaccc aaccaggtcg aacctttcgt >1 gcacccgctt cggcaatgtc tggaagacgc ccaaggcggc ctcgataccg gattcgccgg H gtccaccggg atttatgacc agcgaaccga tcttgtctcc cgtcgccgga aagcgaatca )1 gcgccagcgc cgccacgtca ccatcggggc ggtcgtagtc gaccggtaca gcgagcttgc )1 cgcataacgc gccgccgggg atctttactt gcgggtttga cgaccggcac ggtgtccact >1 ccaccggctg gcccagcttc ggctccgcca tacgagcgcg tcccccgacc acgcggatgc 51 agcccacaag aaccaacgcc acggcggcga gcgcggccca gatcaacagc atgcgcgcga U tcttgtcgcg gcgagacagc ctcatgccca caatgctgcc agagcagacc cgagatcctg )1 gccagcggcc accgtcggcc gactaaccgg ccgctgccag cagtcctgcc atcgccgatg >1 gcgaactcgt cggccatccc ccatacgtcc ggtaacagat ccgggcaaga caccgacccg 1 tcgaccggat ccggcacggg cgcgtcggcc tcggcggtgc acaactgcga catcaggttg 51 gcgctggcac cccgtccacg ccggcatggt gcaccttggc catcgcccga gggcgatccc H cgatgccgtc caccccttcg acgaacccat ctcccacggc ggtcgccggc agcgacgcga )1 tgtggccgca gatctccgag agttcggccc gcccgcccgg cgacggcaac ccgatgccgt >1 gcaagtgacg atcgatgtga ggttcaaggt tcagcgcact gctggcaagc tttttccgaa 11 accgcggcct cgccttgatc tggagtcaga acgcgtcacg cagccggtca aaggcgtaac 1 ccatgctcga gcaaacatgc atgggctgag tggacgtttc cagacacagc aactggcgtc H caggccactg agccgctgca tgcgcgatgg tatgccgatg ggggccccgg gcgcgtctga )1 ggggaagaag tggcagactg tcagggtccg acgaacccgg ggaccctaac gggccacgag >1 gatcgacccg accaccatta gggacagtga tgtctgagca gactatctat ggggccaata il cccccggagg ctccgggccg cggaccaaga tccgcaccca ccacctacag agatggaagg il ccgacggcca caagtgggcc atgctgacgg cctacgacta ttcgacggcc cggatcttcg 1044 acgaggccgg catcccggtg ctgctggtcg gtgattcggc ggccaacgtc gtgtacggct 1050 acgacaccac cgtgccgatc tccatcgacg agctgatccc gctggtccgt ggcgtggtgc 1056 ggggtgcccc gcacgcactg gtcgtcgccg acctgccgtt cggcagctac gaggcggggc 1062 ccaccgccgc gttggccgcc gccacccggt tcctcaagga cggcggcgca catgcggtca 1068 agctcgaggg cggtgagcgg gtggccgagc aaatcgcctg tctgaccgcg gcgggcatcc 1074 cggtgatggc acacatcggc ttcaccccgc aaagcgtcaa caccttgggc ggcttccggg 1080 tgcagggccg cggcgacgcc gccgaacaaa ccatcgccga cgcgatcgcc gtcgccgaag 1086 ccggagcgtt tgccgtcgtg atggagatgg tgcccgccga gttggccacc cagatcaccg 1092 gcaagcttac cattccgacg gtcgggatcg gcgctgggcc caactgcgac ggccaggtcc 1098 tggtatggca ggacatggcc gggttcagcg gcgccaagac cgcccgcttc gtcaaacggt 1104 atgccgatgt cggtggtgaa ctacgccgtg ctgcaatgca atacgcccaa gaggtggccg 1110 gcggggtatt ccccgctgac gaacacagtt tctgaccaag ccgaatcagc ccgatgcgcg 1116 ggcattgcgg tggcgccctg gatgccgtcg acgccggatt gccggcgcgg acgcgccagc 1122 gggacccatc ggcgtcgcgt tcgccggttg agcccggggt gagcccagac attcgatgtg 1128 cccaacacca tccgccacag cccaattgat gtggcactct atgcatgcct atccccgacc 1134 aaccaccacc gcggcgacgc atcatgaccg gaggcgaaga tgccagtaga ggcgcccaga 1140 ccagcgcgcc atctggaggt cgagcgcaag ttcgacgtga tcgagtcgac ggtgtcgccg 1146 tcgttcgagg gcatcgccgc ggtggttcgc gtcgagcagt cgccgaccca gcagctcgac 1152 gcggtgtact tcgacacacc gtcgcacgac ctggcgcgca accagatcac cttgcggcgc 1158 cgcaccggcg gcgccgacgc cggctggcat ctgaagctgc cggccggacc cgacaagcgc 1164 accgagatgc gagcaccgct gtccgcatca ggcgacgctg tgccggccga gttgttggat 1170 gtggtgctgg cgatcgtccg cgaccagccg gttcagccgg tcgcgcggat cagcactcac 1176 cgcgaaagcc agatcctgta cggcgccggg ggcgacgcgc tggcggaatt ctgcaacgac 1182 gacgtcaccg catggtcggc cggggcattc cacgccgctg gtgcagcgga caacggccct 1188 gccgaacagc agtggcgcga atgggaactg gaactggtca ccacggatgg gaccgccgat 1194 accaagctac tggaccggct agccaaccgg ctgctcgatg ccggtgccgc acctgccggc 1200 cacggctcca aactggcgcg ggtgctcggt gcgacctctc ccggtgagct gcccaacggc 1206 ccgcagccgc cggcggatcc agtacaccgc gcggtgtccg agcaagtcga gcagctgctg 1212 ctgtgggatc gggccgtgcg ggccgacgcc tatgacgccg tgcaccagat gcgagtgacg 1218 acccgcaaga tccgcagctt gctgacggat tcccaggagt cgtttggcct gaaggaaagt 1224 gcgtgggtca tcgatgaact gcgtgagctg gccgatgtcc tgggcgtagc ccgggacgcc 1230 gaggtactcg gtgaccgcta ccagcgcgaa ctggacgcgc tggcgccgga gctggtacgc 1236 ggccgggtgc gcgagcgcct ggtagacggg gcgcggcggc gataccagac cgggctgcgg 1242 cgatcactga tcgcattgcg gtcgcagcgg tacttccgtc tgctcgacgc tctagacgcg 1248 cttgtgtccg aacgcgccca tgccacttct ggggaggaat cggcaccggt aaccatcgat 1254 gcggcctacc ggcgagtccg caaagccgca aaagccgcaa agaccgccgg cgaccaggcg 1260 ggcgaccacc accgcgacga ggcattgcac ctgatccgca agcgcgcgaa gcgattacgc 1266 tacaccgcgg cggctactgg ggcggacaat gtgtcacaag aagccaaggt catccagacg 1272 ttgctaggcg atcatcaaga cagcgtggtc agccgggaac atctgatcca gcaggccata 1278 gccgcgaaca ccgccggcga ggacaccttc acctacggtc tgctctacca acaggaagcc 1284 gacttggccg agcgctgccg ggagcagctt gaagccgcgc tgcgcaaact cgacaaggcg 1290 gtccgcaaag cacgggattg agcccgccag gggcggacga gttggcctgt aagccggatt 1296 ctgttccgcg ccgccacagc caagctaacg gcggcacggc ggcgaccatc catctggaca 1302 caccgttacc gggtgcctcg agcggcctac ccgcaggctc gggcgagcaa ccctcaagcg 1308 cctgcgcggc cgcactttcg gtgcggcctt cttggccttg cttcgggtgg ggtttgccta 1314 gccaccccgg tcacccggaa tgctggtgcg ctcttaccgc accgtttcac ccttgccacc 1320 acgaggatgg cggtctgttt tctgtggcac tttcccgcga gtcacctcgg attgccgtta 1326 gcaatcaccc tgctctgtga agtccggact ttcctcgact cgacgctgaa cctcgtgaat 1332 ccacacaagc cctacgcgag ccgcggccgc ccagccaact catccgcgac gaccacgcta 1338 ccccgctggg cggtgtcgcg gccagtgtga ccgctggacg acacggctag tcggacagcc 1344 gatccggcgg gcagtcctta tcgtggactg gtgacacggt gggacaaacg cgtcgactcc 1350 ggcgactggg acgccatcgc tgccgaggtc agcgagtacg gtggcgcact gctacctcgg 1356 ctgatcaccc ccggcgaggc cgcccggctg cgcaagctgt acgccgacga cggcctgttt 1362 cgctcgacgg tcgatatggc atccaagcgg tacggcgccg ggcagtatcg atatttccat 1368 gccccctatc ccgagtgatc gagcgtctca agcaggcgct gtatcccaaa ctgctgccga 1374 tagcgcgcaa ctggtgggcc aaactgggcc gggaggcgcc ctggccagac agccttgatg 1380 actggttggc gagctgtcat gccgccggcc aaacccgatc cacagcgctg atgttgaagt 1386 acggcaccaa cgactggaac gccctacacc aggatctcta cggcgagttg gtgtttccgc 1392 tgcaggtggt gatcaacctg agcgatccgg aaaccgacta caccggcggc gagttcctgc 1398 ttgtcgaaca gcggcctcgc gcccaatccc ggggtaccgc aatgcaactt ccgcagggac 1404 atggttatgt gttcacgacc cgtgatcggc cggtgcggac tagccgtggc tggtcggcat 1410 ctccagtgcg ccatgggctt tcgactattc gttccggcga acgctatgcc atggggctga 1416 tctttcacga cgcagcctga ttgcacgcca tctatagata gcctgtctga ttcaccaatc 1422 gcaccgacga tgccccatcg gcgtagaact cggcgatgct cagcgatgcc agatcaagat 1428 gcaaccgata taggacgccc gacccggcat ccaacgccag ccgcaacaac attttgatcg 1434 gcgtgacatg tgacaccacc agcaccgtcg cgccttcgta gccaacgatg atccgatcac 1440 gtccccgccg aacccgccgc agcacgtcgt cgaagctttc cccacccggg ggcgtgatgc 1446 tggtgtcctg cagccagcga cggtgcagct cgggatcgcg ttctgcggcc tccgcgaacg 1452 tcagcccctc ccaggcgccg aagtcggtct cgaccaggtc gtcatcgacg accacgtcca 1458 gggccagggc tctggcggcg gtcaccgcgg tgtcgtaagc ccgctgtagc ggcgaggaga 1464 ccaccgcagc gatcccgccg cgccgcgcca gatacccggc cgccgcacca acctggcgcc 1470 accccacctc gttcaacccc gggttgccgc gccccgaata gcggcgttgc tccgacagct 1476 ccgtctgccc gtggcgcaac aaaagtagtc gggtgggtgt accgcgggcg ccggtccagc 1482 cgggagatgt cggtgactcg gtcgcaacga ttttggcagg atccgcatcc gccgcagccg 1488 attgcgcggc ggcgtccatc gcgtcattgg ccaaccggtc tgcatacgtg ttccgggcac 1494 gcggaaccca ctcgtagttg atcctgcgaa actgggacgc caacgcctga gcctggacat 1500 agagcttcag cagatccggg tgcttgacct tccaccgccc ggacatctgc tccaccacca 1506 gcttggagtc catcagcacc gcggcctcgg tggcacctag tttcacggcg tcgtccaaac 1512 cggctatcag gccgcggtat tcggcgacgt tgttcgtcgc ccggccgatc gcctgcttgg 1518 actcggccag cacggtggag tgatcggcgg tccacaccac cgcgccgtat ccggccggtc 1524 cgggattgcc ccgcgatccg ccgtcggctt cgatgacaac tttcactcct caaatccttc 1530 gagccgcaac aagatcgctc cgcattccgg gcagcgcacc acttcatcct cggcggccgc 1536 cgagatctgg gccagctcgc cgcggccgat ctcgatccgg caggcaccac atcgatgacc 1542 ttgcaaccgc ccggcccctg gcccgcctcc ggcccgctgt ctttcgtaga gccccgcaag 1548 ctcgggatca agtgtcgccg tcagcatgtc gcgttgcgat gaatgttggt gccgggcttg 1554 gtcgatttcg gcaagtgcct cgtccaaagc ctgctgggcg gcggccaggt cggcccgcaa 1560 cgcttggagc gcccgcgact cggcggtctg ttgagcctgc agctcctcgc ggcgttccag 1566 cacctccagc agggcatctt ccaaactggc ttgacggcgt tgcaagctgt cgagctcgtg 1572 ctgcagatca gccaattgct tggcgtccgt tgcacccgaa gtgagcaacg accggtcccg 1578 gtcgccacgc ttacgcaccg catcgatctc cgactcaaaa cgcgacacct ggccgtccaa 1584 gtcctccgcc gcgattcgca gggccgccat cctgtcgttg gcggcgttgt gctcggcctg 1590 cacctgctgg taagccgccc gctgcggcag atgggtagcc cgatgcgcga tccgggtcag 1596 ctcagcatcc agcttcgcca attccagtag cgaccgttgc tgtgccactc cggctttcat 1602 gcctgatctc tcccagtttc gtgatcgagg ttccacgggt cggtgcagat ggtgcacaca 1608 cgcaccggca gcgacgcgcc gaaatgagac cgcaacactt cggcggcctg gccgcaccac 1614 gggaattcgc ttgcccaatg cgcgacgtcg atcagggcca cttgcgaagc tcggcaatgc 1620 tcgtcggctg gatgatgtcg cagatcggcc gtaacgtacg cttgcacgtc cgcggcggcc 1626 acggtggcaa gcaacgagtc cccggcgccg ccgcagaccg cgacccgcga caccagcagg 1632 tcgggatccc cggcggcgcg cacaccggtc gcagtcggcg gcaacgcggc ctccagacgg 1638 gcaacaaagg tgcgcagcgg ttcgggtttt ggcagtctgc caatccggcc taacccgctg 1644 ccgaccggcg gtggtaccag cgcgaagatg tcgaatgccg gctcctcgta agggtgcgcg 1650 gcgcgcatcg ccgccaacac ctcggcgcgc gctcgtgcgg gtgcgacgac ctcgacccgg 1656 tcctcggcca cccgttcgac ggtaccgacg ctgcctatgg cgggcgacgc cccgtcgtgc 1662 gccaggaact gcccggtacc cgcgacactc cagctgcagt gcgagtagtc gccgatatgg 1668 ccggcaccgg cctcaaagac cgctgcccgc accgcctctg agttctcgcg cggcacatag 1674 atgacccact tgtcgagatc ggccgctccg ggcaccgggt cgagaacggc gtcgacggtc 1680 agaccaacag cgtgtgccag cgcgtcggac acacccggcg acgccgagtc ggcgttggtg 1686 tgcgcggtaa acaacgagcg accggtccgg atcaggcggt gcaccagcac accctttggc 1692 gtgttggccg cgaccgtatc gaccccacgc agtaacaacg ggtggtgcac caatagcagt 1698 ccggcctggg gaacctggtc caccaccgcc ggcgtcgcgt ccaccgcaac ggtcaccgaa 1704 tccaccacgt cgtcggggtc gccgcacacc agacccaccg aatcccacga ctgggcaagc 1710 cgcggcgggt aggcctggtc cagcacgtcg atgacatcgg ccagccgcac actcatcggc 1716 gtcctccacg ctttgcccac tcggcgatcg ccgccaccag cacgggccac tccgggcgca 1722 ccgccgcccg caggtaccgc gcgtccaggc cgacgaaggt gtcaccgcgg cgcaccgcaa 1728 ttcctttgct ctgcaaatag tttcgtaatc cgtcagcatc ggcgatgttg aacagtacga 1734 aaggggccgc accatcgacc acctcggcac ccaccgatct cagtccggcc accatctccg 1740 cgcgcagcgc cgtcaaccgc accgcatcgg ctgcggcagc ggcgaccgcc cggggggcgc 1746 agcaagcagc gatggccgtc agttgcaatg ttcccaacgg ccagtgcgct cgctgcacgg 1752 tcaaccgagc cagcacgtct ggcgagccga gcgcgtagcc cacccgcaat ccggccagcg 1758 accacgtttt cgtcaagcta cggagcacca gcacatcggg cagcgagtca tcggccaacg 1764 attgcggctc gccgggaacc caatcagcga acgcctcgtc gaccaccagg atgcgtcccg 1770 gccggcgtaa ctcgagcagc tgctcgcgga ggtgcagcac cgaggtgggg ttggtcggat 1776 tacccacgac gacaaggtcg gcgtcgtcag gcacgtgcgc ggtgtccagc acgaacggcg 1782 gctttaggac aacatggtgc gccgtgattc cggcagcgct caaggctatg gccggctcgg 1788 tgaacgcggg cacgacgatt gctgcccgca ccggacttag gttgtgcagc aatgcgaatc 1794 cctccgccgc cccgacgagc gggagcactt cgtcacgggt tctgccatga cgttcagcga 1800 ccgcgtcttg cgcccggtgc acatcgtcgg tgctcggata gcgggccagc tccggcagca 1806 gcgcggcgag ctgccggacc aaccattccg ggggccggtc atggcggacg ttgacggcga 1812 agtccagcac gccgggcgcg acatcctgat caccgtggta gcgcgccgcg gcaagcgggc 1818 tagtgtctag actcgccaca gcgtcaaaca gtagtgggcc ggtgtgcggg ccaagaatcc 1824 agagcaccgc cgacgcgttg tctacgcggc gacaaccgcg acatcacagg cagctaacag 1830 ggcgtcggcg gtgatgatcg tcaggccaag cagctgtgcc tgggcgatga gcacacggtc 1836 gaatggatgt cgatggtgat ccggaagctc tgcggtgcgc agtgtgtgcg tggtcaactg 1842 acagcggcga cgtgccgcag cggcgcattc gatcgggcac gtaagaagcc gatggctcgg 1848 gcggcgggag cttgccgagg cggtagttga tcgcgatctc ccaggcactg gcggccgaca 1854 agagaatgct gttgcggacg tcctgaacaa tcgcccgtgt ttcgttgacg gcatccgcag 1860 ccaaacgtgg gtgtcgatga ggtagcgctt caccggtgaa agcgttcgag cacgtcgtct 1866 gacaacggag cgtccaaatc gtcgggcacg cggtacacgc catggtcaat gcctaaccgc 1872 cgagtctcat gaggatgcag cggcacaagc tttgctaccg gctcgccgcg gcgggcaatc 1878 tcaacctctg cccgccgtag acgagccgca gcagctcgga caggcgtgtc ttcgcctcgt 1884 gaacgccgac ccgcttcgca ggcgcccaga ctttcgcgtc gaccacctgc tcaccaaact 1890 tcgcgatcat cgcctgatac cacagcgcca acgggtagcg gtttgtccaa ccgcttcgtc 1896 aacgacaatg ggatcgtgac cgacacgacc gcgagcggga ccaattgccc gcctcctcca 1902 cgcgccgccg cacggcgcgc atcgtcgccg ggtgaatcgc cgcagctggt gatcttcgat 1908 ctggacggca cgctgaccga ctcggcgcgc ggaatcgtat ccagcttccg acacgcgctc 1914 aaccacatcg gtgccccagt acccgaaggc gacctggcca ctcacatcgt cggcccgccc 1920 atgcatgaga cgctgcgcgc catggggctc ggcgaatccg ccgaggaggc gatcgtagcc 1926 taccgggccg actacagcgc ccgcggttgg gcgatgaaca gcttgttcga cgggatcggg 1932 ccgctgctgg ccgacctgcg caccgccggt gtccggctgg ccgtcgccac ctccaaggca 1938 gagccgaccg cacggcgaat cctgcgccac ttcggaattg agcagcactt cgaggtcatc 1944 gcgggcgcga gcaccgatgg ctcgcgaggc agcaaggtcg acgtgctggc ccacgcgctc 1950 gcgcagctgc ggccgctacc cgagcggttg gtgatggtcg gcgaccgcag ccacgacgtc 1956 gacggggcgg ccgcgcacgg catcgacacg gtggtggtcg gctggggcta cgggcgcgcc 1962 gactttatcg acaagacctc caccaccgtc gtgacgcatg ccgccacgat tgacgagctg 1968 agggaggcgc taggtgtctg atccgctgca cgtcacattc gtttgtacgg gcaacatctg 1974 ccggtcgcca atggccgaga agatgttcgc ccaacagctt cgccaccgtg gcctgggtga 1980 cgcggtgcga gtgaccagtg cgggcaccgg gaactggcat gtaggcagtt gcgccgacga 1986 gcgggcggcc ggggtgttgc gagcccacgg ctaccctacc gaccaccggg ccgcacaagt 1992 cggcaccgaa cacctggcgg cagacctgtt ggtggccttg gaccgcaacc acgctcggct 1998 gttgcggcag ctcggcgtcg aagccgcccg ggtacggatg ctgcggtcat tcgacccacg 2004 ctcgggaacc catgcgctcg atgtcgagga tccctactat ggcgatcact ccgacttcga 2010 ggaggtcttc gccgtcatcg aatccgccct gcccggcctg cacgactggg tcgacgaacg 2016 tctcgcgcgg aacggaccga gttgatgccc cgcctagcgt tcctgctgcg gcccggctgg 2022 ctggcgttgg ccctggtcgt ggtcgcgttc acctacctgt gctttacggt gctcgcgccg 2028 tggcagctgg gcaagaatgc caaaacgtca cgagagaacc agcagatcag gtattccctc 2034 gacaccccgc cggttccgct gaaaaccctt ctaccacagc aggattcgtc ggcgccggac 2040 gcgcagtggc gccgggtgac ggcaaccgga cagtaccttc cggacgtgca ggtgctggcc 2046 cgactgcgcg tggtggaggg ggaccaggcg tttgaggtgt tggccccatt cgtggtcgac 2052 ggcggaccaa ccgtcctggt cgaccgtgga tacgtgcggc cccaggtggg ctcgcacgta 2058 ccaccgatcc cccgcctgcc ggtgcagacg gtgaccatca ccgcgcggct gcgtgactcc 2064 gaaccgagcg tggcgggcaa agacccattc gtcagagacg gcttccagca ggtgtattcg 2070 atcaataccg gacaggtcgc cgcgctgacc ggagtccagc tggctgggtc ctatctgcag 2076 ttgatcgaag accaacccgg cgggctcggc gtgctcggcg ttccgcatct agatcccggg 2082 ccgttcctgt cctatggcat ccaatggatc tcgttcggca ttctggcacc gatcggcttg 2088 ggctatttcg cctacgccga gatccgggcg cgccgccggg aaaaagcggg gtcgccacca 2094 ccggacaagc caatgacggt cgagcagaaa ctcgctgacc gctacggccg ccggcggtaa 2100 accaacatca cggccaatac cgcagccccc gcctggacca cccgcgacag caccacggcg 2106 cggcgcagat cggccacctt gggcgaccgg ccgtcgccca aggtgggccg gatctgcaac 2112 tcatggtggt accgggtggg cccacccagc cgcacgtcaa gcgccccagc aaacgccgcc 2118 tcgacgacac cggcgttggg gctgggatgg cgggcggcgt cgcgccgcca ggcccgtacc 2124 gcaccgcggg gcgacccacc gaccaccggc gcgcagatca ccaccagcac cgccgtcgcc 2130 cgtgcgccaa catagttggc ccagtcatcc aatcgtgctg cagcccaacc gaatcggaga 2136 taacgcggcg agcggtagcc gatcatcgag tccagggtgt tgatggcacg atatcccagc 2142 accgcaggca cgccgctcga agccgcccac agcagcggca ccacctgggc gtcggcggtg 2148 ttttcggcca ccgactccag cgcggcacgc gtcaggcccg ggccgcccag ctgggccggg 2154 tcacgcccgc acagcgacgg cagcagccgt cgcgccgcct cgacatcgtc gcgctccaac 2160 aggtccgata tctggcggcc ggtgcgcgcc agcgaagttc cgcccagcgc tgcccaggtg 2166 gccgtcgcgg tggccgccac gggccaggac ctgccgggta gccgctgcag tgccgcgccg 2172 agcaagccca ccgcgccgac cagcaggccg acgtgtaccg caccggcgac ccggccgtca 2178 cggtaggtga tctgctccag cttggcggcc gcccgaccga acagggccac cggatgacct 2184 cgtttggggt cgccgaacac gacgtcgagc aggcagccga tcagcacgcc gacggccctg 2190 gtctgccagg tcgatgcaaa cactccggca gcgtcgcaca cgtggtctac gctcagctat 2196 ttatgacctc atacggcagc tatccacgat gaagcggcca gctacccggg ttgccgacct 2202 gttgaacccg gcggcaatgt tgttgccggc agcgaatgtc atcatgcagc tggcagtgcc 2208 gggtgtcggg tatggcgtgc tggaaagccc ggtggacagc ggcaacgtct acaagcatcc 2214 gttcaagcgg gcccggacca ccggcaccta cctggcggtg gcgaccatcg ggacggaatc 2220 cgaccgagcg ctgatccggg gtgccgtgga cgtcgcgcac cggcaggttc ggtcgacggc 2226 ctcgagccca gtgtcctata acgccttcga cccgaagttg cagctgtggg tggcggcgtg 2232 tctgtaccgc tacttcgtgg accagcacga gtttctgtac ggcccactcg aagatgccac 2238 cgccgacgcc gtctaccaag acgccaaacg gttagggacc acgctgcagg tgccggaggg 2244 gatgtggccg ccggaccggg tcgcgttcga cgagtactgg aagcgctcgc ttgatgggct 2250 gcagatcgac gcgccggtgc gcgagcatct tcgcggggtg gcctcggtag cgtttctccc 2256 gtggccgttg cgcgcggtgg ccgggccgtt caacctgttt gcgacgacgg gattcttggc 2262 accggagttc cgcgcgatgatgcagctgga gtggtcacag gcccagcagc gtcgcttcga 2268 gtggttactt tccgtgctac ggttagccga ccggctgatt ccgcatcggg cctggatctt 2274 cgtttaccag ctttacttgt gggacatgcg gtttcgcgcc cgacacggcc gccgaatcgt 2280 ctgatagagc ccggccgagt gtgagcctga cagcccgaca ccggcggcgt gtgtcgcgtc 2286 gccaggttca cgctcggcga tctagagccg ccgaaaacct acttctgggt tgcctcccga 2292 atcaacgtgc tgatctgctc gagcagctca cgcatatcgg cgcgcatcgc atccaccgcg 2298 gcatacaggt cggccttggt cgccggcagc tggtccgacg tcattggccg caccggcggt 2304 gctgtctgtc gcgccgcgct gtcgctttga aacccaggtc gctcacccac gaccacgaca 2310 ctgccatatc cggcgccccg ccgacaacga agcacagcta gccggtgggc gcggacggga 2316 tcgaaccgcc gaccgctggt gtgtaaaacc agagctctac cgctgagcta cgcgcccatg 2322 accgccgcag gctacacgcc ttgcggccaa gcacccaaaa ccttaggccg taagcgccgc 2328 cagagcgtcg gtccacagcc gctgatcgcg aacttcaccc ggctgcttca tctcggcgaa 2334 ccgaatgatc cctgaccgat cgaccacaaa ggtgccccgg ttagcgatgc cggcctgctc 2340 gttgaagacg ccgtaggcct gactgaccgc gccgtgtggc cagaagtccg acaacagcgg 2346 aaacgtgaat ccgctctgcg tcgcccagat cttgtgagtg ggtggcgggc ccaccgaaat 2352 cgctagcgcg gcgctgtcgt cgttctcaaa ctcgggcagg tgatcacgca actggtccag 2358 ctcgccctgg cagatgcccg tgaacgccaa cggaaagaac accaacagca cgttctttgc 2364 accccggtag ccgcgcaggg tgacaagctg ctgattctgg tcgcgcaacg tgaagtcagg 2370 ggcggtggct ccgacgttca gcatcagcgc ttgccagccc gcgatttcgg ctgtaccaat 2376 ctgctggcgc tccagttgcc cagattgacc gacgaggtcg gcatcagccc agctgtgggc 2382 gccgcctcgg caatctcggc gggcaataca tggccgggct ggccggtctt gggcgtcacc 2388 acccaaatca caccgtcctc ggcgagcggg ccgatcgcat ccatcagggt gtccaccaaa 2394 tcgccgtcgc catcacgcca ccacaacagg acgacatcga tgacctcgtc ggtgtcttca 2400 tcgagcaact ctcccccgca cgcttcttcg atggccgcgc ggatgtcgtc gtcggtgtct 2406 tcgtcccagc cccattcctg gataagttgg tctcgttgga tgcccaattt gcgggcgtag 2412 ttcgaggcgt gatccgccgc gaccaccgtg gaacctcctt cagtctccgc gggccatgtg 2418 cacaccgtcg cgatgggcat tatcgtcgca cagccagaac cggtccaccc gcccgcctca 2424 gaaggcggcc acgcacattg tcaatgcctt tgtcttggtg tcgttgagcc gatcaacccg 2430 ccggttgaat tccgctgtcg acgcgtgcgc accgatggca tttgccaccg cgcgggccgc 2436 gtcgacatat gcgttgagcg catcccccag ttgcgcggac agcgcggcgc tcagactgcc 2442 tgagaccgtc gaggcactgt tgttgagcgc gtcgatggcc ggaccttcgg tcggcccggt 2448 gttgcggccc tgattgaacg cggccacgta ggcgttcacc ttgtcgatgg cgtccttgct 2454 ggtggccgcc agcgcgtcac acgaggtgcg aatcgccttg gtcgtcagcg attgttggcg 2460 ctgcgactcc cggatgctcg acgtcgccgc cgaagccgac accgacgcgg acaccgacga 2466 gcggtaggcc ggtgcgacgt tggtgtcggg catggccgta ccgtcggtga cagtggtaca 2472 tccgacgatc cccatcagca gcagcgcgat gcagccgagc gccagggcgc ctcgcctggg 2478 gagctccccc ccgtgcctgc gaggcacggc gcgccatccg atgagcacgg catgtgaggt 2484 tacctggtcg cagcgcgacc gcgctggccg tggtgtgtcg cgcatccgca gaaccgagcg 2490 gagtgcggct atccgccgcc gacgccggtg cggcacgata gggggacgac catctaaaca 2496 gcacgcaagc ggaagcccgc cacctacagg agtagtgcgt tgaccaccga tttcgcccgc 2502 cacgatctgg cccaaaactc aaacagcgca agcgaacccg accgagttcg ggtgatccgc 2508 gagggtgtgg cgtcgtattt gcccgacatt gatcccgagg agacctcgga gtggctggag 2514 tcctttgaca cgctgctgca acgctgcggc ccgtcgcggg cccgctacct gatgttgcgg 2520 ctgctagagc gggccggcga gcagcgggtg gccatcccgg cattgacgtc taccgactat 2526 gtcaacacca tcccgaccga gctggagccg tggttccccg gcgacgaaga cgtcgaacgt 2532 cgttatcgag cgtggatcag atggaatgcg gccatcatgg tgcaccgtgc gcaacgaccg 2538 ggtgtgggcg tgggtggcca tatctcgacc tacgcgtcgt ccgcggcgct ctatgaggtc 2544 ggtttcaacc acttcttccg cggcaagtcg cacccgggcg gcggcgatca ggtgttcatc 2550 cagggccacg cttccccggg aatctacgcg cgcgccttcc tcgaagggcg gttgaccgcc 2556 gagcaactcg acggattccg ccaggaacac agccatgtcg gcggcgggtt gccgtcctat 2562 ccgcacccgc ggctcatgcc cgacttctgg gaattcccca ccgtgtcgat gggtttgggc 2568 ccgctcaacg ccatctacca ggcacggttc aaccactatc tgcatgaccg cggtatcaaa 2574 gacacctccg atcaacacgt gtggtgtttt ttgggcgacg gcgagatgga cgaacccgag 2580 agccgtgggc tggcccacgt cggcgcgctg gaaggcttgg acaacttgac cttcgtgatc 2586 aactgcaatc tgcagcgact cgacggcccg gtgcgcggca acggcaagat catccaggag 2592 ctggagtcgt tcttccgcgg tgccggctgg aacgtcatca aggtggtgtg gggccgcgaa 2598 tgggatgccc tgctgcacgc cgaccgcgac ggtgcgctgg tgaatttaat gaatacaaca 2604 cccgatggcg attaccagac ctataaggcc aacgacggcg gctacgtgcg tgaccacttc 2610 ttcggccgcg acccacgcac caaggcgctg gtggagaaca tgagcgacca ggatatctgg 2616 aacctcaaac ggggcggcca cgattaccgc aaggtttacg ccgcctaccg cgccgccgtc 2622 gaccacaagg gacagccgac ggtgatcctg gccaagacca tcaaaggcta cgcgctgggc 2628 aagcatttcg aaggacgcaa tgccacccac cagatgaaaa aactgaccct ggaagacctt 2634 aaggagtttc gtgacacgca gcggattccg gtcagcgacg cccagcttga agagaatccg 2640 tacctgccgc cctactacca ccccggcctc aacgccccgg agattcgtta catgctcgac 2646 cggcgccggg ccctcggggg ctttgttccc gagcgcagga ccaagtccaa agcgctgacc 2652 ctgccgggtc gcgacatcta cgcgccgctg aaaaagggct ctgggcacca ggaggtggcc 2658 accaccatgg cgacggtgcg cacgttcaaa gaagtgttgc gcgacaagca gatcgggccg 2664 cggatagtcc cgatcattcc cgacgaggcc cgcaccttcg ggatggactc ctggttcccg 2670 tcgctaaaga tctataaccg caatggccag ctgtataccg cggttgacgc cgacctgatg 2676 ctggcctaca aggagagcga agtcgggcag atcctgcacg agggcatcaa cgaagccggg 2682 tcggtgggct cgttcatcgc ggccggcacc tcgtatgcga cgcacaacga accgatgatc 2688 cccatttaca tcttctactc gatgttcggc ttccagcgca ccggcgatag cttctgggcc 2694 gcggccgacc agatggctcg agggttcgtg ctcggggcca ccgccgggcg caccaccctg 2700 accggtgagg gcctgcaaca cgccgacggt cactcgttgc tgctggccgc caccaacccg 2706 gcggtggttg cctacgaccc ggccttcgcc tacgaaatcg cctacatcgt ggaaagcgga 2712 ctggccagga tgtgcgggga gaacccggag aacatcttct tctacatcac cgtctacaac 2718 gagccgtacg tgcagccgcc ggagccggag aacttcgatc ccgagggcgt gctgcggggt 2724 atctaccgct atcacgcggc caccgagcaa cgcaccaaca aggcgcagat cctggcctcc 2730 ggggtagcga tgcccgcggc gctgcgggca gcacagatgc tggccgccga gtgggatgtc 2736 gccgccgacg tgtggtcggt gaccagttgg ggcgagctaa accgcgacgg ggtggccatc 2742 gagaccgaga agctccgcca ccccgatcgg ccggcgggcg tgccctacgt gacgagagcg 2748 ctggagaatg ctcggggccc ggtgatcgcg gtgtcggact ggatgcgcgc ggtccccgag 2754 cagatccgac cgtgggtgcc gggcacatac ctcacgttgg gcaccgacgg gttcggcttt 2760 tccgacactc ggcccgccgc tcgccgctac ttcaacaccg acgccgaatc ccaggtggtc 2766 gcggttttgg aggcgttggc gggcgacggc gagatcgacc catcggtgcc ggtcgcggcc 2772 gcccgccagt accggatcga cgacgtggcg gctgcgcccg agcagaccac ggatcccggt 2778 cccggggcct aacgccggcg agccgaccgc ctttggccga atcttccaga aatctggcgt 2784 agcttttagg agtgaacgac aatcagttgg ctccagttgc ccgcccgagg tcgccgctcg 2790 aactgctgga cactgtgccc gattcgctgc tgcggcggtt gaagcagtac tcgggccggc 2796 tggccaccga ggcagtttcg gccatgcaag aacggttgcc gttcttcgcc gacctagaag 2802 cgtcccagcg cgccagcgtg gcgctggtgg tgcagacggc cgtggtcaac ttcgtcgaat 2808 ggatgcacga cccgcacagt gacgtcggct ataccgcgca ggcattcgag ctggtgcccc 2814 aggatctgac gcgacggatc gcgctgcgcc agaccgtgga catggtgcgg gtcaccatgg 2820 agttcttcga agaagtcgtg cccctgctcg cccgttccga agagcagttg accgccctca 2826 cggtgggcat tttgaaatac agccgcgacc tggcattcac cgccgccacg gcctacgccg 2832 atgcggccga ggcacgaggc acctgggaca gccggatgga ggccagcgtg gtggacgcgg 2838 tggtacgcgg cgacaccggt cccgagctgc tgtcccgggc ggccgcgctg aattgggaca 2844 ccaccgcgcc ggcgaccgta ctggtgggaa ctccggcgcc cggtccaaat ggctccaaca 2850 gcgacggcga cagcgagcgg gccagccagg atgtccgcga caccgcggct cgccacggcc 2856 gcgctgcgct gaccgacgtg cacggcacct ggctggtggc gatcgtctcc ggccagctgt 2862 cgccaaccga gaagttcctc aaagacctgc tggcagcatt cgccgacgcc ccggtggtca 2868 tcggccccac ggcgcccatg ctgaccgcgg cgcaccgcag cgctagcgag gcgatctccg 2874 ggatgaacgc cgtcgccggc tggcgcggag cgccgcggcc cgtgctggct agggaacttt 2880 tgcccgaacg cgccctgatg ggcgacgcct cggcgatcgt ggccctgcat accgacgtga 2886 tgcggcccct agccgatgcc ggaccgacgc tcatcgagac gctagacgca tatctggatt 2892 gtggcggcgc gattgaagct tgtgccagaa agttgttcgt tcatccaaac acagtgcggt 2898 accggctcaa gcggatcacc gacttcaccg ggcgcgatcc cacccagcca cgcgatgcct 2904 atgtccttcg ggtggcggcc accgtgggtc aactcaacta tccgacgccg cactgaagca 2910 tcgacagcaa tgccgtgtca tagattccct cgccggtcag agggggtcca gcaggggccc 2916 cggaaagata ccaggggcgc cgtcggacgg aaagtgatcc agacaacagg tcgcgggacg 2922 atctcaaaaa catagcttac aggcccgttt tgttggttat atacaaaaac ctaagacgag 2928 gttcataatc tgttacaccg cgcaaaaccg tcttcacagt gttctcttag acacgtgatt 2934 gcgttgctcg cacccggaca gggttcgcaa accgagggaa tgttgtcgcc gtggcttcag 2940 ctgcccggcg cagcggacca gatcgcggcg tggtcgaaag ccgctgatct agatcttgcc 2946 cggctgggca ccaccgcctc gaccgaggag atcaccgaca ccgcggtcgc ccagccattg 2952 atcgtcgccg cgactctgct ggcccaccag gaactggcgc gccgatgcgt gctcgccggc 2958 aaggacgtca tcgtggccgg ccactccgtc ggcgaaatcg cggcctacgc aatcgccggt 2964 gtgatagccg ccgacgacgc cgtcgcgctg gccgccaccc gcggcgccga gatggccaag 2970 gcctgcgcca ccgagccgac cggcatgtct gcggtgctcg gcggcgacga gaccgaggtg 2976 ctgagtcgcc tcgagcagct cgacttggtc ccggcaaacc gcaacgccgc cggccagatc 2982 gtcgctgccg gccggctgac cgcgttggag aagctcgccg aagacccgcc ggccaaggcg 2988 cgggtgcgtg cactgggtgt cgccggagcg ttccacaccg agttcatggc gcccgcactt 2994 gacggctttg cggcggccgc ggccaacatc gcaaccgccg accccaccgc cacgctgctg 3000 tccaaccgcg acgggaagcc ggtgacatcc gcggccgcgg cgatggacac cctggtctcc 3006 cagctcaccc aaccggtgcg atgggacctg tgcaccgcga cgctgcgcga acacacagtc 3012 acggcgatcg tggagttccc ccccgcgggc acgcttagcg gtatcgccaa acgcgaactt 3018 cggggggttc cggcacgcgc cgtcaagtca cccgcagacc tggacgagct ggcaaaccta 3024 taaccgcgga ctcggccaga acaaccacat acccgtcagt tcgatttgta cacaacatat 3030 tacgaaggga agcatgctgt gcctgtcact caggaagaaa tcattgccgg tatcgccgag 3036 atcatcgaag aggtaaccgg tatcgagccg tccgagatca ccccggagaa gtcgttcgtc 3042 gacgacctgg acatcgactc gctgtcgatg gtcgagatcg ccgtgcagac cgaggacaag 3048 tacggcgtca agatccccga cgaggacctc gccggtctgc gtaccgtcgg tgacgttgtc 3054 gcctacatcc agaagctcga ggaagaaaac ccggaggcgg ctcaggcgtt gcgcgcgaag 3060 attgagtcgg agaaccccga tgccgttgcc aacgttcagg cgaggcttga ggccgagtcc 3066 aagtgagtca gccttccacc gctaatggcg gtttccccag cgttgtggtg accgccgtca 3072 cagcgacgac gtcgatctcg ccggacatcg agagcacgtg gaagggtctg ttggccggcg 3078 agagcggcat ccacgcactc gaagacgagt tcgtcaccaa gtgggatcta gcggtcaaga 3084 tcggcggtca cctcaaggat ccggtcgaca gccacatggg ccgactcgac atgcgacgca 3090 tgtcgtacgt ccagcggatg ggcaagttgc tgggcggaca gctatgggag tccgccggca 3096 gcccggaggt cgatccagac cggttcgccg ttgttgtcgg caccggtcta ggtggagccg 3102 agaggattgt cgagagctac gacctgatga atgcgggcgg cccccggaag gtgtccccgc 3108 tggccgttca gatgatcatg cccaacggtg ccgcggcggt gatcggtctg cagcttgggg 3114 cccgcgccgg ggtgatgacc ccggtgtcgg cctgttcgtc gggctcggaa gcgatcgccc 3120 acgcgtggcg tcagatcgtg atgggcgacg ccgacgtcgc cgtctgcggc ggtgtcgaag 3126 gacccatcga ggcgctgccc atcgcggcgt tctccatgat gcgggccatg tcgacccgca 3132 acgacgagcc tgagcgggcc tcccggccgt tcgacaagga ccgcgacggc tttgtgttcg 3138 gcgaggccgg tgcgctgatg ctcatcgaga cggaggagca cgccaaagcc cgtggcgcca 3144 agccgttggc ccgattgctg ggtgccggta tcacctcgga cgcctttcat atggtggcgc 3150 ccgcggccga tggtgttcgt gccggtaggg cgatgactcg ctcgctggag ctggccgggt 3156 tgtcgccggc ggacatcgac cacgtcaacg cgcacggcac ggcgacgcct atcggcgacg 3162 ccgcggaggc caacgccatc cgcgtcgccg gttgtgatca ggccgcggtg tacgcgccga 3168 agtctgcgct gggccactcg atcggcgcgg tcggtgcgct cgagtcggtg ctcacggtgc 3174 tgacgctgcg cgacggcgtc atcccgccga ccctgaacta cgagacaccc gatcccgaga 3180 tcgaccttga cgtcgtcgcc ggcgaaccgc gctatggcga ttaccgctac gcagtcaaca 3186 actcgttcgg gttcggcggc cacaatgtgg cgcttgcctt cgggcgttac tgaagcacga 3192 catcgcgggt cgcgaggccc gaggtggggg tccccccgct tgcgggggcg agtcggaccg 3198 atatggaagg aacgttcgca agaccaatga cggagctggt taccgggaaa gcctttccct 3204 acgtagtcgt caccggcatc gccatgacga ccgcgctcgc gaccgacgcg gagactacgt 3210 ggaagttgtt gctggaccgc caaagcggga tccgtacgct cgatgaccca ttcgtcgagg 3216 agttcgacct gccagttcgc atcggcggac atctgcttga ggaattcgac caccagctga 3222 cgcggatcga actgcgccgg atgggatacc tgcagcggat gtccaccgtg ctgagccggc 3228 gcctgtggga aaatgccggc tcacccgagg tggacaccaa tcgattgatg gtgtccatcg 3234 gcaccggcct gggttcggcc gaggaactgg tcttcagtta cgacgatatg cgcgctcgcg 3240 gaatgaaggc ggtctcgccg ctgaccgtgc agaagtacat gcccaacggg gccgccgcgg 3246 cggtcgggtt ggaacggcac gccaaggccg gggtgatgac gccggtatcg gcgtgcgcat 3252 ccggcgccga ggccatcgcc cgtgcgtggc agcagattgt gctgggagag gccgatgccg 3258 ccatctgcgg cggcgtggag accaggatcg aagcggtgcc catcgccggg ttcgctcaga 3264 tgcgcatcgt gatgtccacc aacaacgacg accccgccgg tgcatgccgc ccattcgaca 3270 gggaccgcga cggctttgtg ttcggcgagg gcggcgccct tctgttgatc gagaccgagg 3276 agcacgccaa ggcacgtggc gccaacatcc tggcccggat catgggcgcc agcatcacct 3282 ccgatggctt ccacatggtg gccccggacc ccaacgggga acgcgccggg catgcgatta 3288 cgcgggcgat tcagctggcg ggcctcgccc ccggcgacat cgaccacgtc aatgcgcacg 3294 ccaccggcac ccaggtcggc gacctggccg aaggcagggc catcaacaac gccttgggcg 3300 gcaaccgacc ggcggtgtac gcccccaagt ctgccctcgg ccactcggtg ggcgcggtcg 3306 gcgcggtcga atcgatcttg acggtgctcg cgttgcgcga tcaggtgatc ccgccgacac 3312 tgaatctggt aaacctcgat cccgagatcg atttggacgt ggtggcgggt gaaccgcgac 3318 cgggcaatta ccggtatgcg atcaataact cgttcggatt cggcggccac aacgtggcaa 3324 tcgccttcgg acggtactaa accccagcgt tacgcgacag gagacctgcg atgacaatca 3330 tggcccccga ggcggttggc gagtcgctcg acccccgcga tccgctgttg cggctgagca 3336 acttcttcga cgacggcagc gtggaattgc tgcacgagcg tgaccgctcc ggagtgctgg 3342 ccgcggcggg caccgtcaac ggtgtgcgca ccatcgcgtt ctgcaccgac ggcaccgtga 3348 tgggcggcgc catgggcgtc gaggggtgca cgcacatcgt caacgcctac gacactgcca 3354 tcgaagacca gagtcccatc gtgggcatct ggcattcggg tggtgcccgg ctggctgaag 3360 gtgtgcgggc gctgcacgcg gtaggccagg tgttcgaagc catgatccgc gcgtccggct 3366 acatcccgca gatctcggtg gtcgtcggtt tcgccgccgg cggcgccgcc tacggaccgg 3372 cgttgaccga cgtcgtcgtc atggcgccgg aaagccgggt gttcgtcacc gggcccgacg 3378 tggtgcgcag cgtcaccggc gaggacgtcg acatggcctc gctcggtggg ccggagaccc 3384 accacaagaa gtccggggtg tgccacatcg tcgccgacga cgaactcgat gcctacgacc 3390 gtgggcgccg gttggtcgga ttgttctgcc agcaggggca tttcgatcgc agcaaggccg 3396 aggccggtga caccgacatc cacgcgctgc tgccggaatc ctcgcgacgt gcctacgacg 3402 tgcgtccgat cgtgacggcg atcctcgatg cggacacacc gttcgacgag ttccaggcca 3408 attgggcgcc gtcgatggtg gtcgggctgg gtcggctgtc gggtcgcacg gtgggtgtac 3414 tggccaacaa cccgctacgc ctgggcggct gcctgaactc cgaaagcgca gagaaggcag 3420 cgcgtttcgt gcggctgtgc gacgcgttcg ggattccgct ggtggtggtg gtcgatgtgc 3426 cgggctatct gcccggtgtc gaccaggagt ggggtggcgt ggtgcgccgt ggcgccaagt 3432 tgctgcacgc gttcggcgag tgcaccgttc cgcgggtcac gctggtcacc cgaaagacct 3438 acggcggggc atacattgcg atgaactccc ggtcgttgaa cgcgaccaag gtgttcgcct 3444 ggccggacgc cgaggtcgcg gtgatgggcg ctaaggcggc cgtcggcatc ctgcacaaga 3450 agaagttggc cgccgctccg gagcacgaac gcgaagcgct gcacgaccag ttggccgccg 3456 agcatgagcg catcgccggc ggggtcgaca gtgcgctgga catcggtgtg gtcgacgaga 3462 agatcgaccc ggcgcatact cgcagcaagc tcaccgaggc gctggcgcag gctccggcac 3468 ggcgcggccg ccacaagaac atcccgctgt agttctgacc gcgagcagac gcagaatcgc 3474 acgcgcgagg tccgcgccgt gcgattctgc gtctgctcgc cagttatccc cagcggtggc 3480 tggtcaacgc gaggcgctcc tcgcatgctc ggacggtgcc taccgacgcg ctaacaattc 3486 tcgagaaggc cggcgggttc gccaccaccg cgcaattgct cacggtcatg acccgccaac 3492 agctcgacgt ccaagtgaaa aacggcggcc tcgttcgcgt ttggtacggg gtctacgcgg 3498 cacaagagcc ggacctgttg ggccgcttgg cggctctcga tgtgttcatg ggggggcacg 3504 ccgtcgcgtg tctgggcacc gccgccgcgt tgtatggatt cgacacggaa aacaccgtcg 3510 ctatccatat gctcgatccc ggagtaagga tgcggcccac ggtcggtctg atggtccacc 3516 aacgcgtcgg tgcccggctc caacgggtgt caggtcgtct cgcgaccgcg cccgcatgga 3522 ctgccgtgga ggtcgcacga cagttgcgcc gcccgcgggc gctggccacc ctcgacgccg 3528 cactacggtc aatgcgctgc gctcgcagtg aaattgaaaa cgccgttgct gagcagcgag 3534 gccgccgagg catcgtcgcg gcgcgcgaac tcttaccctt cgccgacgga cgcgcggaat 3540 cggccatgga gagcgaggct cggctcgtca tgatcgacca cgggctgccg ttgcccgaac 3546 ttcaataccc gatacacggc cacggtggtg aaatgtggcg agtcgacttc gcctggcccg 3552 acatgcgtct cgcggccgaa tacgaaagca tcgagtggca cgcgggaccg gcggagatgc 3558 tgcgcgacaa gacacgctgg gccaagctcc aagagctcgg gtggacgatt gtcccgattg 3564 tcgtcgacga tgtcagacgc gaacccggcc gcctggcggc ccgcatcgcc cgccacctcg 3570 accgcgcgcg tatggccggc tgaccgctgg tgagcagacg cagagtcgca ctgcggccgg 3576 cgcagtgcga ctctgcgtct gctcgcgctc aacggctgag gaactcctta gccacggcga 3582 ctacgcgctc gcgatcccgt ggcaccagac cgatccgggt ccggcggtcg aggatatcgt 3588 ccacatccag cgccccctca tgggtcaccg cgtattcgaa ctccgcccgg gtcacgtcga 3594 tgccgtcggc gaccggctcg gtgggccgct cacatgtggc ggcggcagcg acgttggccg 3600 cctcggcccc gtaccgcgcc accagcgact cgggcaatcc ggcgcccgat ccgggggccg 3606 gcccagggtt cgccggtgcg ccgatcagcg gcaggttgcg agtgcggcac ttcgcggctc 3612 gcaggtgtcg cagcgtgatg gcgcgattca gcacatcctc tgccatgtag cggtattccg 3618 tcagcttgcc gccgaccaca ctgatcacgc ccgacggcga ttcaaaaaca gcgtggtcac 3624 gcgaaacgtc ggcggtgcgg ccctggacac cagcaccgcc ggtgtcgatt agcggccgca 3630 atcccgcata ggcaccgatg acatccttgg tgccgaccgc cgtccccaat gcggtgttca 3636 ccgtatccag caggaacgtg atctcttccg aagacggttg tggcacatcg ggaatcgggc 3642 cgggtgcgtc ttcgtcggtc agcccgagat agatccggcc cagctgctcg ggcatggcga 3648 acacgaagcg gttcagctca ccggggatcg gaatggtcag cgcggcagtc ggattggcaa 3654 acgacttcgc gtcgaagacc agatgtgtgc cgcggctggg gcgtagcctc agggacgggt 3660 cgatctcacc cgcccacacg cccgccgcgt tgatgacggc acgcgccgac agcgcgaacg 3666 actgccgggt gcgccggtcg gtcaactcca ccgaagtgcc ggtgacattc gacgcgccca 3672 cgtaagtgag gatgcgggcg ccgtgctggg ccgcggtgcg cgcgacggcc atgaccagcc 3678 gggcgtcgtc gatcaattgc ccgtcgtacg cgagcagacc accgtcgagg ccgtcccgcc 3684 gaacggtggg agcaatctcc accacccgtg acgccgggat tcggcgcgat cggggcaacg 3690 tcgccgccgg cgtacccgct agcacccgca aagcgtcgcc ggccaggaaa ccggcacgca 3696 ccaacgcccg cttggtgtga cccatcgacg gcaacaacgg gaccagttgc ggcatggcat 3702 gcacgagatg aggagcgttg cgtgtcatca ggattccgcg ttcgacggcg ctgcgccggg 3708 cgatgcccac gttgccgctg gccagatagc gcagaccgcc gtgcaccaac ttcgagctcc 3714 agcggctggt gccgaacgcc agatcatgct tttccaccaa ggccaccgtc agaccgcggg 3720 tggcagcatc taaggcaatg ccaacaccgg taatgccgcc gcctatcacg atgacgtcga 3726 gtgcgccacc gtcggccagt gcggtcaggt cggcggagcg acgcgccgcg ttgagtgcag 3732 ccgagtgggg catcagcaca aatatccgtt cagtgcgtgg gtaagttcgg tggccagcgc 3738 ggcggaatcg aggatcgaat cgacgatgtc cgcggactgg atggtcgact gggcgatcag 3744 caacaccatg gtcgccagtc gacgagcgtc gccggagcgc acactgcccg accgctgcgc 3750 cactgtcagc cgggcggcca acccctcgat caggacctgc tggctggtgc cgaggcgctc 3756 ggtgatgtac accctggcca gctccgagtg catgaccgac atgatcagat cgtcaccccg 3762 caaccggtcg gccaccgcga caatctgctt taccaacgct tcccggtcgt ccccgtcgag 3768 gggcacctcc cgcagcacgt cggcgatatg gctggtcagc atggacgcca tgatcgaccg 37741 ggtgtccggc cagcgacggt atacggtcgg gcggctcacg cccgcgcgcc gggcgatctc 37801 ggcaagtgtc acccggtcca cgccgtaatc gacgacgcag ctcgccgctg cccgcaggat 37861 acgaccaccg gtatccgcgc ggtcattact cattgacagc atgtgtaata ctgtaacgcg 37921 tgactcaccg cgaggaactc cttccaccga tgaaatggga cgcgtgggga gatcccgccg 37981 cggccaagcc actttctgat ggcgtccggt cgttgctgaa gcaggttgtg ggcctagcgg 38041 actcggagca gcccgaactc gaccccgcgc aggtgcagct gcgcccgtcc gccctgtcgg 38101 gggcagacca (SEQ ID NO: 24)

6.9. X-linked Inhibitor of Apoptosis Protein ("XIAP")

GenBank Accession # U45880:

1 gaaaaggtgg acaagtccta ttttcaagag aagatgactt ttaacagttt tgaaggatct 61 aaaacttgtg tacctgcaga catcaataag gaagaagaat ttgtagaaga gtttaataga 121 ttaaaaactt ttgctaattt tccaagtggt agtcctgttt cagcatcaac actggcacga 181 gcagggtttc tttatactgg tgaaggagat accgtgcggt gctttagttg tcatgcagct 241 gtagatagat ggcaatatgg agactcagca gttggaagac acaggaaagt atccccaaat 301 tgcagattta tcaacggctt ttatcttgaa aatagtgcca cgcagtctac aaattctggt 361 atccagaatg gtcagtacaa agttgaaaac tatctgggaa gcagagatca ttttgcctta 421 gacaggccat ctgagacaca tgcagactat cttttgagaa ctgggcaggt tgtagatata 481 tcagacacca tatacccgag gaaccctgcc atgtattgtg aagaagctag attaaagtcc 541 tttcagaact ggccagacta tgctcaccta accccaagag agttagcaag tgctggactc 601 tactacacag gtattggtga ccaagtgcag tgcttttgtt gtggtggaaa actgaaaaat 661 tgggaacctt gtgatcgtgc ctggtcagaa cacaggcgac actttcctaa ttgcttcttt 721 gttttgggcc ggaatcttaa tattcgaagt gaatctgatg ctgtgagttc tgataggaat 781 ttcccaaatt caacaaatct tccaagaaat ccatccatgg cagattatga agcacggatc 841 tttacttttg ggacatggat atactcagtt aacaaggagc agcttgcaag agctggattt 901 tatgctttag gtgaaggtga taaagtaaag tgctttcact gtggaggagg gctaactgat 961 tggaagccca gtgaagaccc ttgggaacaa catgctaaat ggtatccagg gtgcaaatat 1021 ctgttagaac agaagggaca agaatatata aacaatattc atttaactca ttcacttgag 1081 gagtgtctgg taagaactac tgagaaaaca ccatcactaa ctagaagaat tgatgatacc 1141 atcttccaaa atcctatggt acaagaagct atacgaatgg ggttcagttt caaggacatt 1201 aagaaaataa tggaggaaaa aattcagata tctgggagca actataaatc acttgaggtt 1261 ctggttgcag atctagtgaa tgctcagaaa gacagtatgc aagatgagtc aagtcagact 1321 tcattacaga aagagattag tactgaagag cagctaaggc gcctgcaaga ggagaagctt 1381 tgcaaaatct gtatggatag aaatattgct atcgtttttg ttccttgtgg acatctagtc 1441 acttgtaaac aatgtgctga agcagttgac aagtgtccca tgtgctacac agtcattact 1501 ttcaagcaaa aaatttttat gtcttaatct aactctatag taggcatgtt atgttgttct 1561 tattaccctg attgaatgtg tgatgtgaac tgactttaag taatcaggat tgaattccat 1621 tagcatttgc taccaagtag gaaaaaaaat gtacatggca gtgttttagt tggcaatata 1681 atctttgaat ttcttgattt ttcagggtat tagctgtatt atccattttt tttactgtta 1741 tttaattgaa accatagact aagaataaga agcatcatac tataactgaa cacaatgtgt 1801 attcatagta tactgattta atttctaagt gtaagtgaat taatcatctg gattttttat 1861 tcttttcaga taggcttaac aaatggagct ttctgtatat aaatgtggag attagagtta 1921 atctccccaa tcacataatt tgttttgtgt gaaaaaggaa taaattgttc catgctggtg 1981 gaaagataga gattgttttt agaggttggt tgttgtgttt taggattctg tccattttct 2041 tgtaaaggga taaacacgga cgtgtgcgaa atatgtttgt aaagtgattt gccattgttg 2101 aaagcgtatt taatgataga atactatcga gccaacatgt actgacatgg aaagatgtca 2161 gagatatgtt aagtgtaaaa tgcaagtggc gggacactat gtatagtctg agccagatca 2221 aagtatgtat gttgttaata tgcatagaac gagagatttg gaaagatata caccaaactg 2281 ttaaatgtgg tttctcttcg gggagggggg gattggggga ggggccccag aggggtttta 2341 gaggggcctt ttcactttcg acttttttca ttttgttctg ttcggatttt ttataagtat 2401 gtagaccccg aagggtttta tgggaactaa catcagtaac ctaacccccg tgactatcct 2461 gtgctcttcc tagggagctg tgttgtttcc cacccaccac ccttccctct gaacaaatgc 2521 ctgagtgctg gggcactttg (SEQ ID NO: 25)

General Target Region:

Internal Ribosome Entry Site (IRES) in 5' untranslated region: 5AGCUCCUAUAACAAAAGUCUGUUGCUUGUGUUUCACAUUUUGGAUU UCCUAAUAUAAUGUUCUCUUUUUAGAAAAGGUGGACAAGUCCUAUUU UCAAGAGAAG3' (SEQ ID NO: 26)

Initial Specific Target Motif:

RNP core binding site within XIAP IRES 5'GGAUUUCCUAAUAUAAUGUUCUCUUUUU3* (SEQ ID NO: 27)

6.10. Survivin

GenBank Accession # NM_001168:

1 ccgccagatt tgaatcgcgg gacccgttgg cagaggtggc ggcggcggca tgggtgcccc 61 gacgttgccc cctgcctggc agccctttct caaggaccac cgcatctcta cattcaagaa 121 ctggcccttc ttggagggct gcgcctgcac cccggagcgg atggccgagg ctggcttcat 181 ccactgcccc actgagaacg agccagactt ggcccagtgt ttcttctgct tcaaggagct 241 ggaaggctgg gagccagatg acgaccccat agaggaacat aaaaagcatt cgtccggttg

301 cgctttcctt tctgtcaaga agcagtttga agaattaacc cttggtgaat ttttgaaact

361 ggacagagaa agagccaaga acaaaattgc aaaggaaacc aacaataaga agaaagaatt

421 tgaggaaact gcgaagaaag tgcgccgtgc catcgagcag ctggctgcca tggattgagg

481 cctctggccg gagctgcctg gtcccagagt ggctgcacca cttccagggt ttattccctg

541 gtgccaccag ccttcctgtg ggccccttag caatgtctta ggaaaggaga tcaacatttt

601 caaattagat gtttcaactg tgctcctgtt ttgtcttgaa agtggcacca gaggtgcttc

661 tgcctgtgca gcgggtgctg ctggtaacag tggctgcttc tctctctctc tctctttttt

721 gggggctcat ttttgctgtt ttgattcccg ggcttaccag gtgagaagtg agggaggaag

781 aaggcagtgt cccttttgct agagctgaca gctttgttcg cgtgggcaga gccttccaca

841 gtgaatgtgt ctggacctca tgttgttgag gctgtcacag tcctgagtgt ggacttggca

901 ggtgcctgtt gaatctgagc tgcaggttcc ttatctgtca cacctgtgcc tcctcagagg

961 acagtttttt tgttgttgtg tttttttgtt tttttttttt ggtagatgca tgacttgtgt

1021 gtgatgagag aatggagaca gagtccctgg ctcctctact gtttaacaac atggctttct

1081 tattttgttt gaattgttaa ttcacagaat agcacaaact acaattaaaa ctaagcacaa

1141 agccattcta agtcattggg gaaacggggt gaacttcagg tggatgagga gacagaatag

1201 agtgatagga agcgtctggc agatactcct tttgccactg ctgtgtgatt agacaggccc

1261 agtgagccgc ggggcacatg ctggccgctc ctccctcaga aaaaggcagt ggcctaaatc

1321 ctttttaaat gacttggctc gatgctgtgg gggactggct gggctgctgc aggccgtgtg

1381 tctgtcagcc caaccttcac atctgtcacg ttctccacac gggggagaga cgcagtccgc

1441 ccaggtcccc gctttctttg gaggcagcag ctcccgcagg gctgaagtct ggcgtaagat

1501 gatggatttg attcgccctc ctccctgtca tagagctgca gggtggattg ttacagcttc

1561 gctggaaacc tctggaggtc atctcggctg ttcctgagaa ataaaaagcc tgtcatttc (SEQ ID NO: 28)

7. EXAMPLE: IDENTIFICATION OF A DYE-LABELED TARGET RNA

BOUND TO SMALL MOLECULAR WEIGHT COMPOUNDS

The results presented in this Example indicate that gel mobility shift assays can be used to detect the binding of small molecules, such as the Tat peptide and gentamicin, to their respective target RNAs.

7.1. Materials and Methods

7.1.1. Buffers Tris-potassium chloride (TK) buffer is composed of 50 mM Tris-HCI pH

7.4, 20mM KCl, 0.1%Triton X-100, and 0.5mM MgCl₂. Tris-borate-EDTA (TBE) buffer is composed of 45 mM Tris-borate pH 8.0, and 1 mM EDTA. Tris-Potassium chloride- magnesium (TKM) buffer is composed of 50 mM Tris-HCI pH 7.4, 20mM KCl, 0.1%Triton X-100 and 5mM MgCl₂.

5

7.1.1. Gel retardation analysis

RNA oligonucleotides were purchased from Dharmacon, Inc, Lafayette,

CO). 500 pmole of either a 5' fluorescein labeled oligonucleotide corresponding to the 16S rRNA A site (5'-GGCGUCACACCUUCGGGUGAAGUCGCC-3' (SEQ ID NO: 29);

Moazed & Noller, 1987, Nature 327:389-394; Woodcock et al, 1991, EMBO J. 10:3099-

3103; Yoshizawa et al, 1998, EMBO J. 17:6437-6448) or a 5' fluorescein labeled oligonucleotide corresponding to the HIV-1 TAR element TAR RNA (5'-

GGCGUCACACCUUCGGGUGAAGUCGCC-3' (SEQ ID NO: 30); Huq et al, 1999,

Nucleic Acids Research. 27:1084-1093; Hwang et al, 1999, Proc. Natl. Acad. Sci. USA

96:12997-13002) was 3' labeled with 5'-³²P cytidine 3', 5'-bis(phosphate) (NEN) and T4

RNA ligase (NEBiolabs) in 10% DMSO as per manufacturer's instructions. The labeled oligonucleotides were purified using G-25 Sephadex columns (Boehringer Mannheim).

For Tat-TAR gel retardation reactions the method of Huq et al. (Nucleic Acids Research,

1999, 27:1084-1093) was utilized with TK buffer containing 0.5mM MgCl₂and a 12-mer

Tat peptide (YGRKKRRQRRRP (SEQ ID NO: 31); single letter amino acid code). For .zu

16S rRNA-gentamicin reactions, the method of Huq et al. was used with TKM buffer. In 20 μl reaction volumes 50 pmoles of ³²P cytidine-labeled oligonucleotide and either gentamicin sulfate (Sigma) or the short Tat peptide (Tat₄₇._5g) in TK or TKM buffer were heated at 90 °C for 2 minutes and allow to cool to room temperature (approximately 24 °C) ry r over 2 hours. Then 10 μl of 30% glycerol was added to each reaction tube and the entire sample was loaded onto a TBE non-denaturing polyacrylamide gel and electrophoresed at 1200-1600 volt-hours at 4°C. The gel was exposed to an intensifying screen and radioactivity was quantitated using a Typhoon phosporimager (Molecular Dynamics).

_a 7.2. Background

One method used to demonstrate small molecule interactions with natural occurring RNA structures such as ribosomes is by a method called chemical footprinting or toe printing (Moazed & Noller, 1987, Nature 327:389-394; Woodcock et al, 1991, EMBO J. 10:3099-3103; Yoshizawa et al, 1998, EMBO J. 17:6437-6448). Here the use of gel mobility shift assays to monitor RNA-small molecule interactions are described. This

35 approach allows for rapid visualization of small molecule-RNA interactions based on the difference between mobility of RNA alone versus RNA in a complex with a small molecule. To validate this approach, an RNA oligonucleotide corresponding to the well- characterized gentamicin binding site on the 16S rRNA (Moazed & Noller, 1987, Nature 327:389-394) and the equally well-characterized EDV-l TAT protein binding site on the HIV-1 TAR element (Huq et al, 1999, Nucleic Acids Res. 27: 1084-1093) were chosen. The purpose of these experiments is to lay the groundwork for the use of chromatographic techniques in a high throughput fashion, such as microcapillary electrophoresis, for drug discovery.

10

7.3. Results

A gel retardation assay was performed using the Tat₄₇.₅₈ peptide and the TAR RNA oligonucleotide. As shown in Figure 1, in the presence of the Tat peptide, a clear shift is visible when the products are separated on a 12% non-denaturing polyacrylamide gel. In the reaction that lacks peptide, only the free RNA is visible. These observations confirm previous reports made using other Tat peptides (Hamy et al, 1997, Proc. Natl. Acad. Sci. USA 94:3548-3553; Huq et al, 1999, Nucleic Acids Res. 27: 1084- 1093).

Based on the results of Figure 1, it was hypothesized that RNA interactions with small organic molecules could also be visualized using this method. As shown in

Figure 2, the addition of varying concentrations of gentamicin to an RNA oligonucleotide corresponding to the 16S rRNA A site produces a mobility shift. These results demonstrate that the binding of the small molecule gentamicin to an RNA oligonucleotide having a defined structure in solution can be monitored using this approach. In addition, as shown in Figure 2, a concentration as low as lOng/ml gentamicin produces the mobility shift. To determine whether lower concentrations of gentamicin would be sufficient to produce a gel shift, similar experiment was performed, as shown in Figure 2, except that the concentrations of gentamicin ranged from 100 ng/ml to 10 pg/ml. As shown in Figure 3, gel mobility shifts are produced when the gentamicin concentration is as low as 10 pg/ml. Further, the results shown in Figure 3 demonstrate that the shift is specific to the 16S rRNA oligonucleotide as the use of an unrelated oligonucleotide, corresponding to the HIV TAR RNA element, does not result in a gel mobility shift when incubated with 10 μg/ml gentamicin. In addition, if a concentration as low as 10 pg/ml gentamicin produces a gel mobility shift then it should be possible to detect changes to RNA structural motifs j j- when small amounts of compound from a library of diverse compounds is screened in this fashion. Further analysis of the gentamicin-RNA interaction indicates that the interaction is Mg- and temperature dependent. As shown in Figure 4, when MgCl₂ is not present (TK buffer), lmg/ml of gentamicin must be added to the reaction to produce a gel shift.

Similarly, the temperature of the reaction when gentamicin is added is also important. When gentamicin is present in the reaction during the entire denaturation/renaturation cycle, that is, when gentamicin is added at 90C°C or 85 °C, a gel shift is visualized (data not shown). In contrast, when gentamicin is added after the renaturation step has proceeded to 75 °C, a mobility shift is not produced. These results are

10 consistent with the notion that gentamicin may recognize and interact with an RNA structure formed early in the renaturation process.

8. EXAMPLE: IDENTIFICATION OF A DYE-LABELED TARGET RNA

BOUND TO SMALL MOLECULAR WEIGHT COMPOUNDS 15 BY CAPILLARY ELECTROPHORESIS

The results presented in this Example indicate that interactions between a peptide and its target RNA, such as the Tat peptide and TAR RNA, can be monitored by gel retardation assays in an automated capillary electrophoresis system.

20

8.1. Materials and Methods

8.1.1. Buffers

Tris-potassium chloride (TK) buffer is composed of 50 mM Tris-HCI pH 7.4, 20mM KCl, 0.1%Triton X-100, and 0.5mM MgCl₂. Tris-borate-EDTA (TBE) buffer is

25 composed of 45 mM Tris-borate pH 8.0, and 1 mM EDTA. Tris-Potassium chloride- magnesium (TKM) buffer is composed of 50 mM Tris-HCI pH 7.4, 20mM KCl, 0.1%Triton X-100 and 5mM MgCl₂.

, « 8.1.1. Gel Retardation Analysis Using Capillary Electrophoresis

RNA oligonucleotides were purchased from Dharmacon, Inc, Lafayette, CO). 500 pmole of a 5' fluorescein labeled oligonucleotide corresponding to the HIV-1 TAR element TAR RNA (5'-GGCGUCACACCUUCGGGUGAAGUCGCC-3' (SEQ ID NO: 30); Huq et al, 1999, Nucleic Acids Research. 27:1084-1093; Hwang et al, 1999, Proc. Natl. Acad. Sci. USA 96:12997-13002) was used. For Tat-TAR gel retardation

35 reactions the method of Huq et al. (Nucleic Acids Research, 1999, 27:1084-1093) was utilized with TK buffer containing 0.5mM MgCl₂ and a 12-mer Tat peptide (YGRKKRRQRRRP (SEQ ID NO: 31); single letter amino acid code). In 20 μl reaction volumes 50 pmoles of labeled oligonucleotide and the short Tat peptide (Tat_47.58) in TK or - TKM buffer were heated at 90 °C for 2 minutes and allow to cool to room temperature (approximately 24 °C) over 2 hours. The reactions were loaded onto a SCE9610 automated capillary electrophoresis apparatus (SpectruMedix; State College, Pennsylvania).

8.2. Results

, ^ As presented in the previous Example in Section 7, interactions between a peptide and RNA can be monitored by gel retardation assays. It was hypothesized that interactions between a peptide and RNA could be monitored by gel retardation assays by an automated capillary electrophoresis system. To test this hypothesis, a gel retardation assay by an automated capillary electrophoresis system was performed using the Tat₄₇.₅₈ peptide

, g. and the TAR RNA oligonucleotide. As shown in Figure 5 using the capillary electrophoresis system, in the presence of the Tat peptide, a clear shift is visible upon the addition of increasing concentrations of Tat peptide. In the reaction that lacks peptide, only a peak corresponding to the free RNA is observed. These observations confirm previous reports made using other Tat peptides (Hamy et αl, 1997, Proc. Natl. Acad. Sci. USA

_2Q 94:3548-3553; Huq et αl, 1999, Nucleic Acids Res. 27: 1084-1093).

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing r description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

30

35 The invention can be illustrated by the following embodiments enumerated in the numbered paragraphs that follow:

1. A method for identifying a test compound that binds to a target RNA molecule, comprising the steps of (a) contacting a detectably labeled target RNA molecule with a library of test compounds under conditions that permit direct binding of the labeled target RNA to a member of the library of test compounds so that a detectably labeled target RNA:test compound complex is formed; (b) separating the detectably labeled target RNA:test compound complex formed in step(a) from uncomplexed target RNA molecules and test compounds; and (c) determining a structure of the test compound bound to the RNA in the RNA:test compound complex.

2. The method of paragraph 1 in which the target RNA molecule contains an HIV TAR element, internal ribosome entry site, "slippery site", instability element, or adenylate uridylate-rich element.

3. The method of paragraph 1 in which the RNA molecule is an element derived from the mRNA for tumor necrosis factor alpha ("TNF-α"), granulocyte- „ macrophage colony stimulating factor ("GM-CSF"), interleukin 2 ("IL-2"), interleukin 6 ("IL-6"), vascular endothelial growth factor ("VEGF"), human immunodeficiency virus I ("HIV-1"), hepatitis C virus ("HCV" - genotypes la & lb), ribonuclease P RNA ("RNaseP"), X-linked inhibitor of apoptosis protein ("XIAP"), or survivin.

_r 4. The method of paragraph 1 in which the detectably labeled RNA is labeled with a fluorescent dye, phosphorescent dye, ultraviolet dye, infrared dye, visible dye, radiolabel, enzyme, spectroscopic colorimetric label, affinity tag, or nanoparticle.

5. The method of paragraph 1 in which the test compound is selected

„_n from a combinatorial library comprising peptoids; random bio-oligomers; diversomers such as hydantoins, benzodiazepines and dipeptides; vinylogous polypeptides; nonpeptidal peptidomimetics; oligocarbamates; peptidyl phosphonates; peptide nucleic acid libraries; antibody libraries; carbohydrate libraries; and small organic molecule libraries, including but not limited to, libraries of benzodiazepines, isoprenoids, thiazolidinones, „ - metathiazanones, pyrrolidines, morpholino compounds, or diazepindiones. 6. The method of paragraph 1 in which screening a library of test compounds comprises contacting the test compound with the target nucleic acid in the presence of an aqueous solution, the aqueous solution comprising a buffer and a combination of salts, preferably approximating or mimicking physiologic conditions.

7. The method of paragraph 6 in which the aqueous solution optionally further comprises non-specific nucleic acids comprising DNA, yeast tRNA, salmon sperm DNA, homoribopolymers, and nonspecific RNAs.

8. The method of paragraph 6 in which the aqueous solution further comprises a buffer, a combination of salts, and optionally, a detergent or a surfactant. In another embodiment, the aqueous solution further comprises a combination of salts, from about 0 mM to about 100 mM KCl, from about 0 mM to about 1 M NaCl, and from about 0 mM to about 200 mM MgCl₂. In a preferred embodiment, the combination of salts is about 100 mM KCl, 500 mM NaCl, and 10 mM MgCl₂. In another embodiment, the solution optionally comprises from about 0.01% to about 0.5% (w/v) of a detergent or a surfactant.

9. Any method that detects an altered physical property of a target nucleic acid complexed to a test compound from the unbound target nucleic acid may be used for separation of the complexed and non-complexed target nucleic acids in the method of paragraph 1. In a preferred embodiment, electrophoresis is used for separation of the complexed and non-complexed target nucleic acids. In a preferred embodiment, the electrophoresis is capillary electrophoresis. In other embodiments, fluorescence spectroscopy, surface plasmon resonance, mass spectrometry, scintillation, proximity assay, structure-activity relationships ("SAR") by NMR spectroscopy, size exclusion chromatography, affinity chromatography, and nanoparticle aggregation are used for the separation of the complexed and non-complexed target nucleic acids.

10. The structure of the test compound of the RNA:test compound complex of paragraph 1 is determined, in part, by the type of library of test compounds. In a preferred embodiment wherein the combinatorial libraries are small organic molecule libraries, mass spectroscopy, NMR, or vibration spectroscopy are used to determine the structure of the test compounds.

Claims

WHAT IS CLAIMED IS:

1. A method for identifying a test compound that binds to a target RNA molecule, comprising the steps of:

(a) contacting a detectably labeled target RNA molecule with a library of test compounds under conditions that permit direct binding of the labeled target RNA to a member of the library of test compounds so that a detectably labeled target RNA:test compound complex is formed;

(b) separating the detectably labeled target RNA:test compound complex formed in step(a) from uncomplexed target RNA molecules and test compounds by capillary gel electrophoresis; and

(c) determining a structure of the test compound bound to the RNA in the RNA:test compound complex by mass spectroscopy.